[{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-LEARN-Baseline-Characteristics.html","id":"load-required-r-packages","dir":"Articles","previous_headings":"","what":"Load required R packages","title":"A4 and LEARN Screening and Baseline","text":"","code":"library(tidyverse) library(arsenal) library(A4LEARN)"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-LEARN-Baseline-Characteristics.html","id":"prepare-data","dir":"Articles","previous_headings":"","what":"Prepare data","title":"A4 and LEARN Screening and Baseline","text":"Rescreens Participants re-screened may appear data twice different BIDs time. A4LEARN::SUBJINFO derived dataset indicates participants re-screens, re-screen BIDs mapped . code also accounts set removal duplicate appearances. Gather Amyloid PET data Amyloid PET quantitative data (A4LEARN::imaging_SUVR_amyloid) long format one row per region. use tidyr::pivot_wider transform wide format one column per region. Baseline PACC Prepare data table","code":"rescreens <- A4LEARN::SUBJINFO %>%   filter(!is.na(PREVBID)) %>%   rename(BID1 = PREVBID, BID2 = BID) %>%   select(BID1, BID2) pet <- A4LEARN::imaging_SUVR_amyloid %>%    filter(brain_region != '' & VISCODE == 2) %>%   pivot_wider(id_cols='BID', names_from=brain_region, values_from=suvr_cer) %>%   left_join(A4LEARN::imaging_PET_VA, by='BID') %>%   left_join(rescreens, by=c('BID' = 'BID1')) %>%    mutate( # update PET BIDs to second BID if necessary     BID = case_when(       !is.na(BID2) ~ BID2,       TRUE ~ BID)) %>%   arrange(BID, BID2) %>%   filter(!duplicated(BID, fromLast = TRUE)) %>%   select(-BID2) pacc_bl <- A4LEARN::PACC %>%    filter(VISCODE == 6) %>%   select(BID, PACC.raw, MMSCORE, LDELTOTAL, DIGITTOTAL, FCTOTAL96) dd <- A4LEARN::SUBJINFO %>% select(BID, APOEGN) %>%   left_join(A4LEARN::ptdemog, by='BID') %>%   left_join(pet, by=c('SUBSTUDY','BID')) %>%   left_join(pacc_bl, by=c('BID')) %>%   # remove first appearance of rescreens:   filter(!BID %in% rescreens$BID1) %>%    rename(`A4 amyloid eligibility` = overall_score) %>%   rename(     `Age at screening (yrs)` = PTAGE,     `APOE genotype` = APOEGN,      `Education (yrs)` = PTEDUCAT,      `Amyloid PET SUVr^b^` = Composite_Summary,     Sex = PTGENDER,     Ethnicity = PTETHNIC,     `Marital status` = PTMARRY,     `Participant retired` = PTNOTRT,     PACC = PACC.raw,      MMSE = MMSCORE,      `Logical memory delay` = LDELTOTAL,      `Digit symbol` = DIGITTOTAL,      `FCSRT (2xFree + Cued)` = FCTOTAL96,     `A4 amyloid eligibility^b^` = `A4 amyloid eligibility`) %>%    # rename values and fields for footnote setup in summary table   mutate(SUBSTUDY = factor(SUBSTUDY, levels = c('A4', 'LEARN'),     labels = c('A4^a^' , 'LEARN')))"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-LEARN-Baseline-Characteristics.html","id":"characteristics-by-screening-amyloid-pet-status","dir":"Articles","previous_headings":"","what":"Characteristics by screening amyloid PET status","title":"A4 and LEARN Screening and Baseline","text":"Characteristics underwent screening amyloid PET comparison Elevated (Aβ−) Elevated Amyloid (Aβ+) groups","code":"tableby(`A4 amyloid eligibility^b^` ~ .,   data = dd %>%     filter(!is.na(`Amyloid PET SUVr^b^`)) %>%     select(`A4 amyloid eligibility^b^`, `Age at screening (yrs)`,        `Education (yrs)`, `APOE genotype`, `Amyloid PET SUVr^b^`,        Sex, Ethnicity, `Marital status`, `Participant retired`, PACC, MMSE,        `Logical memory delay`, `Digit symbol`, `FCSRT (2xFree + Cued)`),    digits = 2) %>%   summary(title = \"Characteristics of all who underwent screening amyloid PET with comparison of Not Elevated (Aβ−) and Elevated Amyloid (Aβ+) groups\")"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-LEARN-Baseline-Characteristics.html","id":"characteristics-by-a4-vs-learn","dir":"Articles","previous_headings":"","what":"Characteristics by A4 vs LEARN","title":"A4 and LEARN Screening and Baseline","text":"Baseline characteristics A4-randomizeda LEARN-enrolled cohorts A4-randomized cohort (n=1169) includes participants addition modified intention--treat population (mITT n=1147) reported A4 trial (Sperling et al. 2023). modified intention--treat population population reported A4 trial results include received least one dose solanezumab placebo underwent assessment primary end point. Please refer vignette(topic = 'A4-Primary-Results') file code reproduce baseline characteristics primary findings A4 study.b Refer A4 Amyloid PET Eligibility Methods PDF document (vignette(topic = 'imaging_PET_VA_methods')) regarding amyloid-related measures, eligibility determination process modifications made SUVR algorithm.","code":"tableby(SUBSTUDY ~ .,   data = dd %>%     filter(!SUBSTUDY %in% 'SF') %>% # excluding screen-fails     select(SUBSTUDY, `A4 amyloid eligibility^b^`, `Age at screening (yrs)`,        `Education (yrs)`, `APOE genotype`, `Amyloid PET SUVr^b^`, Sex, Ethnicity,       `Marital status`, `Participant retired`, PACC, MMSE,        `Logical memory delay`, `Digit symbol`, `FCSRT (2xFree + Cued)`),    digits = 2) %>%   summary(title = \"Baseline characteristics of A4-randomized^a^ and LEARN-enrolled cohorts\")"},{"path":[]},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-Primary-Results.html","id":"load-required-r-packages","dir":"Articles","previous_headings":"","what":"Load required R packages","title":"A4 Primary Results","text":"","code":"library(tidyverse) library(arsenal) library(kableExtra) library(nlme) library(emmeans) library(splines) library(clubSandwich) library(A4LEARN)  formatp <- function(x) case_when(   x < 0.001 ~ \"p<0.001\",   x > 0.01 ~ Hmisc::format.pval(x, digits=2, eps=0.01, nsmall=2),   TRUE ~ Hmisc::format.pval(x, digits=3, eps=0.001, nsmall=3))"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-Primary-Results.html","id":"organize-data","dir":"Articles","previous_headings":"","what":"Organize data","title":"A4 Primary Results","text":"","code":"# Outcomes collected at Visit 1 V1OUTCOME <- A4LEARN::ADQS %>%   dplyr::filter(VISITCD == \"001\") %>%   select(BID, QSTESTCD, QSSTRESN) %>%   pivot_wider(values_from = QSSTRESN, names_from = QSTESTCD)  # Outcomes collected at Visit 6 V6OUTCOME <- A4LEARN::ADQS %>%   dplyr::filter(VISITCD == \"006\") %>%   select(BID, QSTESTCD, QSSTRESN) %>%   pivot_wider(values_from = QSSTRESN, names_from = QSTESTCD)  SUBJINFO <- A4LEARN::SUBJINFO %>%   left_join(V6OUTCOME, by = \"BID\") %>%   left_join(V1OUTCOME %>%       select(BID, CDRSB, CFITOTAL, CFISP, CFIPT, ADLPQPT, ADLPQSP),      by = \"BID\")  # Filter A4LEARN::ADQS for PACC collected in the blinded phases among mITT population ADQS_PACC <- A4LEARN::ADQS %>%   dplyr::filter(MITTFL== 1) %>%   dplyr::filter(EPOCH == \"BLINDED TREATMENT\" | AVISIT == \"006\") %>%   dplyr::filter(QSTESTCD == \"PACC\") %>%   rename(PACC = QSSTRESN) %>%   select(BID, ASEQNCS, TX, ADURW, TX, AGEYR,      AAPOEGNPRSNFLG, EDCCNTU, SUVRCER, QSVERSION, PACC) %>%   mutate(TX = factor(TX, levels = c(\"Placebo\", \"Solanezumab\"))) %>%   arrange(BID, ADURW) %>%   na.omit()"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-Primary-Results.html","id":"baseline-characteristics-of-the-a4-trial","dir":"Articles","previous_headings":"","what":"Baseline characteristics of the A4 trial","title":"A4 Primary Results","text":"Characteristics A4 participants randomized treatment group (Modified Intention--Treat Population received least one dose solanezumab placebo underwent assessment primary end point).","code":"A4labels <- list(TX = \"Treatment group\", AGEYR = \"Age (y)\",    EDCCNTU = \"Education (y)\", SUVRCER = \"FBP SUVr\", AMYLCENT = \"FBP Centiloid\",    LMIIa = \"LM Delayed Recall\",  MMSE = \"MMSE\",    CFITOTAL = \"CFI Combined\", ADLPQSP = \"ADL Partner\", CDRSB = \"CDR-SB\",   SEX = \"Sex\", RACE = \"Racial categories\", ETHNIC = \"Ethnicity\",    MARITAL = \"Marital Status\",  WRKRET = \"Retirement Status\",    APOEGNPRSNFLG = \"APOE e4\", APOEGN = \"APOE Genotype\")  table1 <- tableby(TX ~ AGEYR + EDCCNTU + SEX + RACE + ETHNIC + MARITAL + WRKRET +      SUVRCER + AMYLCENT + chisq(APOEGN) + chisq(APOEGNPRSNFLG) +      PACC + LMIIa + MMSE + CFITOTAL + ADLPQSP + CDRSB,    data = SUBJINFO %>% dplyr::filter(MITTFL== 1),    control = tableby.control(test=TRUE,     stats.labels = list(Nmiss = \"Missing\")))  summary(table1, labelTranslations = A4labels, digits = 1,   title = \"Characteristics of the A4 participants by randomized treatment group (Modified Intention-to-Treat Population of those who received at least one dose of solanezumab or placebo and underwent assessment for the primary end point).\")"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-Primary-Results.html","id":"primary-analyis-of-the-pacc","dir":"Articles","previous_headings":"","what":"Primary analyis of the PACC","title":"A4 Primary Results","text":"Preclinical Alzheimer Cognitive Composite (PACC, Donohue et al. (2014)) data modeled using natural cubic splines described Donohue et al. (2023). fixed effects included following terms: () spline basis expansion terms (two terms), (ii) spline basis expansion terms--treatment interaction (two terms), (iii) PACC test version administered, (iv) baseline age, (v) education, (vi) APOE4 Carrier Status (yes/), (vii) baseline florbetapir cortical SUVr. model constrained allow difference treatment group means baseline. following variance-covariance structures assumed sequence model converged: () heterogeneous unstructured, (ii) heterogeneous Toeplitz, (iii) heterogeneous autoregressive order 1, (iv) heterogeneous compound symmetry, (v) compound symmetry. first structure, heterogeneous unstructured, converge. fit second, heterogeneous Toeplitz, converge. Spaghetti plot PACC data time treatment group. Mean PACC change baseline week 240 treatment group estimated spline model. Mean PACC group change baseline week 240 treatment group estimated spline model. Mean PACC per treatment group time estimated spline model. Shaded region depicts 95% confidence intervals.","code":"ggplot(ADQS_PACC, aes(x=ADURW, y=PACC, color=TX)) +   geom_line(aes(group = BID), alpha=0.2) +   theme(legend.position = \"inside\", legend.position.inside = c(0.2, 0.2)) +   xlab(\"Weeks since Randomization\") +   scale_x_continuous(breaks = seq(0, max(ADQS_PACC$ADURW), by = 24)) # Spline basis expansion functions # CAUTION: these function depend on the ADQS_PACC data frame object in the  # global environment. If ADQS_PACC changes, so do these funtions ns21 <- function(t){   as.numeric(predict(splines::ns(ADQS_PACC$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_PACC$ADURW))), t)[,1]) } ns22 <- function(t){   as.numeric(predict(splines::ns(ADQS_PACC$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_PACC$ADURW))), t)[,2]) }  assign(\"ns21\", ns21, envir = .GlobalEnv) assign(\"ns22\", ns22, envir = .GlobalEnv)  # GLS model fit: pacc_fit <- gls(PACC ~      I(ns21(ADURW)) + I(ns22(ADURW)) +     (I(ns21(ADURW)) + I(ns22(ADURW))):TX +      AGEYR + AAPOEGNPRSNFLG + EDCCNTU + SUVRCER + QSVERSION,   data = ADQS_PACC,   weights = varIdent(form = ~ 1 | ASEQNCS),   correlation = corARMA(form = ~ ASEQNCS | BID, p = 10)) ref_grid(pacc_fit,   at = list(ADURW = c(0,240), TX = levels(ADQS_PACC$TX)),   vcov. = clubSandwich::vcovCR(pacc_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_PACC,    mode = \"satterthwaite\") %>%   emmeans(~ ADURW | TX) %>%   pairs(reverse = TRUE) %>%   as_tibble() %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean PACC change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") contrast240 <- ref_grid(pacc_fit,    at = list(ADURW = 240, TX = levels(ADQS_PACC$TX)),   vcov. = clubSandwich::vcovCR(pacc_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_PACC,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   pairs(reverse = TRUE, adjust = \"none\")  contrast240 %>%    as_tibble() %>%   left_join(contrast240 %>%        confint() %>%       as_tibble() %>%       select(contrast, lower.CL, upper.CL), by=\"contrast\") %>%   relocate(p.value, .after = last_col()) %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean PACC group change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") ref_grid(pacc_fit,    at = list(ADURW = seq(0, 312, by=12), TX = levels(ADQS_PACC$TX)),   vcov. = clubSandwich::vcovCR(pacc_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_PACC,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   as_tibble() %>%   ggplot(aes(x=ADURW, y=emmean)) +   geom_line(aes(color=TX)) +   geom_ribbon(aes(ymin = lower.CL, ymax = upper.CL, fill = TX), alpha = 0.2) +   scale_x_continuous(breaks = seq(0, 312, by=24)) +   ylab(\"Mean PACC with 95% confidence intervals\") +   xlab(\"Weeks since Randomization\") +   theme(legend.position = 'inside', legend.position.inside = c(0.2, 0.2))"},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4-Primary-Results.html","id":"primary-analyis-of-the-cfi","dir":"Articles","previous_headings":"","what":"Primary analyis of the CFI","title":"A4 Primary Results","text":"Spaghetti plot CFI data time treatment group. Mean CFI change baseline week 240 treatment group estimated spline model. Mean CFI group change baseline week 240 treatment group estimated spline model. Mean CFI per treatment group time estimated spline model. Shaded region depicts 95% confidence intervals.","code":"# Filter A4LEARN::ADQS for CFITOTAL collected in the blinded phases among mITT population ADQS_CFI <- A4LEARN::ADQS %>%   dplyr::filter(MITTFL== 1) %>%   dplyr::filter(EPOCH == \"BLINDED TREATMENT\" | AVISIT == \"001\") %>%   dplyr::filter(QSTESTCD == \"CFITOTAL\") %>%   select(BID, ASEQNCS, TX, ADURW, TX, AGEYR,      AAPOEGNPRSNFLG, EDCCNTU, SUVRCER, QSSTRESN) %>%   mutate(TX = factor(TX, levels = c(\"Placebo\", \"Solanezumab\"))) %>%   arrange(BID, ADURW) %>%   na.omit() ggplot(ADQS_CFI, aes(x=ADURW, y=QSSTRESN, color=TX)) +   geom_line(aes(group = BID), alpha=0.2) +   theme(legend.position = \"inside\", legend.position.inside = c(0.2, 0.9)) +   xlab(\"Weeks since Randomization\") +   ylab(\"CFI Participant and Partner\") scale_x_continuous(breaks = seq(0, max(ADQS_CFI$ADURW), by = 24)) <ScaleContinuousPosition>  Range:    Limits:    0 --    1 # Spline basis expansion functions # CAUTION: these function depend on the ADQS_CFI data frame object in the  # global environment. If ADQS_CFI changes, so do these funtions ns21 <- function(t){   as.numeric(predict(splines::ns(ADQS_CFI$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_CFI$ADURW))), t)[,1]) } ns22 <- function(t){   as.numeric(predict(splines::ns(ADQS_CFI$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_CFI$ADURW))), t)[,2]) }  assign(\"ns21\", ns21, envir = .GlobalEnv) assign(\"ns22\", ns22, envir = .GlobalEnv)  # GLS model fit: cfi_fit <- gls(QSSTRESN ~      I(ns21(ADURW)) + I(ns22(ADURW)) +     (I(ns21(ADURW)) + I(ns22(ADURW))):TX +      AGEYR + AAPOEGNPRSNFLG + EDCCNTU + SUVRCER,   data = ADQS_CFI,   weights = varIdent(form = ~ 1 | ASEQNCS),   correlation = corARMA(form = ~ ASEQNCS | BID, p = 5)) ref_grid(cfi_fit,   at = list(ADURW = c(0,240), TX = levels(ADQS_CFI$TX)),   vcov. = clubSandwich::vcovCR(cfi_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_CFI,    mode = \"satterthwaite\") %>%   emmeans(~ ADURW | TX) %>%   pairs(reverse = TRUE) %>%   as_tibble() %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean CFI change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") contrast240 <- ref_grid(cfi_fit,    at = list(ADURW = 240, TX = levels(ADQS_CFI$TX)),   vcov. = clubSandwich::vcovCR(cfi_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_CFI,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   pairs(reverse = TRUE, adjust = \"none\")  contrast240 %>%    as_tibble() %>%   left_join(contrast240 %>%        confint() %>%       as_tibble() %>%       select(contrast, lower.CL, upper.CL), by=\"contrast\") %>%   relocate(p.value, .after = last_col()) %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean CFI group change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") ref_grid(cfi_fit,    at = list(ADURW = seq(0, 312, by=12), TX = levels(ADQS_CFI$TX)),   vcov. = clubSandwich::vcovCR(cfi_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_CFI,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   as_tibble() %>%   ggplot(aes(x=ADURW, y=emmean)) +   geom_line(aes(color=TX)) +   geom_ribbon(aes(ymin = lower.CL, ymax = upper.CL, fill = TX), alpha = 0.2) +   scale_x_continuous(breaks = seq(0, 312, by=24)) +   ylab(\"Mean CFI with 95% confidence intervals\") +   xlab(\"Weeks since Randomization\") +   theme(legend.position = 'inside', legend.position.inside = c(0.2, 0.9))"},{"path":[]},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"introduction","dir":"Articles","previous_headings":"","what":"Introduction","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"Elevated levels brain amyloid cognitively unimpaired older adults associated subsequent cognitive decline increased risk clinical progression.1–5 Anti-Amyloid Treatment Asymptomatic Alzheimer’s Disease (A4) Study, randomized trial solanezumab cognitively normal individuals elevated amyloid PET, demonstrated group-level decline cognitive composite treatment benefit.2 Follow-analyses A4 companion observational study amyloid-negative individuals, Longitudinal Evaluation Amyloid Risk Neurodegeneration (LEARN), confirmed higher baseline amyloid PET plasma phosphorylated tau (P‐tau217) levels associated faster cognitive decline increased functional progression.5 Despite consistent group-level associations, cognitive trajectories among amyloid-positive individuals remain highly variable. Conventional longitudinal models assume individual cognitive trajectories randomly scattered single mean trend given covariate values, potentially obscuring meaningful heterogeneity. better characterize heterogeneity, applied Latent Class Mixed-Effects Model (LCMM)6 A4 LEARN data. approach identifies unobserved subgroups participants distinct longitudinal patterns change allows evaluation baseline biomarkers demographic factors predictors class membership.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"key-points","dir":"Articles","previous_headings":"","what":"Key points","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"Question: Among cognitively unimpaired older adults without Alzheimer’s disease biomarkers, distinct subgroups cognitive decline, can baseline biomarkers predict subgroup membership? Findings: latent class mixed‐effects modeling analysis participants A4 LEARN studies, three subgroups cognitive trajectories identified, representing stable, slow decline, fast decline. Higher baseline plasma P‐tau217 levels, greater baseline hippocampal atrophy, higher baseline tau PET levels associated membership declining subgroups. Even among amyloid-positive participants, approximately 70% classified stable, proportion unexpected given long presymptomatic phase Alzheimer disease, may span decade. Meaning: Substantial heterogeneity exists cognitive decline preclinical phase Alzheimer’s disease. Identifying subgroups decline may improve prognostic modeling guide precision enrollment outcome strategies prevention trials.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"methods","dir":"Articles","previous_headings":"","what":"Methods","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"A4 LEARN studies previously described2,5, briefly summarize key elements. A4 Study multicenter, randomized, double-blind, placebo-controlled secondary prevention trial enrolling cognitively unimpaired older adults aged 65–85 years elevated brain amyloid florbetapir PET. Participants recruited 67 sites United States, Canada, Australia, Japan underwent standardized screening, baseline clinical assessment, biomarker acquisition, neuropsychological testing. eligibility confirmation, participants randomized receive solanezumab placebo assessed longitudinally regular cognitive evaluations, safety monitoring, follow-imaging fluid biomarker collection per protocol. LEARN study conducted parallel observational cohort enrolling individuals met A4 screening criteria except amyloid PET positivity. LEARN participants completed identical clinical cognitive assessments, allowing direct comparison trajectories amyloid-positive amyloid-negative individuals. studies followed harmonized procedures data collection, visit scheduling, quality control ensure comparability longitudinal outcomes. participants studies provided written informed consent, study protocols approved institutional review boards ethics committees participating site. Latent class mixed-effects models (LCMMs) extend traditional mixed-effects models identifying unobserved subgroups, latent classes, individuals follow distinct longitudinal trajectories. context cognitive decline Alzheimer’s disease, LCMMs allow estimation population-level trends capturing individual variability uncovering hidden subpopulations may progress different rates. Analyses conducted using harmonized data A4 LEARN studies, accessed A4LEARN R data package (version 1.1.202508087,8). package provides curated datasets metadata derived A4 LEARN clinical studies reproducible statistical analysis. Code reproduce results paper available A4LEARN GitHub repository9. dependent variable Box-Cox-transformed Preclinical Alzheimer’s Cognitive Composite (PACC) score visit. Box-Cox transformation parameter (λ\\lambda) selected maximize likelihood transformed data approximated normality. Time modeled continuous variable representing years since baseline. Natural cubic spline basis functions one, two three degrees freedom evaluated model nonlinear trajectories, boundary knots baseline maximum follow-time interior knots median tertiles observation time. choice degrees freedom number classes (also one, two, three) determined model fit criteria (Bayesian Information Criterion [BIC] Integrated Complete Likelihood [ICL]).10 model included class-specific spline-based time effects, well subject-specific random intercepts. effect baseline covariates shared across latent classes included: randomized solanezumab (1 active group, 0 placebo LEARN), plasma P-tau217 concentration, florbetapir cortical standardized uptake value ratio (SUVr), APOE ϵ4\\epsilon 4 carrier status, sex, age, education, hippocampal atrophy, PACC test stimulus version administered (alternated per study protocol). Plasma P-tau217 concentrations measured using immunoassay developed Eli Lilly reported arbitrary units per milliliter (U/mL), “U” denotes generic assay unit proportional signal intensity. Absolute calibration mass concentration (e.g., pg/mL) available. Hippocampal atrophy measures derived first residualizing respect intracranial volume, standardizing mean zero variance one (.e. z-scoring). LCMM includes two linked submodels. longitudinal submodel captures within-class trajectories cognitive change time. class set spline coefficients, allowing class-specific shapes decline. class membership submodel defines probability belonging latent class multinomial logistic function baseline covariates (includes covariates listed except spline terms PACC test version). secondary analysis, fit model subset participants baseline flortaucipir (tau) PET imaging. Tau PET summarized mean SUVr across eight cortical regions: entorhinal cortex, inferior temporal, inferior parietal, posterior cingulate, caudal middle frontal, middle temporal, superior parietal, frontal pole. composite measure included additional covariate longitudinal class membership submodels assess whether tau pathology improved prediction cognitive decline patterns latent class assignment. assess reliability potential predictive utility latent class membership model, examined posterior probabilities class assignment participant. High posterior probabilities indicate greater certainty latent class classification. summarized distributions across classes computed mean posterior probability within group index classification confidence. evaluate prospective discrimination, performed ten-fold cross-validation stratified P-tau217 latent class. ten folds, 90% data used re-train LCMM, re-trained model used predict latent classes 10% held-test set using baseline data. Model performance summarized using area precision-recall curve (AUPRC) discrimination class versus others. approach can informative receiver operating characteristic (ROC) curves group sizes imbalance.11 evaluate whether latent classes distinguished baseline characteristics combination binary decision rules, conducted post-hoc classification tree analysis12,13. Class assignments optimal latent class mixed model used outcome variable, baseline demographic clinical characteristics predictors (randomized solanezumab, plasma P-tau217 concentration, florbetapir PET, APOE ϵ4\\epsilon 4 carrier status, sex, age, education, hippocampal atrophy, PACC). separately considered regression tree tau PET additional predictor. Hyperparameter tuning performed using 10-fold cross-validation. optimal hyperparameters selected based maximum cross-validated accuracy. final tree structure visualized illustrate hierarchy decision rules class assignment. Variable importance calculated based total reduction node impurity attributed splits predictor. approach provides interpretable framework understanding multivariate profile latent class assessing whether classes can reliably separated using clinically available baseline information. analyses conducted using R (version 4.5.2; R Foundation Statistical Computing) lcmm package (version 2.2.1).","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"conduct-of-the-a4-and-learn-studies","dir":"Articles","previous_headings":"","what":"Conduct of the A4 and LEARN Studies","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"A4 LEARN studies previously described2,5, briefly summarize key elements. A4 Study multicenter, randomized, double-blind, placebo-controlled secondary prevention trial enrolling cognitively unimpaired older adults aged 65–85 years elevated brain amyloid florbetapir PET. Participants recruited 67 sites United States, Canada, Australia, Japan underwent standardized screening, baseline clinical assessment, biomarker acquisition, neuropsychological testing. eligibility confirmation, participants randomized receive solanezumab placebo assessed longitudinally regular cognitive evaluations, safety monitoring, follow-imaging fluid biomarker collection per protocol. LEARN study conducted parallel observational cohort enrolling individuals met A4 screening criteria except amyloid PET positivity. LEARN participants completed identical clinical cognitive assessments, allowing direct comparison trajectories amyloid-positive amyloid-negative individuals. studies followed harmonized procedures data collection, visit scheduling, quality control ensure comparability longitudinal outcomes. participants studies provided written informed consent, study protocols approved institutional review boards ethics committees participating site.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"statistical-analysis","dir":"Articles","previous_headings":"","what":"Statistical Analysis","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"Latent class mixed-effects models (LCMMs) extend traditional mixed-effects models identifying unobserved subgroups, latent classes, individuals follow distinct longitudinal trajectories. context cognitive decline Alzheimer’s disease, LCMMs allow estimation population-level trends capturing individual variability uncovering hidden subpopulations may progress different rates. Analyses conducted using harmonized data A4 LEARN studies, accessed A4LEARN R data package (version 1.1.202508087,8). package provides curated datasets metadata derived A4 LEARN clinical studies reproducible statistical analysis. Code reproduce results paper available A4LEARN GitHub repository9. dependent variable Box-Cox-transformed Preclinical Alzheimer’s Cognitive Composite (PACC) score visit. Box-Cox transformation parameter (λ\\lambda) selected maximize likelihood transformed data approximated normality. Time modeled continuous variable representing years since baseline. Natural cubic spline basis functions one, two three degrees freedom evaluated model nonlinear trajectories, boundary knots baseline maximum follow-time interior knots median tertiles observation time. choice degrees freedom number classes (also one, two, three) determined model fit criteria (Bayesian Information Criterion [BIC] Integrated Complete Likelihood [ICL]).10 model included class-specific spline-based time effects, well subject-specific random intercepts. effect baseline covariates shared across latent classes included: randomized solanezumab (1 active group, 0 placebo LEARN), plasma P-tau217 concentration, florbetapir cortical standardized uptake value ratio (SUVr), APOE ϵ4\\epsilon 4 carrier status, sex, age, education, hippocampal atrophy, PACC test stimulus version administered (alternated per study protocol). Plasma P-tau217 concentrations measured using immunoassay developed Eli Lilly reported arbitrary units per milliliter (U/mL), “U” denotes generic assay unit proportional signal intensity. Absolute calibration mass concentration (e.g., pg/mL) available. Hippocampal atrophy measures derived first residualizing respect intracranial volume, standardizing mean zero variance one (.e. z-scoring). LCMM includes two linked submodels. longitudinal submodel captures within-class trajectories cognitive change time. class set spline coefficients, allowing class-specific shapes decline. class membership submodel defines probability belonging latent class multinomial logistic function baseline covariates (includes covariates listed except spline terms PACC test version). secondary analysis, fit model subset participants baseline flortaucipir (tau) PET imaging. Tau PET summarized mean SUVr across eight cortical regions: entorhinal cortex, inferior temporal, inferior parietal, posterior cingulate, caudal middle frontal, middle temporal, superior parietal, frontal pole. composite measure included additional covariate longitudinal class membership submodels assess whether tau pathology improved prediction cognitive decline patterns latent class assignment. assess reliability potential predictive utility latent class membership model, examined posterior probabilities class assignment participant. High posterior probabilities indicate greater certainty latent class classification. summarized distributions across classes computed mean posterior probability within group index classification confidence. evaluate prospective discrimination, performed ten-fold cross-validation stratified P-tau217 latent class. ten folds, 90% data used re-train LCMM, re-trained model used predict latent classes 10% held-test set using baseline data. Model performance summarized using area precision-recall curve (AUPRC) discrimination class versus others. approach can informative receiver operating characteristic (ROC) curves group sizes imbalance.11 evaluate whether latent classes distinguished baseline characteristics combination binary decision rules, conducted post-hoc classification tree analysis12,13. Class assignments optimal latent class mixed model used outcome variable, baseline demographic clinical characteristics predictors (randomized solanezumab, plasma P-tau217 concentration, florbetapir PET, APOE ϵ4\\epsilon 4 carrier status, sex, age, education, hippocampal atrophy, PACC). separately considered regression tree tau PET additional predictor. Hyperparameter tuning performed using 10-fold cross-validation. optimal hyperparameters selected based maximum cross-validated accuracy. final tree structure visualized illustrate hierarchy decision rules class assignment. Variable importance calculated based total reduction node impurity attributed splits predictor. approach provides interpretable framework understanding multivariate profile latent class assessing whether classes can reliably separated using clinically available baseline information. analyses conducted using R (version 4.5.2; R Foundation Statistical Computing) lcmm package (version 2.2.1).","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"ten-fold-cross-validation-of-latent-class-predictions","dir":"Articles","previous_headings":"Methods","what":"Ten-fold cross-validation of latent class predictions","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"evaluate prospective discrimination, performed ten-fold cross-validation stratified P-tau217 latent class. ten folds, 90% data used re-train LCMM, re-trained model used predict latent classes 10% held-test set using baseline data. Model performance summarized using area precision-recall curve (AUPRC) discrimination class versus others. approach can informative receiver operating characteristic (ROC) curves group sizes imbalance.11","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"regression-tree-analysis-for-latent-class-characterization","dir":"Articles","previous_headings":"Methods","what":"Regression Tree Analysis for Latent Class Characterization","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"evaluate whether latent classes distinguished baseline characteristics combination binary decision rules, conducted post-hoc classification tree analysis12,13. Class assignments optimal latent class mixed model used outcome variable, baseline demographic clinical characteristics predictors (randomized solanezumab, plasma P-tau217 concentration, florbetapir PET, APOE ϵ4\\epsilon 4 carrier status, sex, age, education, hippocampal atrophy, PACC). separately considered regression tree tau PET additional predictor. Hyperparameter tuning performed using 10-fold cross-validation. optimal hyperparameters selected based maximum cross-validated accuracy. final tree structure visualized illustrate hierarchy decision rules class assignment. Variable importance calculated based total reduction node impurity attributed splits predictor. approach provides interpretable framework understanding multivariate profile latent class assessing whether classes can reliably separated using clinically available baseline information. analyses conducted using R (version 4.5.2; R Foundation Statistical Computing) lcmm package (version 2.2.1).","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"results","dir":"Articles","previous_headings":"","what":"Results","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"total N=1,629N=1,629 participants included analytic sample base model (without tau PET), comprising N=1,110N=1,110 A4 Study N=519N=519 LEARN study. mean (standard deviation [SD]) age baseline 71.46 (4.69) years, 60.2% female. median follow-time 6.0 years (interquartile range 3.9 7.0). Baseline characteristics stratified latent class membership presented Table 1. total N=427N=427 individuals tau PET data submitted tau PET model. tau PET subset included N=372N=372 A4 Study N=55N=55 LEARN study. Baseline characteristics tau PET subset presented Supplementary Table S1. Table 1: Baseline Demographic, Clinical, Biomarker Characteristics Latent Class Cognitive Decline. Baseline characteristics participants classified latent class mixed model (LCMM) Preclinical Alzheimer’s Cognitive Composite (PACC) trajectories. Classes represent distinct longitudinal cognitive patterns: stable, slow decliner, fast decliner. Continuous variables presented mean (SD); categorical variables . (%). Abbreviations: APOE = apolipoprotein E; PET = positron emission tomography; P-tau217 = plasma phosphorylated tau 217; SUVr = standardized uptake value ratio; U/mL = arbitrary units proportional assay signal; . = American; PI = Pacific Islander; CDR = Clinical Dementia Rating; Prog. = Progressor. Footnotes: Amyloid PET tau PET SUVr values represent mean cortical uptake relative cerebellar reference region. Hippocampal atrophy residualized intracranial volume z-scored. Education reported years formal schooling. CDR Progressors observed CDR Global score greater zero two consecutive visits, last visit. Figure 1: Individual Mean PACC Trajectories Latent Class. Left panel (): Spaghetti plot individual participant trajectories Preclinical Alzheimer Cognitive Composite (PACC), colored latent class derived latent class mixed model (LCMM). line represents one participant’s observed scores time. Right panel (B): Estimated mean PACC trajectories latent class, shaded regions indicating 95% confidence intervals. Higher PACC scores indicate better cognitive performance. Figure 2: Distribution Baseline Demographic Biomarker Variables Latent Class Cognitive Decline. Sina plots show distribution selected baseline variables among latent classes identified latent class mixed model (LCMM) Preclinical Alzheimer’s Cognitive Composite (PACC) trajectories: stable, slow decliner, fast decliner. Variables include age, baseline PACC score, plasma phosphorylated tau 217 (P-tau217), amyloid positron emission tomography (PET) standardized uptake value ratio (SUVr), tau PET SUVr (subset tau PET available), hippocampal atrophy (volume normalized intracranial volume). dot represents individual participant; box plots represent quartiles. Higher PACC scores indicate better cognitive performance. Abbreviations: PET = positron emission tomography; P-tau217 = plasma phosphorylated tau 217; SUVr = standardized uptake value ratio; U/mL = arbitrary units proportional assay signal. Figure 3: Association Baseline Predictors Latent Class Membership Longitudinal Cognitive Decline Models Without Tau PET. Panels B display results latent class mixed model (LCMM) excluding tau PET; panels C D show corresponding results model including tau PET additional predictor. (, C) Odds ratios (95% CIs) LCMM class-membership submodel represent relative likelihood belonging slow- fast-declining classes relative stable class. (B, D) Standardized coefficients (95% CIs) LCMM longitudinal submodel show associations baseline predictors rate change Preclinical Alzheimer’s Cognitive Composite (PACC). continuous predictors PACC outcome standardized (z-scored) analysis enable comparison effect magnitudes. Higher PACC scores indicate better cognitive performance; thus, larger positive coefficients correspond slower decline better preservation cognition time. Individual base LCMM (excluding Tau PET) mean trajectories shown Figure 1. Model selection criteria identified model two degrees freedom three latent classes, labeled stable (77%), slow decliner (16%), fast decliner (7%). next best fitting model three classes three degrees freedom (Δ\\Delta BIC = 22.2, Δ\\Delta ICL = 22.2). best fitting Tau PET LCMM two degrees freedom three latent classes (Supplementary Figure S1) next best fitting model two classes two degrees freedom (Δ\\Delta BIC = 376.4, Δ\\Delta ICL = 336.9). two models largely agreed individual classifications. 7/427 (1.6%) individuals reclassified one model next, none fast decliners. Posterior class probabilities (Supplementary Figure S2) indicated good separation (mean posterior probability, 0.94), indicating model confidence class assignment. three classes significantly separated starting immediately baseline. base model, participants classified fast decliners started mean -0.98 (95% confidence interval [CI] -1.44 -0.52) PACC points declined mean -15.8 (95% CI -16.7 -15.0) six years. contrast stable individuals started mean 0.52 (95% CI 0.37 0.67) PACC points improved mean 1.16 (95% CI 1.00 1.31) six years. Slow decliners intermediate two classes starting mean -0.13 (95% CI -0.44 0.17) PACC points declining mean -4.74 (95% CI -5.22 -4.26). Clinical relevance PACC latent classes supported differences functional outcomes. proportion participants observed progress Clinical Dementia Rating (CDR) Global score increased monotonically across latent classes, lowest rate among stable individuals (22.8%) progressively higher rates among slow- (71.9%) fast-decliners (88.2%) (Table 1). However, discordance PACC latent class labels observed CDR progression common. CDR Global scores greater zero possible without indication memory issues, explains little discordance. Among CDR progressors, proportion individuals CDR Memory Box score zero 8.4% PACC stable individuals, 5.5% slow decliners, 4.8% fast decliners. distribution continuous baseline variables latent class shown Figure 2 Figure 3 summarizes standardized coefficients 95% CIs components LCMM. Figure 3 Panels C depicts odds ratios (ORs) class membership submodels base model tau PET model. Continuous predictors standardized ORs reflect change odds belonging fast- slow declining class compared stable class per one SD increase continuous baseline predictor. base model (Panel ), higher plasma P-tau217 levels (3.2, 95% CI 2.4 4.1), elevated amyloid PET centiloid (1.4, 95% CI 1.0 1.9), greater hippocampal atrophy scores (3.9, 95% CI 2.7 5.6) associated increased odds belonging faster-declining classes. Interestingly, P-tau217 hippocampal atrophy numerically stronger effects amyloid PET. Also interest, fast decliners numerically younger (mean 73.1 years, SD 4.7), average, slow decliners (mean 74.1 years, SD 5.2) increased age associated membership slow declining group (1.4, 95% CI 1.1 1.7) fast declining group (0.93, 95% CI 0.69 1.2). Tau PET model results largely similar, confidence intervals wider, likely due smaller available sample (N=427N=427 vs N=1,629N=1,629). Increased tau PET associated increased odds slow- (= 1.8, 95% CI 1.2 2.8) fast-declining groups (= 3.6, 95% CI 2.1 6.1). Figure 3 Panels B D presents standardized coefficients longitudinal submodels, representing associations covariate PACC outcome. Higher PACC scores correspond better cognitive performance continuous variables standardized oriented positive coefficients indicate better performance. see females increased risk fast decliners (2.5, 95% CI 1.5 4.4), better PACC performance given class membership (0.30 PACC points, 95% CI 0.24 0.35). APOE ϵ4\\epsilon 4 carriage associated increased risk slow (1.9, 95% CI 1.3 2.8) fast (2.9, 95% CI 1.6 5.3) declining class versus stable class, negligible remaining effect PACC. Education effect class membership, associated better PACC performance (0.12 PACC points per SD education, 95% CI 0.095 0.15). overall cross-validated accuracy 0.80 (95% CI 0.79 0.82) base model 0.756 (95% CI 0.73 0.78) tau PET model. However, accuracy rate inflated large number stable individuals (1,257/1,629 = 77.2%), relatively easy model identify. AUPRCs base model 0.95, 0.41, 0.49 non-, slow-, fast decliners versus rest; 0.70 either slow- fast decliner vs stable (Supplementary Figure S3). AUPRCs tau PET model 0.92, 0.31, 0.56 non-, slow-, fast decliners versus rest; 0.71 either slow- fast decliner vs stable (Supplementary Figure S4). optimally-tuned classification tree without tau PET achieved mean balanced accuracy 0.63 (standard error 0.014) 10-fold cross-validation (Figure 4). Variable importance analysis identified baseline P-tau217 (56.2%), baseline PACC (15.5%), amyloid PET (13.1%), hippocampal atrophy (10.0%) important; though amyloid PET included tree, likely due correlation P-tau217. tree structure revealed hierarchical decision process participants baseline P-tau217 < 0.29 classified stable individuals, though miss-classifies N=155N=155 decliners. P-tau217 ≥\\geq 0.29 parsed hippocampal atrophy, PACC, P-tau217. one leaf contains majority fast decliners, contains 1% initial sample. tree demonstrates relative importance utility predictors, also demonstrates high degree miss-classification (31.4%). Cross-validated balanced accuracy improved addition tau PET (mean 0.70, standard error 0.011; Supplementary Figure S5). Tau PET second largest variable importance (22.5%), P-tau217 (29.8%) hippocampal atrophy (17.4%). tree tau PET results larger proportion leaves majority fast decliners (8.5% versus 1% without tau PET). () Figure 4: Classification tree analysis latent class assignment Base Model. () Relative importance baseline predictors class separation. (B) Classification tree showing binary decision rules assigning subjects latent classes based predictors. Terminal nodes show predicted class, number subjects, percentage total sample. optimal tree complexity determined using 10-fold cross-validation 1-standard error rule, resulting tree 6 splits (mean balanced accuracy = 0.63, standard error 0.007) characterize biological differences among latent trajectory groups, compared longitudinal changes amyloid PET, plasma P-tau217, tau PET (medial temporal neocortical), hippocampal volume across four classes (Figure 5). expected, slow fast decliners showed rapid biomarker progression across modalities, consistent steeper cognitive decline. contrast, Aβ– stable individuals demonstrated minimal change time biomarkers, supporting classification biologically clinically stable. Notably, Aβ+ stable individuals, despite showing PACC trajectories closely resembled Aβ– stable individuals, exhibited clear evidence biomarker progression, including increasing amyloid burden, rising plasma PET tau signals, accelerating hippocampal atrophy. findings suggest many Aβ+ stable individuals may represent earlier stage preclinical disease transition declining classes extended follow-, highlighting temporal dissociation biomarker progression short-term cognitive change. Figure 5: Longitudinal Biomarker Trajectories PACC Latent Class. panel displays individual biomarker trajectories (light lines) estimated mean trajectory (bold black line) linear mixed-effects model random slopes natural cubic spline fixed effects (2 degrees freedom). Columns correspond Aβ– stable, Aβ+ stable, slow decliner, fast decliner. Rows represent five longitudinal biomarkers: amyloid PET (Centiloids), plasma P-tau217 (U/mL), medial temporal lobe (MTL) tau PET SUVR, neocortical tau PET SUVR, hippocampal volume. Aβ– Aβ+ stable individuals demonstrate similarly stable cognitive trajectories, Aβ+ stable individuals exhibit clear biomarker progression across amyloid, tau, neurodegeneration measures, suggesting many may earlier stage preclinical disease transition declining classes longer follow-.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"study-participants","dir":"Articles","previous_headings":"","what":"Study Participants","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"total N=1,629N=1,629 participants included analytic sample base model (without tau PET), comprising N=1,110N=1,110 A4 Study N=519N=519 LEARN study. mean (standard deviation [SD]) age baseline 71.46 (4.69) years, 60.2% female. median follow-time 6.0 years (interquartile range 3.9 7.0). Baseline characteristics stratified latent class membership presented Table 1. total N=427N=427 individuals tau PET data submitted tau PET model. tau PET subset included N=372N=372 A4 Study N=55N=55 LEARN study. Baseline characteristics tau PET subset presented Supplementary Table S1. Table 1: Baseline Demographic, Clinical, Biomarker Characteristics Latent Class Cognitive Decline. Baseline characteristics participants classified latent class mixed model (LCMM) Preclinical Alzheimer’s Cognitive Composite (PACC) trajectories. Classes represent distinct longitudinal cognitive patterns: stable, slow decliner, fast decliner. Continuous variables presented mean (SD); categorical variables . (%). Abbreviations: APOE = apolipoprotein E; PET = positron emission tomography; P-tau217 = plasma phosphorylated tau 217; SUVr = standardized uptake value ratio; U/mL = arbitrary units proportional assay signal; . = American; PI = Pacific Islander; CDR = Clinical Dementia Rating; Prog. = Progressor. Footnotes: Amyloid PET tau PET SUVr values represent mean cortical uptake relative cerebellar reference region. Hippocampal atrophy residualized intracranial volume z-scored. Education reported years formal schooling. CDR Progressors observed CDR Global score greater zero two consecutive visits, last visit.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"characterization-and-prediction-of-latent-classes","dir":"Articles","previous_headings":"","what":"Characterization and Prediction of Latent Classes","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"Figure 1: Individual Mean PACC Trajectories Latent Class. Left panel (): Spaghetti plot individual participant trajectories Preclinical Alzheimer Cognitive Composite (PACC), colored latent class derived latent class mixed model (LCMM). line represents one participant’s observed scores time. Right panel (B): Estimated mean PACC trajectories latent class, shaded regions indicating 95% confidence intervals. Higher PACC scores indicate better cognitive performance. Figure 2: Distribution Baseline Demographic Biomarker Variables Latent Class Cognitive Decline. Sina plots show distribution selected baseline variables among latent classes identified latent class mixed model (LCMM) Preclinical Alzheimer’s Cognitive Composite (PACC) trajectories: stable, slow decliner, fast decliner. Variables include age, baseline PACC score, plasma phosphorylated tau 217 (P-tau217), amyloid positron emission tomography (PET) standardized uptake value ratio (SUVr), tau PET SUVr (subset tau PET available), hippocampal atrophy (volume normalized intracranial volume). dot represents individual participant; box plots represent quartiles. Higher PACC scores indicate better cognitive performance. Abbreviations: PET = positron emission tomography; P-tau217 = plasma phosphorylated tau 217; SUVr = standardized uptake value ratio; U/mL = arbitrary units proportional assay signal. Figure 3: Association Baseline Predictors Latent Class Membership Longitudinal Cognitive Decline Models Without Tau PET. Panels B display results latent class mixed model (LCMM) excluding tau PET; panels C D show corresponding results model including tau PET additional predictor. (, C) Odds ratios (95% CIs) LCMM class-membership submodel represent relative likelihood belonging slow- fast-declining classes relative stable class. (B, D) Standardized coefficients (95% CIs) LCMM longitudinal submodel show associations baseline predictors rate change Preclinical Alzheimer’s Cognitive Composite (PACC). continuous predictors PACC outcome standardized (z-scored) analysis enable comparison effect magnitudes. Higher PACC scores indicate better cognitive performance; thus, larger positive coefficients correspond slower decline better preservation cognition time. Individual base LCMM (excluding Tau PET) mean trajectories shown Figure 1. Model selection criteria identified model two degrees freedom three latent classes, labeled stable (77%), slow decliner (16%), fast decliner (7%). next best fitting model three classes three degrees freedom (Δ\\Delta BIC = 22.2, Δ\\Delta ICL = 22.2). best fitting Tau PET LCMM two degrees freedom three latent classes (Supplementary Figure S1) next best fitting model two classes two degrees freedom (Δ\\Delta BIC = 376.4, Δ\\Delta ICL = 336.9). two models largely agreed individual classifications. 7/427 (1.6%) individuals reclassified one model next, none fast decliners. Posterior class probabilities (Supplementary Figure S2) indicated good separation (mean posterior probability, 0.94), indicating model confidence class assignment. three classes significantly separated starting immediately baseline. base model, participants classified fast decliners started mean -0.98 (95% confidence interval [CI] -1.44 -0.52) PACC points declined mean -15.8 (95% CI -16.7 -15.0) six years. contrast stable individuals started mean 0.52 (95% CI 0.37 0.67) PACC points improved mean 1.16 (95% CI 1.00 1.31) six years. Slow decliners intermediate two classes starting mean -0.13 (95% CI -0.44 0.17) PACC points declining mean -4.74 (95% CI -5.22 -4.26). Clinical relevance PACC latent classes supported differences functional outcomes. proportion participants observed progress Clinical Dementia Rating (CDR) Global score increased monotonically across latent classes, lowest rate among stable individuals (22.8%) progressively higher rates among slow- (71.9%) fast-decliners (88.2%) (Table 1). However, discordance PACC latent class labels observed CDR progression common. CDR Global scores greater zero possible without indication memory issues, explains little discordance. Among CDR progressors, proportion individuals CDR Memory Box score zero 8.4% PACC stable individuals, 5.5% slow decliners, 4.8% fast decliners. distribution continuous baseline variables latent class shown Figure 2 Figure 3 summarizes standardized coefficients 95% CIs components LCMM. Figure 3 Panels C depicts odds ratios (ORs) class membership submodels base model tau PET model. Continuous predictors standardized ORs reflect change odds belonging fast- slow declining class compared stable class per one SD increase continuous baseline predictor. base model (Panel ), higher plasma P-tau217 levels (3.2, 95% CI 2.4 4.1), elevated amyloid PET centiloid (1.4, 95% CI 1.0 1.9), greater hippocampal atrophy scores (3.9, 95% CI 2.7 5.6) associated increased odds belonging faster-declining classes. Interestingly, P-tau217 hippocampal atrophy numerically stronger effects amyloid PET. Also interest, fast decliners numerically younger (mean 73.1 years, SD 4.7), average, slow decliners (mean 74.1 years, SD 5.2) increased age associated membership slow declining group (1.4, 95% CI 1.1 1.7) fast declining group (0.93, 95% CI 0.69 1.2). Tau PET model results largely similar, confidence intervals wider, likely due smaller available sample (N=427N=427 vs N=1,629N=1,629). Increased tau PET associated increased odds slow- (= 1.8, 95% CI 1.2 2.8) fast-declining groups (= 3.6, 95% CI 2.1 6.1). Figure 3 Panels B D presents standardized coefficients longitudinal submodels, representing associations covariate PACC outcome. Higher PACC scores correspond better cognitive performance continuous variables standardized oriented positive coefficients indicate better performance. see females increased risk fast decliners (2.5, 95% CI 1.5 4.4), better PACC performance given class membership (0.30 PACC points, 95% CI 0.24 0.35). APOE ϵ4\\epsilon 4 carriage associated increased risk slow (1.9, 95% CI 1.3 2.8) fast (2.9, 95% CI 1.6 5.3) declining class versus stable class, negligible remaining effect PACC. Education effect class membership, associated better PACC performance (0.12 PACC points per SD education, 95% CI 0.095 0.15).","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"predictive-performance-and-cross-validation","dir":"Articles","previous_headings":"","what":"Predictive Performance and Cross-Validation","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"overall cross-validated accuracy 0.80 (95% CI 0.79 0.82) base model 0.756 (95% CI 0.73 0.78) tau PET model. However, accuracy rate inflated large number stable individuals (1,257/1,629 = 77.2%), relatively easy model identify. AUPRCs base model 0.95, 0.41, 0.49 non-, slow-, fast decliners versus rest; 0.70 either slow- fast decliner vs stable (Supplementary Figure S3). AUPRCs tau PET model 0.92, 0.31, 0.56 non-, slow-, fast decliners versus rest; 0.71 either slow- fast decliner vs stable (Supplementary Figure S4).","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"post-hoc-regression-tree","dir":"Articles","previous_headings":"","what":"Post-hoc Regression Tree","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"optimally-tuned classification tree without tau PET achieved mean balanced accuracy 0.63 (standard error 0.014) 10-fold cross-validation (Figure 4). Variable importance analysis identified baseline P-tau217 (56.2%), baseline PACC (15.5%), amyloid PET (13.1%), hippocampal atrophy (10.0%) important; though amyloid PET included tree, likely due correlation P-tau217. tree structure revealed hierarchical decision process participants baseline P-tau217 < 0.29 classified stable individuals, though miss-classifies N=155N=155 decliners. P-tau217 ≥\\geq 0.29 parsed hippocampal atrophy, PACC, P-tau217. one leaf contains majority fast decliners, contains 1% initial sample. tree demonstrates relative importance utility predictors, also demonstrates high degree miss-classification (31.4%). Cross-validated balanced accuracy improved addition tau PET (mean 0.70, standard error 0.011; Supplementary Figure S5). Tau PET second largest variable importance (22.5%), P-tau217 (29.8%) hippocampal atrophy (17.4%). tree tau PET results larger proportion leaves majority fast decliners (8.5% versus 1% without tau PET). () Figure 4: Classification tree analysis latent class assignment Base Model. () Relative importance baseline predictors class separation. (B) Classification tree showing binary decision rules assigning subjects latent classes based predictors. Terminal nodes show predicted class, number subjects, percentage total sample. optimal tree complexity determined using 10-fold cross-validation 1-standard error rule, resulting tree 6 splits (mean balanced accuracy = 0.63, standard error 0.007)","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"longitudinal-biomarker-progression-across-latent-classes","dir":"Articles","previous_headings":"","what":"Longitudinal Biomarker Progression Across Latent Classes","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"characterize biological differences among latent trajectory groups, compared longitudinal changes amyloid PET, plasma P-tau217, tau PET (medial temporal neocortical), hippocampal volume across four classes (Figure 5). expected, slow fast decliners showed rapid biomarker progression across modalities, consistent steeper cognitive decline. contrast, Aβ– stable individuals demonstrated minimal change time biomarkers, supporting classification biologically clinically stable. Notably, Aβ+ stable individuals, despite showing PACC trajectories closely resembled Aβ– stable individuals, exhibited clear evidence biomarker progression, including increasing amyloid burden, rising plasma PET tau signals, accelerating hippocampal atrophy. findings suggest many Aβ+ stable individuals may represent earlier stage preclinical disease transition declining classes extended follow-, highlighting temporal dissociation biomarker progression short-term cognitive change. Figure 5: Longitudinal Biomarker Trajectories PACC Latent Class. panel displays individual biomarker trajectories (light lines) estimated mean trajectory (bold black line) linear mixed-effects model random slopes natural cubic spline fixed effects (2 degrees freedom). Columns correspond Aβ– stable, Aβ+ stable, slow decliner, fast decliner. Rows represent five longitudinal biomarkers: amyloid PET (Centiloids), plasma P-tau217 (U/mL), medial temporal lobe (MTL) tau PET SUVR, neocortical tau PET SUVR, hippocampal volume. Aβ– Aβ+ stable individuals demonstrate similarly stable cognitive trajectories, Aβ+ stable individuals exhibit clear biomarker progression across amyloid, tau, neurodegeneration measures, suggesting many may earlier stage preclinical disease transition declining classes longer follow-.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"discussion","dir":"Articles","previous_headings":"","what":"Discussion","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"latent class mixed-model analysis cognitively unimpaired older adults, identified distinct trajectories PACC performance evaluated extent plasma imaging biomarkers prospectively distinguished individuals remained cognitively stable showed slow rapid decline. Several findings highlight challenges prognostic modeling preclinical stage Alzheimer disease direct implications secondary prevention trial design. Although plasma P-tau217 amyloid PET associated latent class membership, neither biomarker alone, combination, achieved high accuracy predicting cognitive decline. key observation high frequency cognitive stability among amyloid-positive participants. shown Table 1, 776 1,110 amyloid-positive A4 participants (69.9%) classified stable individuals, indicating substantial amyloid burden necessarily translate measurable cognitive change timescales typical prevention trials. However, consistent pre-symptomatic phase disease believed last long 15 years. Compared 30.1% amyloid-positive individuals classified decliners, small minority amyloid-negative LEARN participants classified decliners. Thirty-eight 519 (7.3%) amyloid-negative individuals classified slow fast decliners, suggesting causes decline may reflect non–AD processes, early AD pathology PET detection thresholds baseline accumulated 5 year period, cognitive measurement variability. findings reinforce amyloid positivity, necessary defining AD pathophysiologic continuum, insufficient standalone predictor short- intermediate-term cognitive decline. Plasma P-tau217 demonstrated stronger prognostic associations amyloid PET, consistent biomarker models positioning tau abnormalities closer symptom onset. observation aligns prior reports, showing improved prognostic accuracy plasma tau markers.5 However, classification tree analyses indicated single P-tau217 threshold meaningfully enriched decliners without simultaneously excluding many true decliners, underscoring limitations threshold-based enrichment strategies. Tau PET provided incremental predictive value beyond plasma P-tau217 amyloid PET, although gains modest. tau PET captures later-stage pathologic changes, results biologically plausible. Nevertheless, logistical financial limitations tau PET constrain feasibility routine screening tool large-scale prevention trials. findings several implications design interpretation secondary prevention trials preclinical Alzheimer disease. Participant Selection. majority amyloid-positive individuals remained cognitively stable, restricting eligibility based solely amyloid positivity invariably enroll many stable individuals, reducing statistical power cognitive endpoints. Plasma P-tau217 may aid enrichment insufficient isolate predominantly decliner cohort. complex multimodal strategies repeated biomarker assessments may required achieve adequate prognostic discrimination. Modeling Treatment Effects Heterogeneous Cohorts. Latent class distinctions complicate assumptions expected treatment benefit. Fast decliners may show larger measurable benefit yet may represent individuals along disease continuum. Stable individuals present additional challenge: stability limits detectable cognitive benefit even biological effects occur. Power simulations trial analyses may therefore need incorporate class-specific trajectories assume differential treatment effects across latent classes. Added Value Tau PET. Although tau PET contributed additional predictive information, incremental value must interpreted context feasibility. future enrichment, tau-PET-based staging may offer specific approach identifying individuals closer clinical transition, though widespread implementation prevention trials remains challenging. Outcome Selection. limited cognitive change observed stable individuals raises important questions sensitivity traditional cognitive outcomes early stage AD. individuals, early synaptic dysfunction, measured learning curves assessed daily digital testing,14 /biological endpoints (e.g., plasma tau PET measures) may provide responsive markers treatment effect may serve important secondary exploratory outcomes. Nonetheless, given evidence tau PET closely linked concurrent future cognitive decline amyloid biomarkers,15 plausible longitudinal tau PET, plasma P-tau217, may offer greater utility monitoring treatment response detecting early trajectory divergence. Future work applying latent class related trajectory models longitudinal biomarker measures may help clarify whether biomarker-defined progressors can identified earlier reliably cognitive progressors. Early Intervention. symptomatic disease, observed anti-amyloid therapies can demonstrate larger benefits less tau pathology16, supporting theory earlier intervention yield greater benefit. presymptomatic decline unfolds gradually decade , treatment trials beginning relatively early trajectory may struggle demonstrate delay cognitive change within feasible trial windows. Accordingly, refining validating sensitive digital /biomarker-based endpoints essential advancing preclinical therapy development. Sensitive, reproducible measures target engagement disease progression improve enrichment, increase statistical power, enable detection treatment effects even among participants remain cognitively stable. summary, data-driven cognitive trajectories among initially unimpaired older adults exhibited substantial heterogeneity, widely used biomarkers, including plasma P-tau217 amyloid PET, partially effective predicting decline time frame prevention trial. limitations highlight need improved prognostic tools, potentially incorporating longitudinal biomarker dynamics, multimodal risk models, digital assessments. , secondary prevention trials must account substantial heterogeneity cognitive trajectories planning enrollment, power calculations, trial simulations, analytic strategies. study several strengths. leveraged large, deeply phenotyped cohort cognitively unimpaired older adults longitudinal cognitive assessments harmonized biomarker data, using A4LEARN R package standardize reproducibly analyze data across A4 LEARN cohorts. latent class mixed-model approach allowed us identify data-driven cognitive trajectories rather relying predefined thresholds single-outcome definitions decline. inclusion plasma P-tau217, amyloid PET, , within subset, tau PET enabled evaluation multiple biomarkers spanning distinct phases Alzheimer disease pathophysiology. study also limitations. First, although latent class methods improve characterization heterogeneity, class assignments probabilistic sensitive model specification. Second, follow-duration, substantial, may still insufficient capture long-term cognitive change among stable individuals. Third, tau PET available subset, limiting statistical power comparisons involving biomarker potentially reducing generalizability. Fourth, although examined broad panel covariates, unmeasured factors, including comorbidities, lifestyle variables, scanner-related differences, may influence biomarker levels cognitive outcomes. Finally, highly selected sample individuals either eligible A4 study, ineligible owing low amyloid PET signal, may fully represent community-dwelling older adults.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"available-predictors-only-partially-discriminate-future-decline","dir":"Articles","previous_headings":"","what":"Available Predictors Only Partially Discriminate Future Decline","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"Although plasma P-tau217 amyloid PET associated latent class membership, neither biomarker alone, combination, achieved high accuracy predicting cognitive decline. key observation high frequency cognitive stability among amyloid-positive participants. shown Table 1, 776 1,110 amyloid-positive A4 participants (69.9%) classified stable individuals, indicating substantial amyloid burden necessarily translate measurable cognitive change timescales typical prevention trials. However, consistent pre-symptomatic phase disease believed last long 15 years. Compared 30.1% amyloid-positive individuals classified decliners, small minority amyloid-negative LEARN participants classified decliners. Thirty-eight 519 (7.3%) amyloid-negative individuals classified slow fast decliners, suggesting causes decline may reflect non–AD processes, early AD pathology PET detection thresholds baseline accumulated 5 year period, cognitive measurement variability. findings reinforce amyloid positivity, necessary defining AD pathophysiologic continuum, insufficient standalone predictor short- intermediate-term cognitive decline.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"relative-contributions-of-plasma-p-tau217-and-tau-pet","dir":"Articles","previous_headings":"","what":"Relative Contributions of Plasma P-tau217 and Tau PET","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"Plasma P-tau217 demonstrated stronger prognostic associations amyloid PET, consistent biomarker models positioning tau abnormalities closer symptom onset. observation aligns prior reports, showing improved prognostic accuracy plasma tau markers.5 However, classification tree analyses indicated single P-tau217 threshold meaningfully enriched decliners without simultaneously excluding many true decliners, underscoring limitations threshold-based enrichment strategies. Tau PET provided incremental predictive value beyond plasma P-tau217 amyloid PET, although gains modest. tau PET captures later-stage pathologic changes, results biologically plausible. Nevertheless, logistical financial limitations tau PET constrain feasibility routine screening tool large-scale prevention trials.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"implications-for-secondary-prevention-trial-design","dir":"Articles","previous_headings":"","what":"Implications for Secondary Prevention Trial Design","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"findings several implications design interpretation secondary prevention trials preclinical Alzheimer disease. Participant Selection. majority amyloid-positive individuals remained cognitively stable, restricting eligibility based solely amyloid positivity invariably enroll many stable individuals, reducing statistical power cognitive endpoints. Plasma P-tau217 may aid enrichment insufficient isolate predominantly decliner cohort. complex multimodal strategies repeated biomarker assessments may required achieve adequate prognostic discrimination. Modeling Treatment Effects Heterogeneous Cohorts. Latent class distinctions complicate assumptions expected treatment benefit. Fast decliners may show larger measurable benefit yet may represent individuals along disease continuum. Stable individuals present additional challenge: stability limits detectable cognitive benefit even biological effects occur. Power simulations trial analyses may therefore need incorporate class-specific trajectories assume differential treatment effects across latent classes. Added Value Tau PET. Although tau PET contributed additional predictive information, incremental value must interpreted context feasibility. future enrichment, tau-PET-based staging may offer specific approach identifying individuals closer clinical transition, though widespread implementation prevention trials remains challenging. Outcome Selection. limited cognitive change observed stable individuals raises important questions sensitivity traditional cognitive outcomes early stage AD. individuals, early synaptic dysfunction, measured learning curves assessed daily digital testing,14 /biological endpoints (e.g., plasma tau PET measures) may provide responsive markers treatment effect may serve important secondary exploratory outcomes. Nonetheless, given evidence tau PET closely linked concurrent future cognitive decline amyloid biomarkers,15 plausible longitudinal tau PET, plasma P-tau217, may offer greater utility monitoring treatment response detecting early trajectory divergence. Future work applying latent class related trajectory models longitudinal biomarker measures may help clarify whether biomarker-defined progressors can identified earlier reliably cognitive progressors. Early Intervention. symptomatic disease, observed anti-amyloid therapies can demonstrate larger benefits less tau pathology16, supporting theory earlier intervention yield greater benefit. presymptomatic decline unfolds gradually decade , treatment trials beginning relatively early trajectory may struggle demonstrate delay cognitive change within feasible trial windows. Accordingly, refining validating sensitive digital /biomarker-based endpoints essential advancing preclinical therapy development. Sensitive, reproducible measures target engagement disease progression improve enrichment, increase statistical power, enable detection treatment effects even among participants remain cognitively stable.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"overall-interpretation","dir":"Articles","previous_headings":"","what":"Overall Interpretation","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"summary, data-driven cognitive trajectories among initially unimpaired older adults exhibited substantial heterogeneity, widely used biomarkers, including plasma P-tau217 amyloid PET, partially effective predicting decline time frame prevention trial. limitations highlight need improved prognostic tools, potentially incorporating longitudinal biomarker dynamics, multimodal risk models, digital assessments. , secondary prevention trials must account substantial heterogeneity cognitive trajectories planning enrollment, power calculations, trial simulations, analytic strategies.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"strengths-and-limitations","dir":"Articles","previous_headings":"","what":"Strengths and Limitations","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"study several strengths. leveraged large, deeply phenotyped cohort cognitively unimpaired older adults longitudinal cognitive assessments harmonized biomarker data, using A4LEARN R package standardize reproducibly analyze data across A4 LEARN cohorts. latent class mixed-model approach allowed us identify data-driven cognitive trajectories rather relying predefined thresholds single-outcome definitions decline. inclusion plasma P-tau217, amyloid PET, , within subset, tau PET enabled evaluation multiple biomarkers spanning distinct phases Alzheimer disease pathophysiology. study also limitations. First, although latent class methods improve characterization heterogeneity, class assignments probabilistic sensitive model specification. Second, follow-duration, substantial, may still insufficient capture long-term cognitive change among stable individuals. Third, tau PET available subset, limiting statistical power comparisons involving biomarker potentially reducing generalizability. Fourth, although examined broad panel covariates, unmeasured factors, including comorbidities, lifestyle variables, scanner-related differences, may influence biomarker levels cognitive outcomes. Finally, highly selected sample individuals either eligible A4 study, ineligible owing low amyloid PET signal, may fully represent community-dwelling older adults.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"conclusions","dir":"Articles","previous_headings":"","what":"Conclusions","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"Among cognitively unimpaired older adults, cognitive trajectories showed marked heterogeneity, widely used biomarkers, including plasma P-tau217 amyloid PET, partially effective distinguishing decline. Tau PET provided modest additional predictive value remains impractical widespread enrichment. findings highlight challenge prospectively identifying decliners preclinical Alzheimer disease underscore need improved multimodal prognostic tools. Secondary prevention trials account substantial heterogeneity cognitive trajectories developing enrollment strategies, powering cognitive endpoints, interpreting treatment effects.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"acknowledgements","dir":"Articles","previous_headings":"","what":"Acknowledgements","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"authors like thank A4 LEARN Study Teams site principal investigators staff. Special gratitude A4 LEARN participants study partners, without studies possible. Funding: A4 LEARN Studies supported public-private-philanthropic partnership included funding National Institute Aging National Institutes Health (R01 AG063689, U19AG010483 U24AG057437), Eli Lilly (also supplier active medication placebo), Alzheimer’s Association, Accelerating Medicines Partnership Foundation National Institutes Health, GHR Foundation, Davis Alzheimer Prevention Program, Yugilbar Foundation, anonymous foundation, additional private donors Brigham Women’s Hospital, -kind support Avid Radiopharmaceuticals, Cogstate, Albert Einstein College Medicine Foundation Neurologic Diseases. Conflict Interest Disclosures: Dr Aisen reported personal fees Merck, Biogen, Roche, AbbVie, ImmunoBrain Checkpoint, Bristol Myers Squibb, Neurimmune grants Eisai outside submitted work. Dr Sperling reported consulting fees AbbVie, AC Immune, Acumen, Alector, Apellis, Biohaven, Bristol Myers Squibb, Genentech, Janssen, Nervgen, Oligomerixg, Prothena, Roche, Vigil Neuroscience, Ionis, Vaxxinity outside submitted work. Dr Donohue reported personal fees Roche (consultant) Janssen Pharmaceuticals (spouse full-time employee) outside submitted work. Dr Raman reported grants American Heart Association, Gates Ventures, Eisai, Alzheimer’s Association. disclosures reported.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/articles/A4LEARN-Latent-Classes.html","id":"supplementary-material","dir":"Articles","previous_headings":"","what":"Supplementary Material","title":"Divergent latent classes of cognitive decline in the A4 and LEARN studies","text":"Supplementary Table S1: Baseline Demographic, Clinical, Biomarker Characteristics Latent Class Cognitive Decline Tau PET. Baseline characteristics participants classified latent class mixed model (LCMM) Preclinical Alzheimer’s Cognitive Composite (PACC) trajectories. Classes represent distinct longitudinal cognitive patterns: stable, slow decliner, fast decliner. Continuous variables presented mean (SD); categorical variables . (%). Abbreviations: APOE = apolipoprotein E; PET = positron emission tomography; P-tau217 = plasma phosphorylated tau 217; SUVr = standardized uptake value ratio; U/mL = arbitrary units proportional assay signal; . = American; PI = Pacific Islander; CDR = Clinical Dementia Rating; Prog. = Progressor. Footnotes: Amyloid PET tau PET SUVr values represent mean cortical uptake relative cerebellar reference region. Hippocampal atrophy residualized intracranial volume z-scored. Education reported years formal schooling. CDR Progressors observed CDR Global score greater zero two consecutive visits, last visit.  Supplementary Figure S1: Individual Mean PACC Trajectories Latent Class Model Tau PET. Left panel (): Spaghetti plot individual participant trajectories Preclinical Alzheimer Cognitive Composite (PACC), colored latent class derived latent class mixed model (LCMM) included tau PET predictor. line represents one participant’s observed scores time. Right panel (B): Estimated mean PACC trajectories latent class, shaded regions indicating 95% confidence intervals. Higher PACC scores indicate better cognitive performance. Abbreviations: PET = positron emission tomography.  Supplementary Figure S2: Distribution posterior class membership probabilities assigned latent class, indicating model confidence class assignment. plot shows degree certainty class assignments, good indicator model reliability. Mean posterior probabilities {r}pp_sum[[1,2]], {r}pp_sum[[2,2]], {r}pp_sum[[3,2]] non-, slow-, fast decliners. participants high posterior probabilities (>0.8>0.8) assigned class, class separation strong predictive discrimination good.  Supplementary Figure S3: Cross-validated Precision-Recall Curves Latent Class Membership Model Without Tau PET. Precision-recall curves summarizing 10-fold cross-validated classification performance latent class membership submodel based baseline demographics biomarkers, excluding tau PET. Curves depict ability distinguish given class two. area precision-recall curve (AUPRC) quantifies overall predictive performance, emphasizing recall (sensitivity, TP/(TP+FN)) precision (TP/(TP+FP)) less prevalent classes. Abbreviations: AUPRC = area precision-recall curve; TP = true positive rate; FN = false negative rate; FP = false positive rate.  Supplementary Figure S4: Cross-validated Precision-Recall Curves Latent Class Membership Model Tau PET. Precision-recall curves summarizing 10-fold cross-validated classification performance latent class membership submodel based baseline demographics biomarkers, excluding tau PET. Curves depict ability distinguish given class two. area precision-recall curve (AUPRC) quantifies overall predictive performance, emphasizing recall (sensitivity, TP/(TP+FN)) precision (TP/(TP+FP)) less prevalent classes. Abbreviations: AUPRC = area precision-recall curve; TP = true positive rate; FN = false negative rate; FP = false positive rate.  Supplementary Figure S5: Classification tree analysis latent class assignment Tau PET Model. () Relative importance baseline characteristics class separation. (B) Classification tree showing binary decision rules assigning subjects latent classes based baseline characteristics. Terminal nodes show predicted class, number subjects, percentage total sample. optimal tree complexity determined using 10-fold cross-validation 1-standard error rule, resulting tree 6 splits (mean balanced accuracy = 0.70, standard error 0.011).","code":""},{"path":[]},{"path":"https://atri-biostats.github.io/A4LEARN/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"ATRI Biostatistics. Author, maintainer.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"ATRI Biostatistics (2025). A4LEARN: A4LEARN Study Package. R package version 1.1.20250808, https://www.a4studydata.org.","code":"@Manual{,   title = {A4LEARN: A4LEARN Study Package},   author = {{ATRI Biostatistics}},   year = {2025},   note = {R package version 1.1.20250808},   url = {https://www.a4studydata.org}, }"},{"path":[]},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"overview","dir":"","previous_headings":"","what":"Overview","title":"A4LEARN Study Package","text":"A4LEARN R package containing data code reproduce results Anti-Amyloid Treatment Asymptomatic Alzheimer’s (A4) study (Sperling et al. 2023) Longitudinal Evaluation Amyloid Risk Neurodegeneration (LEARN) study (Sperling et al. 2024). A4LEARN bundle clinical data, analysis code examples, html pdf documentation. Documentation can found https://atri-biostats.github.io/A4LEARN/. data, including A4LEARN R package, available either: https://www.a4studydata.org/ registering agreeing terms use. https://www.synapse.org/a4_learn_datasharing/ registering account, fulfilling actions ‘Access Actions Required’ tab download cart, adding files download.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"installation","dir":"","previous_headings":"","what":"Installation","title":"A4LEARN Study Package","text":"install A4LEARN: Register https://www.a4studydata.org/ https://www.synapse.org/a4_learn_datasharing/ Download A4LEARN_1.1.20250808.tar.gz preferred data sharing platform R, run install.packages(\"path//A4LEARN_1.1.20250808.tar.gz\", repos = NULL, type = \"source\") script build R package can found tools.","code":""},{"path":[]},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"load-required-r-packages","dir":"","previous_headings":"","what":"Load required R packages","title":"A4LEARN Study Package","text":"","code":"library(tidyverse) library(arsenal) library(kableExtra) library(nlme) library(emmeans) library(splines) library(clubSandwich) library(A4LEARN)  formatp <- function(x) case_when(   x < 0.001 ~ \"p<0.001\",   x > 0.01 ~ Hmisc::format.pval(x, digits=2, eps=0.01, nsmall=2),   TRUE ~ Hmisc::format.pval(x, digits=3, eps=0.001, nsmall=3))"},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"organize-data","dir":"","previous_headings":"","what":"Organize data","title":"A4LEARN Study Package","text":"","code":"# Outcomes collected at Visit 1 V1OUTCOME <- A4LEARN::ADQS %>%   dplyr::filter(VISITCD == \"001\") %>%   select(BID, QSTESTCD, QSSTRESN) %>%   pivot_wider(values_from = QSSTRESN, names_from = QSTESTCD)  # Outcomes collected at Visit 6 V6OUTCOME <- A4LEARN::ADQS %>%   dplyr::filter(VISITCD == \"006\") %>%   select(BID, QSTESTCD, QSSTRESN) %>%   pivot_wider(values_from = QSSTRESN, names_from = QSTESTCD)  SUBJINFO <- A4LEARN::SUBJINFO %>%   left_join(V6OUTCOME, by = \"BID\") %>%   left_join(V1OUTCOME %>%       select(BID, CDRSB, CFITOTAL, CFISP, CFIPT, ADLPQPT, ADLPQSP),      by = \"BID\")  # Filter A4LEARN::ADQS for PACC collected in the blinded phases among mITT population ADQS_PACC <- A4LEARN::ADQS %>%   dplyr::filter(MITTFL== 1) %>%   dplyr::filter(EPOCH == \"BLINDED TREATMENT\" | AVISIT == \"006\") %>%   dplyr::filter(QSTESTCD == \"PACC\") %>%   rename(PACC = QSSTRESN) %>%   select(BID, ASEQNCS, TX, ADURW, TX, AGEYR,      AAPOEGNPRSNFLG, EDCCNTU, SUVRCER, QSVERSION, PACC) %>%   mutate(TX = factor(TX, levels = c(\"Placebo\", \"Solanezumab\"))) %>%   arrange(BID, ADURW) %>%   na.omit()"},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"baseline-characteristics-of-the-a4-trial","dir":"","previous_headings":"","what":"Baseline characteristics of the A4 trial","title":"A4LEARN Study Package","text":"Characteristics A4 participants randomized treatment group (Modified Intention--Treat Population received least one dose solanezumab placebo underwent assessment primary end point).","code":"A4labels <- list(TX = \"Treatment group\", AGEYR = \"Age (y)\",    EDCCNTU = \"Education (y)\", SUVRCER = \"FBP SUVr\", AMYLCENT = \"FBP Centiloid\",    LMIIa = \"LM Delayed Recall\",  MMSE = \"MMSE\",    CFITOTAL = \"CFI Combined\", ADLPQSP = \"ADL Partner\", CDRSB = \"CDR-SB\",   SEX = \"Sex\", RACE = \"Racial categories\", ETHNIC = \"Ethnicity\",    MARITAL = \"Marital Status\",  WRKRET = \"Retirement Status\",    APOEGNPRSNFLG = \"APOE e4\", APOEGN = \"APOE Genotype\")  table1 <- tableby(TX ~ AGEYR + EDCCNTU + SEX + RACE + ETHNIC + MARITAL + WRKRET +      SUVRCER + AMYLCENT + chisq(APOEGN) + chisq(APOEGNPRSNFLG) +      PACC + LMIIa + MMSE + CFITOTAL + ADLPQSP + CDRSB,    data = SUBJINFO %>% dplyr::filter(MITTFL== 1),    control = tableby.control(test=TRUE,     stats.labels = list(Nmiss = \"Missing\")))  summary(table1, labelTranslations = A4labels, digits = 1,   title = \"Characteristics of the A4 participants by randomized treatment group (Modified Intention-to-Treat Population of those who received at least one dose of solanezumab or placebo and underwent assessment for the primary end point).\")"},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"primary-analyis-of-the-pacc","dir":"","previous_headings":"","what":"Primary analyis of the PACC","title":"A4LEARN Study Package","text":"Preclinical Alzheimer Cognitive Composite (PACC, Donohue et al. (2014)) data modeled using natural cubic splines described Donohue et al. (2023). fixed effects included following terms: () spline basis expansion terms (two terms), (ii) spline basis expansion terms--treatment interaction (two terms), (iii) PACC test version administered, (iv) baseline age, (v) education, (vi) APOE4 Carrier Status (yes/), (vii) baseline florbetapir cortical SUVr. model constrained allow difference treatment group means baseline. following variance-covariance structures assumed sequence model converged: () heterogeneous unstructured, (ii) heterogeneous Toeplitz, (iii) heterogeneous autoregressive order 1, (iv) heterogeneous compound symmetry, (v) compound symmetry. first structure, heterogeneous unstructured, converge. fit second, heterogeneous Toeplitz, converge. Spaghetti plot PACC data time treatment group. Mean PACC change baseline week 240 treatment group estimated spline model. Mean PACC group change baseline week 240 treatment group estimated spline model. Mean PACC per treatment group time estimated spline model. Shaded region depicts 95% confidence intervals.","code":"ggplot(ADQS_PACC, aes(x=ADURW, y=PACC, color=TX)) +   geom_line(aes(group = BID), alpha=0.2) +   theme(legend.position = \"inside\", legend.position.inside = c(0.2, 0.2)) +   xlab(\"Weeks since Randomization\") +   scale_x_continuous(breaks = seq(0, max(ADQS_PACC$ADURW), by = 24)) # Spline basis expansion functions # CAUTION: these function depend on the ADQS_PACC data frame object in the  # global environment. If ADQS_PACC changes, so do these funtions ns21 <- function(t){   as.numeric(predict(splines::ns(ADQS_PACC$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_PACC$ADURW))), t)[,1]) } ns22 <- function(t){   as.numeric(predict(splines::ns(ADQS_PACC$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_PACC$ADURW))), t)[,2]) }  assign(\"ns21\", ns21, envir = .GlobalEnv) assign(\"ns22\", ns22, envir = .GlobalEnv)  # GLS model fit: pacc_fit <- gls(PACC ~      I(ns21(ADURW)) + I(ns22(ADURW)) +     (I(ns21(ADURW)) + I(ns22(ADURW))):TX +      AGEYR + AAPOEGNPRSNFLG + EDCCNTU + SUVRCER + QSVERSION,   data = ADQS_PACC,   weights = varIdent(form = ~ 1 | ASEQNCS),   correlation = corARMA(form = ~ ASEQNCS | BID, p = 10)) ref_grid(pacc_fit,   at = list(ADURW = c(0,240), TX = levels(ADQS_PACC$TX)),   vcov. = clubSandwich::vcovCR(pacc_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_PACC,    mode = \"satterthwaite\") %>%   emmeans(~ ADURW | TX) %>%   pairs(reverse = TRUE) %>%   as_tibble() %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean PACC change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") contrast240 <- ref_grid(pacc_fit,    at = list(ADURW = 240, TX = levels(ADQS_PACC$TX)),   vcov. = clubSandwich::vcovCR(pacc_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_PACC,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   pairs(reverse = TRUE, adjust = \"none\")  contrast240 %>%    as_tibble() %>%   left_join(contrast240 %>%        confint() %>%       as_tibble() %>%       select(contrast, lower.CL, upper.CL), by=\"contrast\") %>%   relocate(p.value, .after = last_col()) %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean PACC group change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") ref_grid(pacc_fit,    at = list(ADURW = seq(0, 312, by=12), TX = levels(ADQS_PACC$TX)),   vcov. = clubSandwich::vcovCR(pacc_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_PACC,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   as_tibble() %>%   ggplot(aes(x=ADURW, y=emmean)) +   geom_line(aes(color=TX)) +   geom_ribbon(aes(ymin = lower.CL, ymax = upper.CL, fill = TX), alpha = 0.2) +   scale_x_continuous(breaks = seq(0, 312, by=24)) +   ylab(\"Mean PACC with 95% confidence intervals\") +   xlab(\"Weeks since Randomization\") +   theme(legend.position = 'inside', legend.position.inside = c(0.2, 0.2))"},{"path":"https://atri-biostats.github.io/A4LEARN/index.html","id":"primary-analyis-of-the-cfi","dir":"","previous_headings":"","what":"Primary analyis of the CFI","title":"A4LEARN Study Package","text":"Spaghetti plot CFI data time treatment group. Mean CFI change baseline week 240 treatment group estimated spline model. Mean CFI group change baseline week 240 treatment group estimated spline model. Mean CFI per treatment group time estimated spline model. Shaded region depicts 95% confidence intervals.","code":"# Filter A4LEARN::ADQS for CFITOTAL collected in the blinded phases among mITT population ADQS_CFI <- A4LEARN::ADQS %>%   dplyr::filter(MITTFL== 1) %>%   dplyr::filter(EPOCH == \"BLINDED TREATMENT\" | AVISIT == \"001\") %>%   dplyr::filter(QSTESTCD == \"CFITOTAL\") %>%   select(BID, ASEQNCS, TX, ADURW, TX, AGEYR,      AAPOEGNPRSNFLG, EDCCNTU, SUVRCER, QSSTRESN) %>%   mutate(TX = factor(TX, levels = c(\"Placebo\", \"Solanezumab\"))) %>%   arrange(BID, ADURW) %>%   na.omit() ggplot(ADQS_CFI, aes(x=ADURW, y=QSSTRESN, color=TX)) +   geom_line(aes(group = BID), alpha=0.2) +   theme(legend.position = \"inside\", legend.position.inside = c(0.2, 0.9)) +   xlab(\"Weeks since Randomization\") +   ylab(\"CFI Participant and Partner\") scale_x_continuous(breaks = seq(0, max(ADQS_CFI$ADURW), by = 24)) <ScaleContinuousPosition>  Range:    Limits:    0 --    1 # Spline basis expansion functions # CAUTION: these function depend on the ADQS_CFI data frame object in the  # global environment. If ADQS_CFI changes, so do these funtions ns21 <- function(t){   as.numeric(predict(splines::ns(ADQS_CFI$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_CFI$ADURW))), t)[,1]) } ns22 <- function(t){   as.numeric(predict(splines::ns(ADQS_CFI$ADURW, df=2,     Boundary.knots = c(0, max(ADQS_CFI$ADURW))), t)[,2]) }  assign(\"ns21\", ns21, envir = .GlobalEnv) assign(\"ns22\", ns22, envir = .GlobalEnv)  # GLS model fit: cfi_fit <- gls(QSSTRESN ~      I(ns21(ADURW)) + I(ns22(ADURW)) +     (I(ns21(ADURW)) + I(ns22(ADURW))):TX +      AGEYR + AAPOEGNPRSNFLG + EDCCNTU + SUVRCER,   data = ADQS_CFI,   weights = varIdent(form = ~ 1 | ASEQNCS),   correlation = corARMA(form = ~ ASEQNCS | BID, p = 5)) ref_grid(cfi_fit,   at = list(ADURW = c(0,240), TX = levels(ADQS_CFI$TX)),   vcov. = clubSandwich::vcovCR(cfi_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_CFI,    mode = \"satterthwaite\") %>%   emmeans(~ ADURW | TX) %>%   pairs(reverse = TRUE) %>%   as_tibble() %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean CFI change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") contrast240 <- ref_grid(cfi_fit,    at = list(ADURW = 240, TX = levels(ADQS_CFI$TX)),   vcov. = clubSandwich::vcovCR(cfi_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_CFI,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   pairs(reverse = TRUE, adjust = \"none\")  contrast240 %>%    as_tibble() %>%   left_join(contrast240 %>%        confint() %>%       as_tibble() %>%       select(contrast, lower.CL, upper.CL), by=\"contrast\") %>%   relocate(p.value, .after = last_col()) %>%   mutate(p.value = formatp(p.value)) %>%   kable(caption = \"Mean CFI group change from baseline at week 240 by treatment      group estimated from spline model.\", digits = 2, booktabs = TRUE) %>%   kableExtra::kable_styling(latex_options = \"HOLD_position\") ref_grid(cfi_fit,    at = list(ADURW = seq(0, 312, by=12), TX = levels(ADQS_CFI$TX)),   vcov. = clubSandwich::vcovCR(cfi_fit, type = \"CR2\") %>% as.matrix(),    data = ADQS_CFI,    mode = \"satterthwaite\") %>%   emmeans(specs = \"TX\", by = \"ADURW\") %>%   as_tibble() %>%   ggplot(aes(x=ADURW, y=emmean)) +   geom_line(aes(color=TX)) +   geom_ribbon(aes(ymin = lower.CL, ymax = upper.CL, fill = TX), alpha = 0.2) +   scale_x_continuous(breaks = seq(0, 312, by=24)) +   ylab(\"Mean CFI with 95% confidence intervals\") +   xlab(\"Weeks since Randomization\") +   theme(legend.position = 'inside', legend.position.inside = c(0.2, 0.9))"},{"path":[]},{"path":"https://atri-biostats.github.io/A4LEARN/reference/A4LEARN-package.html","id":null,"dir":"Reference","previous_headings":"","what":"A4LEARN: A4LEARN Study Package — A4LEARN-package","title":"A4LEARN: A4LEARN Study Package — A4LEARN-package","text":"A4LEARN data package containing full A4 LEARN dataset.","code":""},{"path":[]},{"path":"https://atri-biostats.github.io/A4LEARN/reference/A4LEARN-package.html","id":"author","dir":"Reference","previous_headings":"","what":"Author","title":"A4LEARN: A4LEARN Study Package — A4LEARN-package","text":"Maintainer: ATRI Biostatistics biostat_request@atrihub.io","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ADQS.html","id":null,"dir":"Reference","previous_headings":"","what":"ADQS: [Derived] Analysis Data Questionnaire Scores — ADQS","title":"ADQS: [Derived] Analysis Data Questionnaire Scores — ADQS","text":"ATRI derived analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ADQS.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"ADQS: [Derived] Analysis Data Questionnaire Scores — ADQS","text":"","code":"data(ADQS)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ADQS.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"ADQS: [Derived] Analysis Data Questionnaire Scores — ADQS","text":"data frame 247289 rows 81 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ADQS.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"ADQS: [Derived] Analysis Data Questionnaire Scores — ADQS","text":"SUBSTUDY: NA BID: NA VISITCD: Visit Code VISIT: Visit AVISIT: Analysis Visit EPOCH: Epoch QSSEQ: Sequence Number given ensure uniqueness subject records within domain. May valid number. QSTESTCD: Topic variable QS. Short name value QSTEST, can used column name converting dataset vertical format horizontal format. value QSTESTCD longer 8 characters, can start number (e.g.”1TEST”). QSTESTCD contain characters letters, numbers, underscores. See QS Terminology Spreadsheet specific text QSTESTCD. Examples: ADCCMD01, BPR0103 QSTEST: Verbatim name question group questions used obtain measurement finding. value QSTEST longer 40 characters. See QS Terminology Spreadsheet specific text QSTEST. Example: Fist, BPR01 - Emotional Withdrawal QSCAT: Used define category related records meaningful Reviewer. See QS Terminology Spreadsheet specific text QSCAT. Examples: ADAS-COG, MDS-UPDRS. QSVERSION: Test version administered. QSLANG: Questionnaire language. QSSTRESN: Used continuous numeric findings standard format; copied numeric format QSSTRESC. QSSTRESN store numeric results findings. QSBLRES: QS Baseline Score QSCHANGE: QS Change Baseline QSBLSD: QS Baseline Standard Deviation QSBLFL: Indicator used identify baseline value. value “Y” null. QSDTC_DAYS_CONSENT: Date questionnaire. registry.EXAMDATE (Derived days since study consent date) QSDTC_DAYS_T0: Date questionnaire. registry.EXAMDATE (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) QSADTC_DAYS_CONSENT: Analysis date questionnaire. registry.EXAMDATE, exists, otherwise manually reviewed missing_pacc_dates_verify.EXAMDATE.verify (Derived days since study consent date) QSADTC_DAYS_T0: Analysis date questionnaire. registry.EXAMDATE, exists, otherwise manually reviewed missing_pacc_dates_verify.EXAMDATE.verify (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) QSDY: Study Day Finding ADURW: Study Week Finding ASEQMMRM: Sequence MMRM, mapped using AVISIT (012->1...066->10) ASEQNCS: Sequence NCS, mapped using AVISIT (006->1...066->11) participant without missing AVISIT, use Visit Number missing AVISIT (max 11 visits, visit code 066 always visit 11) ANL01FL: Y data included NCS. ANL02FL: Y data included MMRM. TX: Random treatment assigment. AGEYR: Age years Consent MARITAL: Marital Status SEX: Sex RACE: Race EDCCNTU: Years education ETHNIC: Ethnicity WRKRET: Participant Retirement Status TESTLNG: Language used testing SAMELNG: Testing Primary Lang RESIDENCE: Type Residence DISCDTC_DAYS_CONSENT: Subject Discontinuation Date Character (Derived days since study consent date) DISCDTC_DAYS_T0: Subject Discontinuation Date Character (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) ENRLDT_DAYS_CONSENT: Enrollment Date (Derived days since study consent date) ENRLDT_DAYS_T0: Enrollment Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) RNDMDT_DAYS_CONSENT: Randomization Date (Derived days since study consent date) RNDMDT_DAYS_T0: Randomization Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) GDSSEVBL: Geriatric Depression Scale Score > 5 SUBJCOMPTR: Subj Completer Set - TR Phase TRTENDT_DAYS_CONSENT: Treatment End Date (Derived days since study consent date) TRTENDT_DAYS_T0: Treatment End Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) TRTSTDT_DAYS_CONSENT: Treatment Start Date (Derived days since study consent date) TRTSTDT_DAYS_T0: Treatment Start Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) HGTCMBL: Height Cm Baseline WGTKGBL: Weight Kg Baseline BMIBL: body mass index (weight (kg) / [height (m)]^2) ALCHLBL: Current Alcohol Consumer Baseline CFBL: Current Caffeine User Baseline TBBL: Current Tobacco User Baseline COGDSSTTSV1: DSST Total Score Visit 1 COGDSSTTSV6: DSST Total Score Visit 6 COGLMDRTSV1: LM Delayed Recall Total Score Visit 1 COGLMDRTSV6: LM Delayed Recall Total Score Visit 6 COGTOTRECSV1: Total Recall Score Visit 1 COGTOTRECSV6: Total Recall Score Visit 6 MMSETSV1: MMSE Total Score Visit 1 MMSETSV6: MMSE Total Score Visit 6 PACCV6: PACC Total Score Visit 6 APOEGN: APOE4 genotype (ε2/ε4, ε3/ε4, ε4/ε4, ε4) APOEGNPRSNFLG: APOE4 carrier status (carrier [ε2/ε4, ε3/ε4, ε4/ε4], noncarrier [ε3/ε3, ε2/ε2,ε3/ε2]) AAPOEGNPRSNFLG: APOE4 carrier status used analysis. APOEGNPRSNFLG missing, carrier status assumed noncarrier randomization plan. SUVRCER: Amyloid PET composite SUVR AMYLCENT: Amyloid PET centiloids. AMYLCENT = 183.07 x SUVRCER – 177.26. SUBJITTTR: Subj Intent Treat Set - TR Phase MITTFL: Modified Intent--Treat Flag SUBJSAFTR: Safety Population Flag PCCPFL: Placebo-Controlled Completers Population Flag PRTVIIE: Protocol Violation - Eligibility Criteria Flag PRTVIMAS: Protocol Violation - Missed ADCS-PACC Flag CON3FL: Protocol Violation - Missed Consecutive Infusions PRTVITMS: Protocol Violation - Missed Infusions PPTRTDUR: Treatment Duration >240wk Completers Flag SUBJPPSTR: Subj Per Protocol Set - TR Phase TAUPETFL: Tau PET (Flortaucipir) mITT Participant Flag","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ADQS.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"ADQS: [Derived] Analysis Data Questionnaire Scores — ADQS","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/COGSTATE_COMPUTERIZED.html","id":null,"dir":"Reference","previous_headings":"","what":"COGSTATE_COMPUTERIZED: [Derived] Cogstate (Computerized) — COGSTATE_COMPUTERIZED","title":"COGSTATE_COMPUTERIZED: [Derived] Cogstate (Computerized) — COGSTATE_COMPUTERIZED","text":"ATRI derived analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/COGSTATE_COMPUTERIZED.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"COGSTATE_COMPUTERIZED: [Derived] Cogstate (Computerized) — COGSTATE_COMPUTERIZED","text":"","code":"data(COGSTATE_COMPUTERIZED)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/COGSTATE_COMPUTERIZED.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"COGSTATE_COMPUTERIZED: [Derived] Cogstate (Computerized) — COGSTATE_COMPUTERIZED","text":"data frame 315596 rows 14 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/COGSTATE_COMPUTERIZED.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"COGSTATE_COMPUTERIZED: [Derived] Cogstate (Computerized) — COGSTATE_COMPUTERIZED","text":"SUBSTUDY: NA BID: NA TESTDATE_DAYS_CONSENT: Test Date (Derived days since study consent date) TESTDATE_DAYS_T0: Test Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) VISIT: Visit number original cogstate_computerized AVISIT: Analysis Visit TESTCD: Computerized test name VALUE: Score TRIAL: Number trial binomial outcomes BASELINE.VALUE: Baseline Score BASELINE.TRIAL: Baseline TRIAL VALUE.DIF: Change score EPOCH: Epoch ADURW: Study Week Finding","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/COGSTATE_COMPUTERIZED.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"COGSTATE_COMPUTERIZED: [Derived] Cogstate (Computerized) — COGSTATE_COMPUTERIZED","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/DS.html","id":null,"dir":"Reference","previous_headings":"","what":"DS: [Derived] Disposition — DS","title":"DS: [Derived] Disposition — DS","text":"ATRI derived analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/DS.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"DS: [Derived] Disposition — DS","text":"","code":"data(DS)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/DS.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"DS: [Derived] Disposition — DS","text":"data frame 16262 rows 9 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/DS.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"DS: [Derived] Disposition — DS","text":"SUBSTUDY: NA BID: NA DSSEQ: Sequence Number given ensure uniqueness subject records within domain. May valid number. DSDECOD: Modified Intent--Treat Flag, randomized subjects baseline observation least one post-baseline observation = 1, others = 0 DSCAT: Used define category related records. DSCAT now “Expected” variable. DSCAT permissible SDTMIG 3.1.1 earlier versions. change “permissible” “expected” based requirement distinguish protocol milestones /events disposition events. DSCAT may null “disposition events”; however, recommended DSCAT always populated. EPOCH: Epoch DSSTDTC_DAYS_CONSENT: Disposition Start Date (Derived days since study consent date) DSSTDTC_DAYS_T0: Disposition Start Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) DSSTDY: Study day start event relative sponsor-defined RFSTDTC","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/DS.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"DS: [Derived] Disposition — DS","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/PACC.html","id":null,"dir":"Reference","previous_headings":"","what":"PACC: [Derived] PACC — PACC","title":"PACC: [Derived] PACC — PACC","text":"ATRI derived analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/PACC.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"PACC: [Derived] PACC — PACC","text":"","code":"data(PACC)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/PACC.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"PACC: [Derived] PACC — PACC","text":"data frame 26780 rows 31 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/PACC.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"PACC: [Derived] PACC — PACC","text":"SUBSTUDY: NA BID: NA VISCODE: Visit Code PACC.raw: PACC raw score PACC: PACC score change baseline PACCIMPFLG: PACC Imputation Flag FCTOTAL96: Free Cued Selective Reminding Total Score (96 max) LDELTOTAL: Cognitive Test - Logical Memory Total Score DIGITTOTAL: Cognitive Test - Digit Symbol Substitution Test Total Score MMSCORE: MMSE: Mini Mental State Examination Score FCTOTAL96.bl: FCTOTAL96 baseline score LDELTOTAL.bl: LDELTOTAL baseline score DIGITTOTAL.bl: DIGITTOTAL baseline score MMSCORE.bl: MMSE baseline score FCTOTAL96.blmean: FCTOTAL96 baseline score mean LDELTOTAL.blmean: LDELTOTAL baseline score mean DIGITTOTAL.blmean: DIGITTOTAL baseline score mean MMSCORE.blmean: MMSE baseline score mean FCTOTAL96.blsd: FCTOTAL96 baseline score standard deviation LDELTOTAL.blsd: LDELTOTAL baseline score standard deviation DIGITTOTAL.blsd: DIGITTOTAL baseline score standard deviation MMSCORE.blsd: MMSE baseline score standard deviation FCTOTAL96.ch: FCTOTAL96 score change baseline LDELTOTAL.ch: LDELTOTAL score change baseline DIGITTOTAL.ch: DIGITTOTAL score change baseline MMSCORE.ch: MMSE score change baseline FCTOTAL96.z: FCTOTAL96 Z-Score (Standrad Score) LDELTOTAL.z: LDELTOTAL Z-Score (Standrad Score) DIGITTOTAL.z: DIGITTOTAL Z-Score (Standrad Score) MMSCORE.z: MMSE Z-Score (Standrad Score) LMSTORY: Logical Memory Story Version","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/PACC.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"PACC: [Derived] PACC — PACC","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/SUBJINFO.html","id":null,"dir":"Reference","previous_headings":"","what":"SUBJINFO: [Derived] Subject Information — SUBJINFO","title":"SUBJINFO: [Derived] Subject Information — SUBJINFO","text":"ATRI derived analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/SUBJINFO.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"SUBJINFO: [Derived] Subject Information — SUBJINFO","text":"","code":"data(SUBJINFO)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/SUBJINFO.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"SUBJINFO: [Derived] Subject Information — SUBJINFO","text":"data frame 6945 rows 64 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/SUBJINFO.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"SUBJINFO: [Derived] Subject Information — SUBJINFO","text":"SUBSTUDY: NA BID: NA TX: Random treatment assigment. AGEYR: Age years Consent MARITAL: Marital Status SEX: Sex RACE: Race EDCCNTU: Years education ETHNIC: Ethnicity WRKRET: Participant Retirement Status TESTLNG: Language used testing SAMELNG: Testing Primary Lang RESIDENCE: Type Residence DISCDTC_DAYS_CONSENT: Subject Discontinuation Date Character (Derived days since study consent date) DISCDTC_DAYS_T0: Subject Discontinuation Date Character (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) ENRLDT_DAYS_CONSENT: Enrollment Date (Derived days since study consent date) ENRLDT_DAYS_T0: Enrollment Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) RNDMDT_DAYS_CONSENT: Randomization Date (Derived days since study consent date) RNDMDT_DAYS_T0: Randomization Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) GDSSEVBL: Geriatric Depression Scale Score > 5 SUBJCOMPTR: Subj Completer Set - TR Phase TRTENDT_DAYS_CONSENT: Treatment End Date (Derived days since study consent date) TRTENDT_DAYS_T0: Treatment End Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) TRTSTDT_DAYS_CONSENT: Treatment Start Date (Derived days since study consent date) TRTSTDT_DAYS_T0: Treatment Start Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) TRTESDT_DAYS_CONSENT: Treatment Escalation Date: Date first visit participant started high dose (800 mg 1600 mg) (Derived days since study consent date) TRTESDT_DAYS_T0: Treatment Escalation Date: Date first visit participant started high dose (800 mg 1600 mg) (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) TRTESVIS: Treatment Escalation Visit: First visit participant started high dose (800 mg 1600 mg) HGTCMBL: Height Cm Baseline WGTKGBL: Weight Kg Baseline BMIBL: body mass index (weight (kg) / [height (m)]^2) ALCHLBL: Current Alcohol Consumer Baseline CFBL: Current Caffeine User Baseline TBBL: Current Tobacco User Baseline COGDSSTTSV1: DSST Total Score Visit 1 COGDSSTTSV6: DSST Total Score Visit 6 COGLMDRTSV1: LM Delayed Recall Total Score Visit 1 COGLMDRTSV6: LM Delayed Recall Total Score Visit 6 COGTOTRECSV1: Total Recall Score Visit 1 COGTOTRECSV6: Total Recall Score Visit 6 MMSETSV1: MMSE Total Score Visit 1 MMSETSV6: MMSE Total Score Visit 6 PACCV6: PACC Total Score Visit 6 APOEGN: APOE4 genotype (ε2/ε4, ε3/ε4, ε4/ε4, ε4) APOEGNPRSNFLG: APOE4 carrier status (carrier [ε2/ε4, ε3/ε4, ε4/ε4], noncarrier [ε3/ε3, ε2/ε2,ε3/ε2]) AAPOEGNPRSNFLG: APOE4 carrier status used analysis. APOEGNPRSNFLG missing, carrier status assumed noncarrier randomization plan. SUVRCER: Amyloid PET composite SUVR AMYLCENT: Amyloid PET centiloids. AMYLCENT = 183.07 x SUVRCER – 177.26. SUBJITTTR: Subj Intent Treat Set - TR Phase MITTFL: Modified Intent--Treat Flag SUBJSAFTR: Safety Population Flag PCCPFL: Placebo-Controlled Completers Population Flag PRTVIIE: Protocol Violation - Eligibility Criteria Flag PRTVIMAS: Protocol Violation - Missed ADCS-PACC Flag CON3FL: Protocol Violation - Missed Consecutive Infusions PRTVITMS: Protocol Violation - Missed Infusions PPTRTDUR: Treatment Duration >240wk Completers Flag SUBJPPSTR: Subj Per Protocol Set - TR Phase LEARNFL: LEARN Participant Flag TAUPETFL: Tau PET (Flortaucipir) Participant Flag FRAMINGHAM: Framingham Risk Score RESCREENFL: Rescreened Participant Flag PREVBID: Previous BID previously screened","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/SUBJINFO.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"SUBJINFO: [Derived] Subject Information — SUBJINFO","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/SV.html","id":null,"dir":"Reference","previous_headings":"","what":"SV: [Derived] Subject Visits — SV","title":"SV: [Derived] Subject Visits — SV","text":"ATRI derived analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/SV.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"SV: [Derived] Subject Visits — SV","text":"","code":"data(SV)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/SV.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"SV: [Derived] Subject Visits — SV","text":"data frame 103351 rows 9 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/SV.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"SV: [Derived] Subject Visits — SV","text":"SUBSTUDY: NA BID: NA VISITCD: Visit Code VISIT: Visit SVSTDTC_DAYS_CONSENT: Start date/time Visit (Derived days since study consent date) SVSTDTC_DAYS_T0: Start date/time Visit (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) SVTYPE: Visit Type: type visit conducted? Standard, Nonstandard, Done SVUSEDTC_DAYS_CONSENT: End date/time Visit (Derived days since study consent date) SVUSEDTC_DAYS_T0: End date/time Visit (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date])","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/SV.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"SV: [Derived] Subject Visits — SV","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/adlpq.html","id":null,"dir":"Reference","previous_headings":"","what":"adlpq: ADCS ADL-Prevention Questionnaire for Participant — adlpq","title":"adlpq: ADCS ADL-Prevention Questionnaire for Participant — adlpq","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/adlpq.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"adlpq: ADCS ADL-Prevention Questionnaire for Participant — adlpq","text":"","code":"data(adlpq)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/adlpq.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"adlpq: ADCS ADL-Prevention Questionnaire for Participant — adlpq","text":"data frame 15334 rows 45 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/adlpq.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"adlpq: ADCS ADL-Prevention Questionnaire for Participant — adlpq","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: ASMETHOD: Method Collection: ASCBOOK: 1. past 3 months, well balance credit card statement, pay bills, use ATM make withdrawal deposit? ASTRAVL: 2. past 3 months, drive car without getting lost, travel wherever needed using public transport? ASAPPLI: 3. past 3 months, use appliance (example, microwave, dishwasher, vacuum cleaner, TV remote), carry household repairs? ASLAUN: 4. past 3 months, laundry? ASPAY: 5. past 3 months, select pay items shopping? ASSNACK: 6. past 3 months, prepare meals snacks? ASTIMES: 7. past 3 months, well remember important dates times, appointments meetings? ASFIND: 8. past 3 months, usually find personal belongings home - example keys, glasses, wallet books? ASWDOWN: 9. past 3 months, well able write things people understood (example, letters detailed notes lists)? ASMOVIE: 10. past 3 months, well follow TV programs movies remember details story? ASCEVNT: 11. past 3 months, well talk remember current events heard read ? ASPHONE: 12. past 3 months, well make telephone calls, including look numbers call directory assistance necessary? ASMEDS: 13. past 3 months, take medications regularly - including prescription counter medications? ASPLAN: 14. past 3 months, plan organize complex activities groups people, example travel, running errands, participating group activities (religious services), carrying hobbies pastimes? ASCOMPL: 15. past 3 months, complete complex activities hobbies pastimes, example playing card games, reading books, gardening? ASCELL: 16. ever use cellphone smartphone? ASCELLUSE: 16a. yes, past 3 months, use cellphone smartphone? ASCALL: 16b.. Make call: ASTEXT: 16b.ii. Send text message: ASINTER: 16b.iii. Access internet (e.g., websites, Facebook, etc): ASAPP: 16b.iv. Use App (including playing game): ASCELLOFTN: 16c. use cellphone smartphone less often usual? ASCELITDIF: 16d. use cellphone smartphone: ASCOMP: 17. ever use computer, tablet, device internet access? ASACCESS: 17a. yes, past 3 months, use computer, tablet, device internet access? ASWEB: 17b.. Access websites, Facebook, email: ASINFO: 17b.ii. Enter information device, e.g, made bookmarks, wrote sent emails, posted Facebook, etc: ASPURCH: 17b.iii. Make purchases reservations: ASPASS: 17b.iv. Use passwords remember find : ASCOMPOFTN: 17c. use computer, tablet, device internet access less often usual? ASCLITDIF: 17d. use computer, tablet, device internet access: ASEREAD: 18. ever use e-reader, e.g. Nook, Kindle tablet? ASEREAD4: 18a. yes, past 3 months, use e-reader, e.g. Nook, Kindle tablet? ASEBOOK: 18b.. Read book article: ASEDLOAD: 18b.ii. Download reading material: ASEADJUST: 18b.iii. Make adjustment appearance e.g., inserted bookmark adjusted settings: ASEOFTEN: 18c. use e-reader less often usual? ASELITDIF: 18d. use e-reader: ASSCORE: Total Score","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/adlpq.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"adlpq: ADCS ADL-Prevention Questionnaire for Participant — adlpq","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/adlpqsp.html","id":null,"dir":"Reference","previous_headings":"","what":"adlpqsp: ADCS ADL-Prevention Questionnaire for Study Partner — adlpqsp","title":"adlpqsp: ADCS ADL-Prevention Questionnaire for Study Partner — adlpqsp","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/adlpqsp.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"adlpqsp: ADCS ADL-Prevention Questionnaire for Study Partner — adlpqsp","text":"","code":"data(adlpqsp)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/adlpqsp.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"adlpqsp: ADCS ADL-Prevention Questionnaire for Study Partner — adlpqsp","text":"data frame 15523 rows 88 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/adlpqsp.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"adlpqsp: ADCS ADL-Prevention Questionnaire for Study Partner — adlpqsp","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: AIMETHOD: Method Collection: BPID: Study Partner ID: AICBOOK: 1. past 3 months, well {P} balance credit card statement, pay bills, use ATM make withdrawal deposit? AISUB1A: difficulty: AISUB1B: NA AISUB1C: NA AITRAVL: 2. past 3 months, {P} drive car without getting lost, travel wherever /needed go using public transport? AISUB2A: difficulty: AISUB2B: NA AISUB2C: NA AIAPPLI: 3. past 3 months, well {P} use appliance (example, microwave, dishwasher, vacuum cleaner, TV remote), carry household repairs? AISUB3A: difficulty: AISUB3B: NA AISUB3C: NA AILAUN: 4. past 3 months, {P} clean load laundry? AISUB4A: difficulty: AISUB4B: NA AISUB4C: NA AIPAY: 5. past 3 months, {P} select pay items shopping? AISUB5A: difficulty: AISUB5B: NA AISUB5C: NA AISNACK: 6. past 3 months, {P} prepare meal snack? AISUB6A: difficulty: AISUB6B: NA AISUB6C: NA AITIMES: 7. past 3 months, well {P} remember important dates times, appointments meetings? AISUB7A: difficulty: AISUB7B: NA AISUB7C: NA AIFIND: 8. past 3 months, {P} usually manage find personal belongings home - example keys, glasses, wallet books? AISUB8A: difficulty: AISUB8B: NA AISUB8C: NA AIWDOWN: 9. past 3 months, well {P} write things , example letters detailed notes lists, people understood ? AISUB9A: difficulty: AISUB9B: NA AISUB9C: NA AIMOVIE: 10. past 3 months, well {P} follow TV programs movies remember details story? AISUB10A: difficulty: AISUB10B: NA AICEVNT: 11. past 3 months, well {P} talk remember current events /heard read ? AISUB11A: difficulty: AISUB11B: NA AIPHONE: 12. past 3 months, well {P} make telephone calls, including looking numbers calling directory assistance necessary? AISUB12A: difficulty: AISUB12B: NA AISUB12C: NA AIMEDS: 13. past 3 months, {P} take medications regularly - including prescription counter medications? AISUB13A: difficulty: AISUB13B: NA AIPLAN: 14. past 3 months, {P} plan organize complex activities /groups people, example travel, running errands, participating group activities (religious services), carrying hobbies pastimes? AISUB14A: difficulty: AISUB14B: NA AISUB14C: NA AICOMPL: 15. past 3 months, {P} complete complex activities hobbies pastimes, example playing card games, reading books, gardening? AISUB15A: difficulty: AISUB15B: NA AISUB15C: NA AICELL: 16. {P} ever use cellphone smartphone? AICELLUSE: 16a. yes, past 3 months, {P} use cellphone smartphone? AICALL: 16b.. Make call: AITEXT: 16b.ii. Send text message: AIINTER: 16b.iii. Access internet (e.g., websites, Facebook, etc): AIAPP: 16b.iv. Use App (including playing game): AICELLOFTN: 16c. {P} use cellphone smartphone less often usual? AICELITDIF: 16d. {P} use cellphone smartphone: AICOMP: 17. {P} ever use computer, tablet, device internet access? AIACCESS: 17a. yes, past 3 months, {P} use computer, tablet, device internet access? AIWEB: 17b.. Access websites, Facebook, email: AIINFO: 17b.ii. Enter information device, e.g, made bookmarks, wrote sent emails, posted Facebook, etc: AIPURCH: 17b.iii. Make purchases reservations: AIPASS: 17b.iv. Use passwords remember find /: AICOMPOFTN: 17c. {P} use computer, tablet, device internet access less often usual? AICLITDIF: 17d. {P} use computer, tablet, device internet access: AIEREAD: 18. {P} ever use e-reader, e.g. Nook, Kindle tablet? AIEREAD4: 18a. yes, past 3 months, {P} use e-reader, e.g. Nook, Kindle tablet? AIEBOOK: 18b.. Read book article: AIEDLOAD: 18b.ii. Download reading material: AIEADJUST: 18b.iii. Make adjustment appearance e.g., inserted bookmark adjusted settings: AIEOFTEN: 18c. {P} use e-reader less often usual? AIELITDIF: 18d. {P} use e-reader: AISCORE: Total Score","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/adlpqsp.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"adlpqsp: ADCS ADL-Prevention Questionnaire for Study Partner — adlpqsp","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_AB_Test.html","id":null,"dir":"Reference","previous_headings":"","what":"biomarker_AB_Test: Biomarker - Amyloid-β Tests — biomarker_AB_Test","title":"biomarker_AB_Test: Biomarker - Amyloid-β Tests — biomarker_AB_Test","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_AB_Test.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"biomarker_AB_Test: Biomarker - Amyloid-β Tests — biomarker_AB_Test","text":"","code":"data(biomarker_AB_Test)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_AB_Test.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"biomarker_AB_Test: Biomarker - Amyloid-β Tests — biomarker_AB_Test","text":"data frame 31480 rows 12 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_AB_Test.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"biomarker_AB_Test: Biomarker - Amyloid-β Tests — biomarker_AB_Test","text":"SUBSTUDY: NA BID: NA VISCODE: NA SAMPLE_ID: Sample Identifier LBNAM: Laboratory Name LBSPEC: Specimen Material Type LBCAT: Category Lab Test LBTESTCD: Short Name Lab Test LBORRES: Lab Result LBORRESU: Lab Results Units LBMETHOD: Method Code Test  LBREASND: Reason Test Done","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_AB_Test.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"biomarker_AB_Test: Biomarker - Amyloid-β Tests — biomarker_AB_Test","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_Plasma_Roche_Results.html","id":null,"dir":"Reference","previous_headings":"","what":"biomarker_Plasma_Roche_Results: Biomarker - Roche Plasma Assay — biomarker_Plasma_Roche_Results","title":"biomarker_Plasma_Roche_Results: Biomarker - Roche Plasma Assay — biomarker_Plasma_Roche_Results","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_Plasma_Roche_Results.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"biomarker_Plasma_Roche_Results: Biomarker - Roche Plasma Assay — biomarker_Plasma_Roche_Results","text":"","code":"data(biomarker_Plasma_Roche_Results)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_Plasma_Roche_Results.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"biomarker_Plasma_Roche_Results: Biomarker - Roche Plasma Assay — biomarker_Plasma_Roche_Results","text":"data frame 13418 rows 14 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_Plasma_Roche_Results.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"biomarker_Plasma_Roche_Results: Biomarker - Roche Plasma Assay — biomarker_Plasma_Roche_Results","text":"SUBSTUDY: NA BID: NA VISCODE: NA LABNAM: Laboratory Name LABD_DAYS_CONSENT: Date Specimen Collection (Derived days since study consent date) LABD_DAYS_T0: Date Specimen Collection (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) SAMPLE_ID: Sample Identifier LBSPEC: Specimen Material Type LBMETHOD: Method Code Test LBTESTCD: Short Name Lab Test LBMTDL: Name Lab Test LABRESN: Lab Result LABORESU: Lab Results Units LABRESC: Reason Done","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_Plasma_Roche_Results.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"biomarker_Plasma_Roche_Results: Biomarker - Roche Plasma Assay — biomarker_Plasma_Roche_Results","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_pTau217.html","id":null,"dir":"Reference","previous_headings":"","what":"biomarker_pTau217: Biomarker - pTau-217 Digital Immunoassay — biomarker_pTau217","title":"biomarker_pTau217: Biomarker - pTau-217 Digital Immunoassay — biomarker_pTau217","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_pTau217.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"biomarker_pTau217: Biomarker - pTau-217 Digital Immunoassay — biomarker_pTau217","text":"","code":"data(biomarker_pTau217)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_pTau217.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"biomarker_pTau217: Biomarker - pTau-217 Digital Immunoassay — biomarker_pTau217","text":"data frame 4538 rows 18 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_pTau217.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"biomarker_pTau217: Biomarker - pTau-217 Digital Immunoassay — biomarker_pTau217","text":"SUBSTUDY: NA BID: NA VISCODE: NA SAMPLE_ID: Sample Identifier TESTCD: Short Name Lab Test TEST: Name Lab Test ORRES: Lab Result ORRESU: Lab Results Units STAT: Completion Status REASND: Reason Done NAM: Laboratory Name SPEC: Specimen Material Type METHOD: Method Code Test COLLECTION_DATE_DAYS_CONSENT: Date Specimen Collection (Derived days since study consent date) COLLECTION_DATE_DAYS_T0: Date Specimen Collection (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) COMMENT: Comments relevant result ORRESRAW: Lab Result (raw value) COMMENT2: Comments relevant result","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/biomarker_pTau217.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"biomarker_pTau217: Biomarker - pTau-217 Digital Immunoassay — biomarker_pTau217","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cdr.html","id":null,"dir":"Reference","previous_headings":"","what":"cdr: Clinical Dementia Rating — cdr","title":"cdr: Clinical Dementia Rating — cdr","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cdr.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"cdr: Clinical Dementia Rating — cdr","text":"","code":"data(cdr)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cdr.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"cdr: Clinical Dementia Rating — cdr","text":"data frame 15511 rows 25 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cdr.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"cdr: Clinical Dementia Rating — cdr","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: CDSPVERS: Version CDPTSRCE: Participant CDSPSRCE: Study Partner BPID: Study Partner ID: MEMORY: Memory Score ORIENT: Orientation Score JUDGE: Judgment Problem Solving Score COMMUN: Community Affairs Score HOME: Home Hobbies Score CARE: Personal Care Score CDSOB: Sum Boxes (system populated) CDGLOBAL: Global CDR (system populated) AVISIT: Analysis visit. CDADTC_DAYS_CONSENT: Analysis date CDR registry.EXAMDATE, exists, otherwise manually reviewed missing_pacc_dates_verify.EXAMDATE.verify (Derived days since study consent date) CDADTC_DAYS_T0: Analysis date CDR registry.EXAMDATE, exists, otherwise manually reviewed missing_pacc_dates_verify.EXAMDATE.verify (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) EPOCH: Epoch. CDDY: Study day CDR collection, measured integer days. CDEVENT: CDR-Global progression event defined two consecutive CDR-Global scores placebo-controlled phase greater zero, final observed CDR-Global score placebo-controlled phase greater zero. time event considered time baseline (days) randomization first two consecutive CDR-Global scores greater zero, final observed CDR-Global score greater zero. participant CDR-Global scores zero every visit, censoring time time last observed CDR-Global score placebo-controlled phase. CDOLEEVENT: OLE CDR-Global progression event defined two consecutive CDR-Global scores placebo-controlled OLE phase greater zero, final observed CDR-Global score placebo-controlled OLE phase greater zero. time event considered time baseline (days) first two consecutive CDR-Global scores greater zero, final observed CDR-Global score greater zero. participant CDR-Global scores zero every visit, censoring time time last observed CDR-Global score either placebo-controlled OLE phase. CDRSB: CDR Sum Boxes score proration missing box scores percent missing <= 30","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cdr.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"cdr: Clinical Dementia Rating — cdr","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cfi.html","id":null,"dir":"Reference","previous_headings":"","what":"cfi: Cognitive Function Index - Participant — cfi","title":"cfi: Cognitive Function Index - Participant — cfi","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cfi.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"cfi: Cognitive Function Index - Participant — cfi","text":"","code":"data(cfi)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cfi.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"cfi: Cognitive Function Index - Participant — cfi","text":"data frame 15354 rows 22 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cfi.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"cfi: Cognitive Function Index - Participant — cfi","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: PMETHOD: Method Collection: MEMORY: 1. Compared one year ago, feel memory declined substantially? REPEAT: 2. others tell tend repeat questions ? MISPLA: 3. misplacing things often? WRITTN: 4. Compared one year ago, find relying written reminders (e.g., shopping lists, calendars)? HELP: 5. need help others remember appointments, family occasions holidays? RECALL: 6. trouble recalling names, finding right word, completing sentences? DRIVE: 7. trouble driving (e.g., drive slowly, trouble night, tend get lost, accidents)? MONEY: 8. Compared one year ago, difficulty managing money (e.g., paying bills, calculating change, completing tax forms)? SOCIAL: 9. less involved social activities? WORK: 10. work performance (paid volunteer) declined significantly compared one year ago? FOLLOW: 11. trouble following news plots books, movies, TV shows? ACTIV: 12. activities (e.g., hobbies, card games, crafts) substantially difficult now compared one year ago? LOST: 13. likely become disoriented, get lost, example traveling another city? APPLIA: 14. Compared one year ago, difficulty using household appliances (washing machine microwave) electronic devices (computer cell phone)? PTCONCERN: 15. past year, seen doctor memory concerns? CFIPTTOTAL: Total Score","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cfi.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"cfi: Cognitive Function Index - Participant — cfi","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cfisp.html","id":null,"dir":"Reference","previous_headings":"","what":"cfisp: Cognitive Function Index - Study Partner — cfisp","title":"cfisp: Cognitive Function Index - Study Partner — cfisp","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cfisp.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"cfisp: Cognitive Function Index - Study Partner — cfisp","text":"","code":"data(cfisp)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cfisp.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"cfisp: Cognitive Function Index - Study Partner — cfisp","text":"data frame 15539 rows 23 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cfisp.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"cfisp: Cognitive Function Index - Study Partner — cfisp","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: BPID: Study Partner ID: SPMETHOD: Method Collection: SPMEMORY: 1. feel participant significant decline memory compared one year ago? SPREPEAT: 2. participant tend ask question ? SPMISPLA: 3. participant misplacing things often? SPWRITTN: 4. Compared one year ago, seem participant relying written reminders (e.g., shopping lists, calendars)? SPHELP: 5. participant need help others remember appointments, family occasions holidays? SPRECALL: 6. participant trouble recalling names, finding right word, completing sentences? SPDRIVE: 7. participant trouble driving (e.g., driving slowly fast, trouble driving night, getting lost, accidents)? SPMONEY: 8. Compared one year ago, participant difficulty managing money (e.g., paying bills, calculating change, completing tax forms)? SPSOCIAL: 9. participant less interested social activities? SPWORK: 10. believe, based observations comments participant's co-workers, participant's work performance (paid volunteer) declined significantly, compared one year ago? SPFOLLOW: 11. participant trouble following news plots books, movies, TV shows? SPACTIV: 12. activities (e.g., hobbies card games, crafts) substantially difficult participant now compared one year ago? SPLOST: 13. participant likely become disoriented, get lost, example traveling another city? SPAPPLIA: 14. Compared one year ago, participant difficulty using household appliances (washing machine microwave) electronic devices (computer cell phone)? SPCONCERN: 15. past year, participant seen doctor memory concerns? CFSPTTOTAL: Total Score","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cfisp.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"cfisp: Cognitive Function Index - Study Partner — cfisp","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/clrm_ecg.html","id":null,"dir":"Reference","previous_headings":"","what":"clrm_ecg: Clinical Laboratory Results Modernization (CLRM) - ECG — clrm_ecg","title":"clrm_ecg: Clinical Laboratory Results Modernization (CLRM) - ECG — clrm_ecg","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/clrm_ecg.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"clrm_ecg: Clinical Laboratory Results Modernization (CLRM) - ECG — clrm_ecg","text":"","code":"data(clrm_ecg)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/clrm_ecg.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"clrm_ecg: Clinical Laboratory Results Modernization (CLRM) - ECG — clrm_ecg","text":"data frame 377439 rows 44 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/clrm_ecg.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"clrm_ecg: Clinical Laboratory Results Modernization (CLRM) - ECG — clrm_ecg","text":"SUBSTUDY: NA BID: NA VISCODE: NA VISIT: LAB VISIT NAME VISITTYP: LAB VISIT TYPE VISITMOD: LAB VISIT SUB TYPE LBNAM: CENTRAL LABORATORY NAME SAMPLE_ID: Sample Identifier LBDTM_DAYS_CONSENT: COLLECTION DATE TIME (Derived days since study consent date) LBDTM_DAYS_T0: COLLECTION DATE TIME (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) RCVDTM_DAYS_CONSENT: RECEIVED (central laboratory) DATE TIME (Derived days since study consent date) RCVDTM_DAYS_T0: RECEIVED (central laboratory) DATE TIME (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) SPECMNUM: SPECIMEN MATERIAL ID LBSPEC: SPECIMEN MATERIAL DESCRIPTION FASTSTAT: FASTING STATUS BATTRID: BASE BATTERY ID BATTRNAM: BASE BATTERY NAME LBTESTCD: LAB TEST CODE LBTEST: TEST NAME TSTSTAT: TEST STATUS TSTDTM_DAYS_CONSENT: TEST DATE TIME (Derived days since study consent date) TSTDTM_DAYS_T0: TEST DATE TIME (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) TSTTYP: TEST TYPE RPTRESC: REPORTED TEXT RESULT RPTRESN: REPORTED NUMERIC RESULT RPTRESNP: REPORTED RESULT NUMERIC PRECISION RPTNRLO: REPORTED Lower limit reference range RPTNRHI: REPORTED Upper limit reference range RPTU: REPORTED UNITS MEASUREMENT CNVRESC: CONVENTIONAL TEXT RESULT CNVRESN: CONVENTIONAL NUMERIC RESULT CNVRESNP: CONVENTIONAL RESULT NUMERIC PRECISION CNVNRLO: CONVENTIONAL REF RANGE LO CNVNRHI: CONVENTIONAL REF RANGE HI CNVU: CONVENTIONAL UOM SIRESC: SI TEXT RESULT SIRESN: SI NUMERIC RESULT SIRESNP: SI RESULT NUMERIC PRECISION SINRLO: SI REF RANGE LO SINRHI: SI REF RANGE HI SIU: SI UOM RPTRTYP: RESULT TYPE ALRTFL: ALERT FLAG DELTFL: DELTA FLAG","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/clrm_ecg.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"clrm_ecg: Clinical Laboratory Results Modernization (CLRM) - ECG — clrm_ecg","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/clrm_lab.html","id":null,"dir":"Reference","previous_headings":"","what":"clrm_lab: Clinical Laboratory Results Modernization (CLRM) - Laboratory Tests — clrm_lab","title":"clrm_lab: Clinical Laboratory Results Modernization (CLRM) - Laboratory Tests — clrm_lab","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/clrm_lab.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"clrm_lab: Clinical Laboratory Results Modernization (CLRM) - Laboratory Tests — clrm_lab","text":"","code":"data(clrm_lab)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/clrm_lab.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"clrm_lab: Clinical Laboratory Results Modernization (CLRM) - Laboratory Tests — clrm_lab","text":"data frame 607613 rows 44 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/clrm_lab.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"clrm_lab: Clinical Laboratory Results Modernization (CLRM) - Laboratory Tests — clrm_lab","text":"SUBSTUDY: NA BID: NA VISCODE: NA VISIT: LAB VISIT NAME VISITTYP: LAB VISIT TYPE VISITMOD: LAB VISIT SUB TYPE LBNAM: CENTRAL LABORATORY NAME SAMPLE_ID: Sample Identifier LBDTM_DAYS_CONSENT: COLLECTION DATE TIME (Derived days since study consent date) LBDTM_DAYS_T0: COLLECTION DATE TIME (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) RCVDTM_DAYS_CONSENT: RECEIVED (central laboratory) DATE TIME (Derived days since study consent date) RCVDTM_DAYS_T0: RECEIVED (central laboratory) DATE TIME (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) SPECMNUM: SPECIMEN MATERIAL ID LBSPEC: SPECIMEN MATERIAL DESCRIPTION FASTSTAT: FASTING STATUS BATTRID: BASE BATTERY ID BATTRNAM: BASE BATTERY NAME LBTESTCD: LAB TEST CODE LBTEST: TEST NAME TSTSTAT: TEST STATUS TSTDTM_DAYS_CONSENT: TEST DATE TIME (Derived days since study consent date) TSTDTM_DAYS_T0: TEST DATE TIME (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) TSTTYP: TEST TYPE RPTRESC: REPORTED TEXT RESULT RPTRESN: REPORTED NUMERIC RESULT RPTRESNP: REPORTED RESULT NUMERIC PRECISION RPTNRLO: REPORTED Lower limit reference range RPTNRHI: REPORTED Upper limit reference range RPTU: REPORTED UNITS MEASUREMENT CNVRESC: CONVENTIONAL TEXT RESULT CNVRESN: CONVENTIONAL NUMERIC RESULT CNVRESNP: CONVENTIONAL RESULT NUMERIC PRECISION CNVNRLO: CONVENTIONAL REF RANGE LO CNVNRHI: CONVENTIONAL REF RANGE HI CNVU: CONVENTIONAL UOM SIRESC: SI TEXT RESULT SIRESN: SI NUMERIC RESULT SIRESNP: SI RESULT NUMERIC PRECISION SINRLO: SI REF RANGE LO SINRHI: SI REF RANGE HI SIU: SI UOM RPTRTYP: RESULT TYPE ALRTFL: ALERT FLAG DELTFL: DELTA FLAG","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/clrm_lab.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"clrm_lab: Clinical Laboratory Results Modernization (CLRM) - Laboratory Tests — clrm_lab","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogdigit.html","id":null,"dir":"Reference","previous_headings":"","what":"cogdigit: Cognitive Test - Digit Symbol Substitution Test — cogdigit","title":"cogdigit: Cognitive Test - Digit Symbol Substitution Test — cogdigit","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogdigit.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"cogdigit: Cognitive Test - Digit Symbol Substitution Test — cogdigit","text":"","code":"data(cogdigit)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogdigit.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"cogdigit: Cognitive Test - Digit Symbol Substitution Test — cogdigit","text":"data frame 26769 rows 7 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogdigit.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"cogdigit: Cognitive Test - Digit Symbol Substitution Test — cogdigit","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: VERSION: Version DIGITTOTAL: Total Score","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogdigit.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"cogdigit: Cognitive Test - Digit Symbol Substitution Test — cogdigit","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogfcsr16.html","id":null,"dir":"Reference","previous_headings":"","what":"cogfcsr16: Cognitive Test - Free and Cued Selective Reminding (16 Pictures) — cogfcsr16","title":"cogfcsr16: Cognitive Test - Free and Cued Selective Reminding (16 Pictures) — cogfcsr16","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogfcsr16.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"cogfcsr16: Cognitive Test - Free and Cued Selective Reminding (16 Pictures) — cogfcsr16","text":"","code":"data(cogfcsr16)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogfcsr16.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"cogfcsr16: Cognitive Test - Free and Cued Selective Reminding (16 Pictures) — cogfcsr16","text":"data frame 26768 rows 19 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogfcsr16.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"cogfcsr16: Cognitive Test - Free and Cued Selective Reminding (16 Pictures) — cogfcsr16","text":"SUBSTUDY: NA BID: Roster ID VISCODE: Visit Code DONE: assessment/procedure done? NDREASON: , reason done: FCVERSION: Version FCFREET1: Free Recall:  Trial 1 FCFREET2: Free Recall:  Trial 2 FCFREET3: Free Recall:  Trial 3 FCCUEDT1: Cued Recall:  Trial 1 FCCUEDT2: Cued Recall:  Trial 2 FCCUEDT3: Cued Recall:  Trial 3 FCCUEDT1_IMPFL: Imputation Flag Cued Recall: Trial 1 FCCUEDT2_IMPFL: Imputation Flag Cued Recall: Trial 2 FCCUEDT3_IMPFL: Imputation Flag Cued Recall: Trial 3 FCTOTF: Total Free Recall: Trials 1-3 FCTOTC: Total Cued Recall: Trials 1-3 FCTOTAL96: Total Recall: Trials 1-3; FCTOTF*2 + FCTOTC FCSRT: FCSRT (PACC Audio Verification)","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogfcsr16.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"cogfcsr16: Cognitive Test - Free and Cued Selective Reminding (16 Pictures) — cogfcsr16","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/coglogic.html","id":null,"dir":"Reference","previous_headings":"","what":"coglogic: Cognitive Test - Logical Memory — coglogic","title":"coglogic: Cognitive Test - Logical Memory — coglogic","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/coglogic.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"coglogic: Cognitive Test - Logical Memory — coglogic","text":"","code":"data(coglogic)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/coglogic.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"coglogic: Cognitive Test - Logical Memory — coglogic","text":"data frame 26787 rows 8 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/coglogic.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"coglogic: Cognitive Test - Logical Memory — coglogic","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: LMSTORY: Version LIMMTOTAL: Immediate Recall Total Score LDELTOTAL: Delayed Recall Total Score","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/coglogic.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"coglogic: Cognitive Test - Logical Memory — coglogic","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_battery.html","id":null,"dir":"Reference","previous_headings":"","what":"cogstate_battery: Cogstate - Computerized Battery — cogstate_battery","title":"cogstate_battery: Cogstate - Computerized Battery — cogstate_battery","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_battery.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"cogstate_battery: Cogstate - Computerized Battery — cogstate_battery","text":"","code":"data(cogstate_battery)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_battery.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"cogstate_battery: Cogstate - Computerized Battery — cogstate_battery","text":"data frame 278212 rows 40 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_battery.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"cogstate_battery: Cogstate - Computerized Battery — cogstate_battery","text":"SUBSTUDY: NA BID: NA Hand: Dominant hand Sex: Sex TDate_DAYS_CONSENT: Test date (Derived days since study consent date) TDate_DAYS_T0: Test date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) Session_ID: Session Identifier (sequentially grouped BID) VISCODE: NA TCode: Test code GMLidx: GML test index mps: Moves per second dur: Duration test (ms) ter: Total errors (count) ler: Legal errors (count) rer: Rule break errors (count) per: Perseverative errors (count) lmn: Speed performance (log10 msec) lsd: Standard deviation speed performance acc: Accuracy (arcsin sqrt proportion) cor: Correct responses (count) err: Errors (count) presnt: Presentation count (Correct + Errors) metric: BPSO metric; ability discriminate ‘lures’ ‘similar’ objects (proportion) percor: Percent correct (proportion) cmv: Correct moves rth: Return head moves sti: Stimuli (count) cfo: Correct foils recalled res: Responses (count) Completion: Test completion flag (0 = pass; 1 = fail) Integrity: Test integrity flag (0 = pass; 1 = fail) SessionNumber: Count attempts single visit SessionCompletion: Session completion criteria ExcludeData: Indicator test use C3Comp: score Cogstate C3 composite, incorporating BPSO, Face Name, Detection, Identification One Card Learning One Back tests, relative age-matched normative data LearnWMComp: score Learning/Working Memory composite, incorporating primary outcome measures One Card Learning One Back tests (Accuracy), relative age-matched normative data OCLONBComp: score Learning/Working Memory composite, incorporating primary outcome measures One Card Learning One Back tests (Accuracy), relative age-matched normative data PsychAttnComp: score Psychomotor Function/Attention composite, incorporating Detection Identification tests, relative age-matched normative data AttnComp: score Attention composite, incorporating Detection, Identification One Back tests, relative age-matched normative data C3AbrComp: score Papp 2019, C3 composite, incorporating BPSO, Face Name (matching) One Card Learning tests, relative age-matched normative data","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_battery.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"cogstate_battery: Cogstate - Computerized Battery — cogstate_battery","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_cpath.html","id":null,"dir":"Reference","previous_headings":"","what":"cogstate_cpath: Cogstate - Critical Path Institute: Activities of Daily Living — cogstate_cpath","title":"cogstate_cpath: Cogstate - Critical Path Institute: Activities of Daily Living — cogstate_cpath","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_cpath.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"cogstate_cpath: Cogstate - Critical Path Institute: Activities of Daily Living — cogstate_cpath","text":"","code":"data(cogstate_cpath)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_cpath.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"cogstate_cpath: Cogstate - Critical Path Institute: Activities of Daily Living — cogstate_cpath","text":"data frame 801134 rows 12 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_cpath.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"cogstate_cpath: Cogstate - Critical Path Institute: Activities of Daily Living — cogstate_cpath","text":"SUBSTUDY: NA BID: NA VISCODE: NA Date_DAYS_CONSENT: Test date (Derived days since study consent date) Date_DAYS_T0: Test date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) Session_ID: Session Identifier (sequentially grouped BID) Instructions: Instructions presented questionnaire. {Note: () Complex Activities Daily Living outcome, “Complex Activities Daily Living Domain Score (CADL)” presented; (ii) Interpersonal Functioning Domain outcome, “Interpersonal Functioning Domain Score ()” presented, (iii) CPATH total score, “Total C-Path Score (total)” presented.} Question Number: Number corresponding question presented questionnaire. (Note: Complex Activities Daily Living outcome, Interpersonal Functioning Domain outcome, CPATH total score, blank.) Question Text: Question presented questionnaire. {Note: () Complex Activities Daily Living outcome, “Complex Activities Daily Living Domain Score (CADL)” presented; (ii) Interpersonal Functioning Domain outcome, “Interpersonal Functioning Domain Score ()” presented; (iii) CPATH total score, “Total C-Path Score (total)” presented.} Answer Text: actual answer given, text format. (Note: Complex Activities Daily Living outcome, Interpersonal Functioning Domain outcome, CPATH total score, blank.) Score: score corresponding answer given question presented questionnaire. {Note: () Complex Activities Daily Living outcome, reflects sum “Score” values questions 1 16; (ii) Interpersonal Functioning Domain outcome, reflects sum “Score” values questions 17 26; (iii) CPATH total score, reflects sum “Score” values individual questions.} LMN: Average Log10 reaction time score questions presented. (Note: individual questions, Complex Activities Daily Living outcome Interpersonal Functioning Domain outcome, blank.)","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_cpath.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"cogstate_cpath: Cogstate - Critical Path Institute: Activities of Daily Living — cogstate_cpath","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_macq.html","id":null,"dir":"Reference","previous_headings":"","what":"cogstate_macq: Cogstate - Memory Complaint Questionnaire — cogstate_macq","title":"cogstate_macq: Cogstate - Memory Complaint Questionnaire — cogstate_macq","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_macq.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"cogstate_macq: Cogstate - Memory Complaint Questionnaire — cogstate_macq","text":"","code":"data(cogstate_macq)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_macq.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"cogstate_macq: Cogstate - Memory Complaint Questionnaire — cogstate_macq","text":"data frame 192097 rows 11 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_macq.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"cogstate_macq: Cogstate - Memory Complaint Questionnaire — cogstate_macq","text":"SUBSTUDY: NA BID: NA VISCODE: NA Date_DAYS_CONSENT: Test date (Derived days since study consent date) Date_DAYS_T0: Test date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) Session_ID: Session Identifier (sequentially grouped BID) Question: Question presented questionnaire. (Note: MCQ total score, “MCQT Total” presented.) Answer: Answer given presented question. (Note: MCQ total score, reflects sum “Answer” values individual questions.) Answer Text: actual answer given, text format. (Note: MCQ total score, blank.) Score: score corresponding answer given question presented questionnaire. (Note: MCQ total score, reflects sum “Score” values individual questions.) LMN: Average Log10 reaction time score questions presented. (Note: individual questions, blank.)","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cogstate_macq.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"cogstate_macq: Cogstate - Memory Complaint Questionnaire — cogstate_macq","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/concerns.html","id":null,"dir":"Reference","previous_headings":"","what":"concerns: Concerns about Alzheimer's Disease Dementia — concerns","title":"concerns: Concerns about Alzheimer's Disease Dementia — concerns","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/concerns.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"concerns: Concerns about Alzheimer's Disease Dementia — concerns","text":"","code":"data(concerns)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/concerns.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"concerns: Concerns about Alzheimer's Disease Dementia — concerns","text":"data frame 15471 rows 12 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/concerns.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"concerns: Concerns about Alzheimer's Disease Dementia — concerns","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: CMETHOD: Method Collection: CADDVLP: 1. concerned develop Alzheimer's disease dementia. CADDVLP5: 2. concerned develop Alzheimer's disease dementia next 5 years. CADKNOW: 3. like know going develop Alzheimer's disease dementia point later life. CADBLIEV: 4. believe someday develop Alzheimer's disease dementia. CADWRST: 5. Alzheimer's disease dementia worst disease can think . CADCNCRN: 6. concern developing Alzheimer's disease dementia greater concern medical problems.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/concerns.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"concerns: Concerns about Alzheimer's Disease Dementia — concerns","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cssrs.html","id":null,"dir":"Reference","previous_headings":"","what":"cssrs: C-SSRS - Baseline/Screening Version — cssrs","title":"cssrs: C-SSRS - Baseline/Screening Version — cssrs","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cssrs.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"cssrs: C-SSRS - Baseline/Screening Version — cssrs","text":"","code":"data(cssrs)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cssrs.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"cssrs: C-SSRS - Baseline/Screening Version — cssrs","text":"data frame 5660 rows 55 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cssrs.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"cssrs: C-SSRS - Baseline/Screening Version — cssrs","text":"SUBSTUDY: NA BID: NA VISCODE: NA WISHLIFE: Lifetime <!–1. Wish Dead–> WISH3: past 3 months <!–1. Wish Dead–> ACTLIFE: Lifetime <!–2. Non-Specific Active Suicidal Thoughts–> ACT3: past 3 months <!–2. Non-Specific Active Suicidal Thoughts–> METHOD: Lifetime <!–3. Active Suicidal Ideation Methods (Plan) without Intent Act–> METHOD3: past 3 months <!–3. Active Suicidal Ideation Methods (Plan) without Intent Act–> INTENT: Lifetime <!–4. Active Suicidal Ideation Intent Act, without Specific Plan–> INTENT3: past 3 months <!–4. Active Suicidal Ideation Intent Act, without Specific Plan–> PLAN: Lifetime <!–5. Active Suicidal Ideation Specific Plan Intent–> PLAN3: past 3 months <!–5. Active Suicidal Ideation Specific Plan Intent–> SEVLIFE: <big header>Intensity Ideation<\/big header><br />Lifetime - Severe Ideation SEV3: Past 3 months - Severe Ideation FREQLIF: Frequency:  Severe - Lifetime FREQCUR: Frequency:  Severe - Past 3 months DURATLIF: Duration:  Severe - Lifetime DURATCUR: Duration:  Severe - Past 3 months CONTROLLIF: Controllability:  Severe - Lifetime CONTROLCUR: Controllability:  Severe - Past 3 months DETERLIF: Deterrents:  Severe - Lifetime DETERCUR: Deterrents:  Severe - Past 3 months REASONLIF: Reasons Ideation:  Severe - Lifetime REASONCUR: Reasons Ideation:  Severe - Past 3 months ATTMPT: Actual Attempt: Lifetime ATTMPT5: Actual Attempt: Past 5 years ATTMPTN: Total number actual attempts - Lifetime ATTMPT5N: Total number actual attempts - Past 5 years NONSUI: Lifetime<!–subject engaged Non-Suicidal Self-Injurious Behavior?–> NONSUI5: Past 5 years<!–subject engaged Non-Suicidal Self-Injurious Behavior?–> INTER: Interrupted Attempt - Lifetime INTER5: Interrupted Attempt - Past 5 years INTERN: Total number interrupted - Lifetime INTER5N: Total number interrupted - Past 5 years ABORT: Aborted Attempt - Lifetime ABORT5: Aborted Attempt - Past 5 years ABORTN: Total number aborted - Lifetime ABORT5N: Total number aborted - Past 5 years PREP: Preparatory Acts Behavior - Lifetime PREP5: Preparatory Acts Behavior - Past 5 years BEHAVLIF: Suicidal Behavior - Lifetime BEHAVREC: Suicidal Behavior - Past 5 years RECENT_DAYS_CONSENT: Recent Attempt Date (Derived days since study consent date) RECENT_DAYS_T0: Recent Attempt Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) RECENTDAM: Actual Lethality/Medical Damage<!–Recent Attempt Date–> RECENTPOT: Potential Lethality<!–Recent Attempt Date–> LETHAL_DAYS_CONSENT: Lethal Attempt Date (Derived days since study consent date) LETHAL_DAYS_T0: Lethal Attempt Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) LETHALDAM: Actual Lethality/Medical Damage<!–Lethal Attempt Date–> LETHALPOT: Potential Lethality<!–Lethal Attempt Date–> FIRST_DAYS_CONSENT: Initial/First Attempt date (Derived days since study consent date) FIRST_DAYS_T0: Initial/First Attempt date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) FIRSTDAM: Actual Lethality/Medical Damage<!–Initial/First Attempt Date–> FIRSTPOT: Potential Lethality<!–Initial/First Attempt Date–>","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cssrs.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"cssrs: C-SSRS - Baseline/Screening Version — cssrs","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cssrslv.html","id":null,"dir":"Reference","previous_headings":"","what":"cssrslv: C-SSRS - Since Last Visit — cssrslv","title":"cssrslv: C-SSRS - Since Last Visit — cssrslv","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cssrslv.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"cssrslv: C-SSRS - Since Last Visit — cssrslv","text":"","code":"data(cssrslv)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cssrslv.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"cssrslv: C-SSRS - Since Last Visit — cssrslv","text":"data frame 18851 rows 30 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cssrslv.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"cssrslv: C-SSRS - Since Last Visit — cssrslv","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: WISHLV: <big header>Suicidal Ideation<\/big header><br><br/>1. Wish Dead - Since Last Visit ACTLV: 2. Non-Specific Active Suicidal Thoughts - Since Last Visit METHODLV: 3. Active Suicidal Ideation Methods (Plan) without Intent Act - Since Last Visit INTENTLV: 4. Active Suicidal Ideation Intent Act, without Specific Plan - Since Last Visit PLANLV: 5. Active Suicidal Ideation Specific Plan Intent - Since Last Visit SEVLV: <big header>Intensity Ideation<\/big header><br><br/>Severe Ideation - Since last visit FREQLV: Frequency: Severe - Since Last Visit DURATLV: Duration: Severe - Since Last Visit CONTROLLV: Controllability: Severe - Since Last Visit DETERLV: Deterrents: Severe - Since Last Visit REASONLV: Reasons Ideation: Severe - Since Last Visit ATTMPTLV: Actual Attempt - Since Last Visit ATTMLVN: Total number actual attempts NONSUILV: subject engaged Non-Suicidal Self-Injurious Behavior - Since Last Visit? INTERLV: Interrupted Attempt - Since Last Visit INTERLVN: Total number interrupted attempts ABORTLV: Aborted Attempt - Since Last Visit ABORTLVN: Total number aborted attempts PREPLV: Preparatory Acts Behavior - Since Last Visit PRESENTLV: Suicidal Behavior - Since Last Visit SUICIDE: Suicide - Since Last Visit LETHALLV_DAYS_CONSENT: Lethal Attempt Date - Since Last Visit (Derived days since study consent date) LETHALLV_DAYS_T0: Lethal Attempt Date - Since Last Visit (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) RECLVDAM: Actual Lethality/Medical Damage RECLVPOT: Potential Lethality","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/cssrslv.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"cssrslv: C-SSRS - Since Last Visit — cssrslv","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/data_download_date.html","id":null,"dir":"Reference","previous_headings":"","what":"A4 LEARN data download date — data_download_date","title":"A4 LEARN data download date — data_download_date","text":"date data package downloaded <https://www.a4studydata.org/>.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/data_download_date.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"A4 LEARN data download date — data_download_date","text":"","code":"data(data_download_date)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/data_download_date.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"A4 LEARN data download date — data_download_date","text":"`Date` class object.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/data_download_date.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"A4 LEARN data download date — data_download_date","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/datadic.html","id":null,"dir":"Reference","previous_headings":"","what":"A4 LEARN data dictionaries — datadic","title":"A4 LEARN data dictionaries — datadic","text":"data files contain meta data data files package.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/datadic.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"A4 LEARN data dictionaries — datadic","text":"","code":"data(clinical_datadic)  data(derived_datadic)  data(external_datadic)  data(visits_datadic)  derived_datadic  external_datadic  visits_datadic"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/datadic.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"A4 LEARN data dictionaries — datadic","text":"data frame object class spec_tbl_df (inherits tbl_df, tbl, data.frame) 207 rows 6 columns. object class spec_tbl_df (inherits tbl_df, tbl, data.frame) 835 rows 6 columns. object class tbl_df (inherits tbl, data.frame) 152 rows 6 columns.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/datadic.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"A4 LEARN data dictionaries — datadic","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/dose.html","id":null,"dir":"Reference","previous_headings":"","what":"dose: Study Drug Therapy — dose","title":"dose: Study Drug Therapy — dose","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/dose.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"dose: Study Drug Therapy — dose","text":"","code":"data(dose)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/dose.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"dose: Study Drug Therapy — dose","text":"data frame 75241 rows 16 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/dose.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"dose: Study Drug Therapy — dose","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: LOCATION: infusion administered? VOLUME: Volume treatment solution administered STARTDATE_DAYS_CONSENT: Treatment Start Date (Derived days since study consent date) STARTDATE_DAYS_T0: Treatment Start Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) ENDDATE_DAYS_CONSENT: Treatment End Date (Derived days since study consent date) ENDDATE_DAYS_T0: Treatment End Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) COMPLETE: Describe infusion time point: ATTEMPTNUM: Total number attempts: DOSELEVEL: Dose Prescribed BLINDDOSE: Blinded dose solanezumab placebo mg administered visit BLINDCUMDOSE: Blinded cumulative dose solanezumab placebo mg administered visit prior visits.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/dose.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"dose: Study Drug Therapy — dose","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/famhxpar.html","id":null,"dir":"Reference","previous_headings":"","what":"famhxpar: Family History - Parents — famhxpar","title":"famhxpar: Family History - Parents — famhxpar","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/famhxpar.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"famhxpar: Family History - Parents — famhxpar","text":"","code":"data(famhxpar)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/famhxpar.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"famhxpar: Family History - Parents — famhxpar","text":"data frame 5907 rows 11 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/famhxpar.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"famhxpar: Family History - Parents — famhxpar","text":"SUBSTUDY: NA BID: NA VISCODE: NA MOTHER: /biological mother dementia significant memory impairment? MOTHAGE: approximate age symptoms start? MOTHDIAG: relative receive diagnosis Alzheimer's disease? MOTHAUT: diagnosis Alzheimer's disease confirmed autopsy? FATHER: /biological father dementia significant memory impairment? FATHAGE: approximate age symptoms start? FATHDIAG: relative receive diagnosis Alzheimer's disease? FATHAUT: diagnosis Alzheimer's disease confirmed autopsy?","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/famhxpar.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"famhxpar: Family History - Parents — famhxpar","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/famhxsib.html","id":null,"dir":"Reference","previous_headings":"","what":"famhxsib: Family History - Sibling Log — famhxsib","title":"famhxsib: Family History - Sibling Log — famhxsib","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/famhxsib.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"famhxsib: Family History - Sibling Log — famhxsib","text":"","code":"data(famhxsib)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/famhxsib.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"famhxsib: Family History - Sibling Log — famhxsib","text":"data frame 14600 rows 11 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/famhxsib.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"famhxsib: Family History - Sibling Log — famhxsib","text":"SUBSTUDY: NA BID: NA VISCODE: NA RECNO: NA SIBYOB: Biological sibling year birth: SIBMOTHER: Specify relationship: SIBFATHER: NA SIBDEMENT: /sibling dementia significant memory impairment? SIBAGE: approximate age symptoms start? SIBDIAG: relative receive diagnosis Alzheimer's disease? SIBAUT: diagnosis Alzheimer's disease confirmed autopsy?","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/famhxsib.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"famhxsib: Family History - Sibling Log — famhxsib","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ftpscale.html","id":null,"dir":"Reference","previous_headings":"","what":"ftpscale: Future Time Perspective Scale — ftpscale","title":"ftpscale: Future Time Perspective Scale — ftpscale","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ftpscale.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"ftpscale: Future Time Perspective Scale — ftpscale","text":"","code":"data(ftpscale)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ftpscale.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"ftpscale: Future Time Perspective Scale — ftpscale","text":"data frame 17664 rows 16 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ftpscale.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"ftpscale: Future Time Perspective Scale — ftpscale","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: FTMETHOD: Method Collection: FTOPPS: 1. Many opportunities await future. FTGOAL: 2. expect set many new goals future. FTPOSSBL: 3. future filled possibilities. FTLIFE: 4. life lies ahead . FTINFINIT: 5. future seems infinite . FTANYTHNG: 6. anything want future. FTNEW: 7. plenty time left life make new plans. FTRUNOUT: 8. sense time running . FTLIMIT: 9. limited possibilities future. FTGETOLD: 10. get older, begin experience time limited.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ftpscale.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"ftpscale: Future Time Perspective Scale — ftpscale","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/habits.html","id":null,"dir":"Reference","previous_headings":"","what":"habits: Habits — habits","title":"habits: Habits — habits","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/habits.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"habits: Habits — habits","text":"","code":"data(habits)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/habits.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"habits: Habits — habits","text":"data frame 14306 rows 13 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/habits.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"habits: Habits — habits","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: SMOKE: Average number packs smoked per day: ALCOHOL: Average number alcoholic drinks consumed per day: CAFFEINE: Average number cups caffeine consumed per day: SUBUSE: participant used substances (e.g. non-pharmacologic substances medical marijuana)? AEROBIC: Average number hours aerobic exercise (.e. jogging, swimming, bicycling) PER WEEK: WALKING: Average number minutes walking per day: SLEEP: Average total number hours slept night: SLEEPDAY: Average total number minutes napped day:","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/habits.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"habits: Habits — habits","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ies.html","id":null,"dir":"Reference","previous_headings":"","what":"ies: Impact of Events Scale — ies","title":"ies: Impact of Events Scale — ies","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ies.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"ies: Impact of Events Scale — ies","text":"","code":"data(ies)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ies.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"ies: Impact of Events Scale — ies","text":"data frame 4391 rows 23 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ies.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"ies: Impact of Events Scale — ies","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: IEDATE_DAYS_CONSENT: Date Collected: (Derived days since study consent date) IEDATE_DAYS_T0: Date Collected: (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) IETHINK: 1. thought mean . IEAVOID: 2. avoided letting get upset thought reminded . IEREMOVE: 3. tried remove memory. IESLEEP: 4. trouble falling asleep, pictures thoughts came mind. IEWAVES: 5. waves strong feelings . IEDREAMS: 6. dreams . IEAWAY: 7. stayed away reminders . IEREAL: 8. felt happened real. IETALK: 9. tried talk . IEMIND: 10. Pictures popped mind. IETHINGS: 11. things kept making think . IEDEAL: 12. aware still lot feelings , deal . IENOTTHNK: 13. tried think . IEREMIND: 14. reminder brought back feelings . IENUMB: 15. feelings kind numb. IESCORE: Total Score","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ies.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"ies: Impact of Events Scale — ies","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_FLAIR_WMH_QC.html","id":null,"dir":"Reference","previous_headings":"","what":"imaging_FLAIR_WMH_QC: Imaging - FLAIR MRI White Matter Hyperintensities (WMH) QC — imaging_FLAIR_WMH_QC","title":"imaging_FLAIR_WMH_QC: Imaging - FLAIR MRI White Matter Hyperintensities (WMH) QC — imaging_FLAIR_WMH_QC","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_FLAIR_WMH_QC.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"imaging_FLAIR_WMH_QC: Imaging - FLAIR MRI White Matter Hyperintensities (WMH) QC — imaging_FLAIR_WMH_QC","text":"","code":"data(imaging_FLAIR_WMH_QC)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_FLAIR_WMH_QC.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"imaging_FLAIR_WMH_QC: Imaging - FLAIR MRI White Matter Hyperintensities (WMH) QC — imaging_FLAIR_WMH_QC","text":"data frame 6793 rows 9 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_FLAIR_WMH_QC.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"imaging_FLAIR_WMH_QC: Imaging - FLAIR MRI White Matter Hyperintensities (WMH) QC — imaging_FLAIR_WMH_QC","text":"SUBSTUDY: NA BID: NA VISCODE: NA foldername: Source proc folder name QC: Codes whether data passed QC QCNotes: Codes QC failed /done fix data WMHvol_masked: Volume White matter hyperintensities cubic mm masking regional freesurfer mask ICV: Estimate total intracranial volume cubic mm WMH_corrected: Variable used analysis. Computed (WMHvol_masked/ICV)*1300","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_FLAIR_WMH_QC.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"imaging_FLAIR_WMH_QC: Imaging - FLAIR MRI White Matter Hyperintensities (WMH) QC — imaging_FLAIR_WMH_QC","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_MRI_reads.html","id":null,"dir":"Reference","previous_headings":"","what":"imaging_MRI_reads: Imaging - MRI Read Results — imaging_MRI_reads","title":"imaging_MRI_reads: Imaging - MRI Read Results — imaging_MRI_reads","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_MRI_reads.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"imaging_MRI_reads: Imaging - MRI Read Results — imaging_MRI_reads","text":"","code":"data(imaging_MRI_reads)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_MRI_reads.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"imaging_MRI_reads: Imaging - MRI Read Results — imaging_MRI_reads","text":"data frame 1797 rows 9 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_MRI_reads.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"imaging_MRI_reads: Imaging - MRI Read Results — imaging_MRI_reads","text":"SUBSTUDY: NA BID: NA VISCODE: NA STUDYDATE_DAYS_CONSENT: Study MRI Date (Derived days since study consent date) STUDYDATE_DAYS_T0: Study MRI Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) Definite.MCH: Total Definite Microhemorrhage Lobar: Total Lobar Microhemorrhage Deep: Total Deep (Subcortical) Microhemorrhage Definite.SS: Definite Superficial Siderosis","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_MRI_reads.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"imaging_MRI_reads: Imaging - MRI Read Results — imaging_MRI_reads","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_PET_VA.html","id":null,"dir":"Reference","previous_headings":"","what":"imaging_PET_VA: Imaging - Amyloid PET Qualitative Visual Assessment — imaging_PET_VA","title":"imaging_PET_VA: Imaging - Amyloid PET Qualitative Visual Assessment — imaging_PET_VA","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_PET_VA.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"imaging_PET_VA: Imaging - Amyloid PET Qualitative Visual Assessment — imaging_PET_VA","text":"","code":"data(imaging_PET_VA)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_PET_VA.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"imaging_PET_VA: Imaging - Amyloid PET Qualitative Visual Assessment — imaging_PET_VA","text":"data frame 4492 rows 12 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_PET_VA.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"imaging_PET_VA: Imaging - Amyloid PET Qualitative Visual Assessment — imaging_PET_VA","text":"SUBSTUDY: NA BID: NA scan_number: Scan number PET Acquisition document VISCODE: NA scan_date_DAYS_CONSENT: NA (Derived days since study consent date) scan_date_DAYS_T0: NA (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) ligand: Ligand pmod_suvr: Composite_Summary value elig_vi_1: Reader 1 eligibility assessment score elig_vi_2: Reader 2 eligibility assessment score consensus: Consensus result overall_score: Indication whether eligibility scan positive negative β‐amyloid. Score negative indicates subject eligible","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_PET_VA.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"imaging_PET_VA: Imaging - Amyloid PET Qualitative Visual Assessment — imaging_PET_VA","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_SUVR_amyloid.html","id":null,"dir":"Reference","previous_headings":"","what":"imaging_SUVR_amyloid: Imaging - Amyloid PET SUVR Quantitative Analysis — imaging_SUVR_amyloid","title":"imaging_SUVR_amyloid: Imaging - Amyloid PET SUVR Quantitative Analysis — imaging_SUVR_amyloid","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_SUVR_amyloid.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"imaging_SUVR_amyloid: Imaging - Amyloid PET SUVR Quantitative Analysis — imaging_SUVR_amyloid","text":"","code":"data(imaging_SUVR_amyloid)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_SUVR_amyloid.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"imaging_SUVR_amyloid: Imaging - Amyloid PET SUVR Quantitative Analysis — imaging_SUVR_amyloid","text":"data frame 45967 rows 12 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_SUVR_amyloid.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"imaging_SUVR_amyloid: Imaging - Amyloid PET SUVR Quantitative Analysis — imaging_SUVR_amyloid","text":"SUBSTUDY: NA BID: NA scan_number: Scan number PET Acquisition document VISCODE: NA scan_date_DAYS_CONSENT: NA (Derived days since study consent date) scan_date_DAYS_T0: NA (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) ligand: Ligand scan_analyzed: scan able analyzed? brain_region: Region interest suvr_cer: Standard Uptake Value Ratio (blcere_all) suvr_persi: Standard uptake value ratio (persi white matter) suvr_crus: Standard uptake value ratio (cerebellar crus)","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_SUVR_amyloid.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"imaging_SUVR_amyloid: Imaging - Amyloid PET SUVR Quantitative Analysis — imaging_SUVR_amyloid","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_SUVR_tau.html","id":null,"dir":"Reference","previous_headings":"","what":"imaging_SUVR_tau: Imaging - Tau PET SUVR Quantitative Analysis — imaging_SUVR_tau","title":"imaging_SUVR_tau: Imaging - Tau PET SUVR Quantitative Analysis — imaging_SUVR_tau","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_SUVR_tau.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"imaging_SUVR_tau: Imaging - Tau PET SUVR Quantitative Analysis — imaging_SUVR_tau","text":"","code":"data(imaging_SUVR_tau)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_SUVR_tau.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"imaging_SUVR_tau: Imaging - Tau PET SUVR Quantitative Analysis — imaging_SUVR_tau","text":"data frame 296679 rows 12 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_SUVR_tau.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"imaging_SUVR_tau: Imaging - Tau PET SUVR Quantitative Analysis — imaging_SUVR_tau","text":"SUBSTUDY: NA BID: NA scan_number: Scan number PET Acquisition document VISCODE: NA scan_date_DAYS_CONSENT: NA (Derived days since study consent date) scan_date_DAYS_T0: NA (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) ligand: Ligand scan_analyzed: scan able analyzed? brain_region: Region interest suvr_cer: Standard Uptake Value Ratio (blcere_all) suvr_persi: Standard uptake value ratio (persi white matter) suvr_crus: Standard uptake value ratio (cerebellar crus)","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_SUVR_tau.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"imaging_SUVR_tau: Imaging - Tau PET SUVR Quantitative Analysis — imaging_SUVR_tau","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_Tau_PET_PetSurfer.html","id":null,"dir":"Reference","previous_headings":"","what":"imaging_Tau_PET_PetSurfer: Imaging - Tau PET (PetSurfer Pipeline) — imaging_Tau_PET_PetSurfer","title":"imaging_Tau_PET_PetSurfer: Imaging - Tau PET (PetSurfer Pipeline) — imaging_Tau_PET_PetSurfer","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_Tau_PET_PetSurfer.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"imaging_Tau_PET_PetSurfer: Imaging - Tau PET (PetSurfer Pipeline) — imaging_Tau_PET_PetSurfer","text":"","code":"data(imaging_Tau_PET_PetSurfer)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_Tau_PET_PetSurfer.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"imaging_Tau_PET_PetSurfer: Imaging - Tau PET (PetSurfer Pipeline) — imaging_Tau_PET_PetSurfer","text":"data frame 445 rows 245 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_Tau_PET_PetSurfer.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"imaging_Tau_PET_PetSurfer: Imaging - Tau PET (PetSurfer Pipeline) — imaging_Tau_PET_PetSurfer","text":"SUBSTUDY: NA BID: NA bi_Accumbens.area: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Amygdala: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Caudate: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Cerebellum.Cortex: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Cerebellum.White.Matter: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Cerebral.White.Matter: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Hippocampus: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_bankssts: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_caudalanteriorcingulate: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_caudalmiddlefrontal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_cuneus: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_entorhinal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_frontalpole: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_fusiform: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_inferiorparietal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_inferiortemporal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_insula: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_isthmuscingulate: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_lateraloccipital: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_lateralorbitofrontal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_lingual: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_medialorbitofrontal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_middletemporal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_paracentral: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_parahippocampal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_parsopercularis: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_parsorbitalis: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_parstriangularis: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_pericalcarine: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_postcentral: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_posteriorcingulate: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_precentral: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_precuneus: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_rostralanteriorcingulate: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_rostralmiddlefrontal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_superiorfrontal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_superiorparietal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_superiortemporal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_supramarginal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_temporalpole: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_transversetemporal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_totalWM: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region NumVoxels_AirCavity: Number voxels FreeSurfer brain region NumVoxels_Brain.Stem: Number voxels FreeSurfer brain region NumVoxels_CSF: Number voxels FreeSurfer brain region NumVoxels_CSF.ExtraCerebral: Number voxels FreeSurfer brain region NumVoxels_Head.ExtraCerebral: Number voxels FreeSurfer brain region NumVoxels_Left.Accumbens.area: Number voxels FreeSurfer brain region NumVoxels_Left.Amygdala: Number voxels FreeSurfer brain region NumVoxels_Left.Caudate: Number voxels FreeSurfer brain region NumVoxels_Left.Cerebellum.Cortex: Number voxels FreeSurfer brain region NumVoxels_Left.Cerebellum.White.Matter: Number voxels FreeSurfer brain region NumVoxels_Left.Cerebral.White.Matter: Number voxels FreeSurfer brain region NumVoxels_Left.Hippocampus: Number voxels FreeSurfer brain region NumVoxels_Left.Pallidum: Number voxels FreeSurfer brain region NumVoxels_Left.Putamen: Number voxels FreeSurfer brain region NumVoxels_Left.Thalamus: Number voxels FreeSurfer brain region NumVoxels_Left.VentralDC: Number voxels FreeSurfer brain region NumVoxels_Left.choroid.plexus: Number voxels FreeSurfer brain region NumVoxels_Pons: Number voxels FreeSurfer brain region NumVoxels_Right.Accumbens.area: Number voxels FreeSurfer brain region NumVoxels_Right.Amygdala: Number voxels FreeSurfer brain region NumVoxels_Right.Caudate: Number voxels FreeSurfer brain region NumVoxels_Right.Cerebellum.Cortex: Number voxels FreeSurfer brain region NumVoxels_Right.Cerebellum.White.Matter: Number voxels FreeSurfer brain region NumVoxels_Right.Cerebral.White.Matter: Number voxels FreeSurfer brain region NumVoxels_Right.Hippocampus: Number voxels FreeSurfer brain region NumVoxels_Right.Pallidum: Number voxels FreeSurfer brain region NumVoxels_Right.Putamen: Number voxels FreeSurfer brain region NumVoxels_Right.Thalamus: Number voxels FreeSurfer brain region NumVoxels_Right.VentralDC: Number voxels FreeSurfer brain region NumVoxels_Right.choroid.plexus: Number voxels FreeSurfer brain region NumVoxels_Skull: Number voxels FreeSurfer brain region NumVoxels_Vermis: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.bankssts: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.caudalanteriorcingulate: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.caudalmiddlefrontal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.cuneus: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.entorhinal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.frontalpole: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.fusiform: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.inferiorparietal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.inferiortemporal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.insula: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.isthmuscingulate: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.lateraloccipital: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.lateralorbitofrontal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.lingual: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.medialorbitofrontal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.middletemporal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.paracentral: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.parahippocampal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.parsopercularis: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.parsorbitalis: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.parstriangularis: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.pericalcarine: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.postcentral: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.posteriorcingulate: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.precentral: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.precuneus: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.rostralanteriorcingulate: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.rostralmiddlefrontal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.superiorfrontal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.superiorparietal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.superiortemporal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.supramarginal: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.temporalpole: Number voxels FreeSurfer brain region NumVoxels_ctx.lh.transversetemporal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.bankssts: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.caudalanteriorcingulate: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.caudalmiddlefrontal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.cuneus: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.entorhinal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.frontalpole: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.fusiform: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.inferiorparietal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.inferiortemporal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.insula: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.isthmuscingulate: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.lateraloccipital: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.lateralorbitofrontal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.lingual: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.medialorbitofrontal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.middletemporal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.paracentral: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.parahippocampal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.parsopercularis: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.parsorbitalis: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.parstriangularis: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.pericalcarine: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.postcentral: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.posteriorcingulate: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.precentral: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.precuneus: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.rostralanteriorcingulate: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.rostralmiddlefrontal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.superiorfrontal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.superiorparietal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.superiortemporal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.supramarginal: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.temporalpole: Number voxels FreeSurfer brain region NumVoxels_ctx.rh.transversetemporal: Number voxels FreeSurfer brain region PVC_AirCavity: Partial volume correction value FreeSurfer brain region PVC_Brain.Stem: Partial volume correction value FreeSurfer brain region PVC_CSF: Partial volume correction value FreeSurfer brain region PVC_CSF.ExtraCerebral: Partial volume correction value FreeSurfer brain region PVC_Head.ExtraCerebral: Partial volume correction value FreeSurfer brain region PVC_Left.Accumbens.area: Partial volume correction value FreeSurfer brain region PVC_Left.Amygdala: Partial volume correction value FreeSurfer brain region PVC_Left.Caudate: Partial volume correction value FreeSurfer brain region PVC_Left.Cerebellum.Cortex: Partial volume correction value FreeSurfer brain region PVC_Left.Cerebellum.White.Matter: Partial volume correction value FreeSurfer brain region PVC_Left.Cerebral.White.Matter: Partial volume correction value FreeSurfer brain region PVC_Left.Hippocampus: Partial volume correction value FreeSurfer brain region PVC_Left.Pallidum: Partial volume correction value FreeSurfer brain region PVC_Left.Putamen: Partial volume correction value FreeSurfer brain region PVC_Left.Thalamus: Partial volume correction value FreeSurfer brain region PVC_Left.VentralDC: Partial volume correction value FreeSurfer brain region PVC_Left.choroid.plexus: Partial volume correction value FreeSurfer brain region PVC_Pons: Partial volume correction value FreeSurfer brain region PVC_Right.Accumbens.area: Partial volume correction value FreeSurfer brain region PVC_Right.Amygdala: Partial volume correction value FreeSurfer brain region PVC_Right.Caudate: Partial volume correction value FreeSurfer brain region PVC_Right.Cerebellum.Cortex: Partial volume correction value FreeSurfer brain region PVC_Right.Cerebellum.White.Matter: Partial volume correction value FreeSurfer brain region PVC_Right.Cerebral.White.Matter: Partial volume correction value FreeSurfer brain region PVC_Right.Hippocampus: Partial volume correction value FreeSurfer brain region PVC_Right.Pallidum: Partial volume correction value FreeSurfer brain region PVC_Right.Putamen: Partial volume correction value FreeSurfer brain region PVC_Right.Thalamus: Partial volume correction value FreeSurfer brain region PVC_Right.VentralDC: Partial volume correction value FreeSurfer brain region PVC_Right.choroid.plexus: Partial volume correction value FreeSurfer brain region PVC_Skull: Partial volume correction value FreeSurfer brain region PVC_Vermis: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.bankssts: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.caudalanteriorcingulate: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.caudalmiddlefrontal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.cuneus: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.entorhinal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.frontalpole: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.fusiform: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.inferiorparietal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.inferiortemporal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.insula: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.isthmuscingulate: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.lateraloccipital: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.lateralorbitofrontal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.lingual: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.medialorbitofrontal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.middletemporal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.paracentral: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.parahippocampal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.parsopercularis: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.parsorbitalis: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.parstriangularis: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.pericalcarine: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.postcentral: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.posteriorcingulate: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.precentral: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.precuneus: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.rostralanteriorcingulate: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.rostralmiddlefrontal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.superiorfrontal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.superiorparietal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.superiortemporal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.supramarginal: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.temporalpole: Partial volume correction value FreeSurfer brain region PVC_ctx.lh.transversetemporal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.bankssts: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.caudalanteriorcingulate: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.caudalmiddlefrontal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.cuneus: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.entorhinal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.frontalpole: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.fusiform: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.inferiorparietal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.inferiortemporal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.insula: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.isthmuscingulate: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.lateraloccipital: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.lateralorbitofrontal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.lingual: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.medialorbitofrontal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.middletemporal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.paracentral: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.parahippocampal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.parsopercularis: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.parsorbitalis: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.parstriangularis: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.pericalcarine: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.postcentral: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.posteriorcingulate: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.precentral: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.precuneus: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.rostralanteriorcingulate: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.rostralmiddlefrontal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.superiorfrontal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.superiorparietal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.superiortemporal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.supramarginal: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.temporalpole: Partial volume correction value FreeSurfer brain region PVC_ctx.rh.transversetemporal: Partial volume correction value FreeSurfer brain region","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_Tau_PET_PetSurfer.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"imaging_Tau_PET_PetSurfer: Imaging - Tau PET (PetSurfer Pipeline) — imaging_Tau_PET_PetSurfer","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_Tau_PET_Stanford.html","id":null,"dir":"Reference","previous_headings":"","what":"imaging_Tau_PET_Stanford: Imaging - Tau PET (Stanford Pipeline) — imaging_Tau_PET_Stanford","title":"imaging_Tau_PET_Stanford: Imaging - Tau PET (Stanford Pipeline) — imaging_Tau_PET_Stanford","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_Tau_PET_Stanford.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"imaging_Tau_PET_Stanford: Imaging - Tau PET (Stanford Pipeline) — imaging_Tau_PET_Stanford","text":"","code":"data(imaging_Tau_PET_Stanford)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_Tau_PET_Stanford.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"imaging_Tau_PET_Stanford: Imaging - Tau PET (Stanford Pipeline) — imaging_Tau_PET_Stanford","text":"data frame 447 rows 275 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_Tau_PET_Stanford.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"imaging_Tau_PET_Stanford: Imaging - Tau PET (Stanford Pipeline) — imaging_Tau_PET_Stanford","text":"SUBSTUDY: NA BID: NA Mean.3rd.Ventricle: Mean intensity FreeSurfer brain region Mean.4th.Ventricle: Mean intensity FreeSurfer brain region Mean.Brain.Stem: Mean intensity FreeSurfer brain region Mean.CC_Anterior: Mean intensity FreeSurfer brain region Mean.CC_Central: Mean intensity FreeSurfer brain region Mean.CC_Mid_Anterior: Mean intensity FreeSurfer brain region Mean.CC_Mid_Posterior: Mean intensity FreeSurfer brain region Mean.CC_Posterior: Mean intensity FreeSurfer brain region Mean.CSF: Mean intensity FreeSurfer brain region Mean.Left.Accumbens.area: Mean intensity FreeSurfer brain region Mean.Left.Amygdala: Mean intensity FreeSurfer brain region Mean.Left.Caudate: Mean intensity FreeSurfer brain region Mean.Left.Cerebellum.Cortex: Mean intensity FreeSurfer brain region Mean.Left.Cerebellum.White.Matter: Mean intensity FreeSurfer brain region Mean.Left.Cerebral.White.Matter: Mean intensity FreeSurfer brain region Mean.Left.Hippocampus: Mean intensity FreeSurfer brain region Mean.Left.Inf.Lat.Vent: Mean intensity FreeSurfer brain region Mean.Left.Lateral.Ventricle: Mean intensity FreeSurfer brain region Mean.Left.Pallidum: Mean intensity FreeSurfer brain region Mean.Left.Putamen: Mean intensity FreeSurfer brain region Mean.Left.Thalamus: Mean intensity FreeSurfer brain region Mean.Left.VentralDC: Mean intensity FreeSurfer brain region Mean.Left.choroid.plexus: Mean intensity FreeSurfer brain region Mean.Left.vessel: Mean intensity FreeSurfer brain region Mean.Optic.Chiasm: Mean intensity FreeSurfer brain region Mean.Right.Accumbens.area: Mean intensity FreeSurfer brain region Mean.Right.Amygdala: Mean intensity FreeSurfer brain region Mean.Right.Caudate: Mean intensity FreeSurfer brain region Mean.Right.Cerebellum.Cortex: Mean intensity FreeSurfer brain region Mean.Right.Cerebellum.White.Matter: Mean intensity FreeSurfer brain region Mean.Right.Cerebral.White.Matter: Mean intensity FreeSurfer brain region Mean.Right.Hippocampus: Mean intensity FreeSurfer brain region Mean.Right.Inf.Lat.Vent: Mean intensity FreeSurfer brain region Mean.Right.Lateral.Ventricle: Mean intensity FreeSurfer brain region Mean.Right.Pallidum: Mean intensity FreeSurfer brain region Mean.Right.Putamen: Mean intensity FreeSurfer brain region Mean.Right.Thalamus: Mean intensity FreeSurfer brain region Mean.Right.VentralDC: Mean intensity FreeSurfer brain region Mean.Right.choroid.plexus: Mean intensity FreeSurfer brain region Mean.Right.vessel: Mean intensity FreeSurfer brain region Mean.Unknown: Mean intensity FreeSurfer brain region Mean.WM.hypointensities: Mean intensity FreeSurfer brain region Mean.ctx.lh.bankssts: Mean intensity FreeSurfer brain region Mean.ctx.lh.caudalanteriorcingulate: Mean intensity FreeSurfer brain region Mean.ctx.lh.caudalmiddlefrontal: Mean intensity FreeSurfer brain region Mean.ctx.lh.cuneus: Mean intensity FreeSurfer brain region Mean.ctx.lh.entorhinal: Mean intensity FreeSurfer brain region Mean.ctx.lh.frontalpole: Mean intensity FreeSurfer brain region Mean.ctx.lh.fusiform: Mean intensity FreeSurfer brain region Mean.ctx.lh.inferiorparietal: Mean intensity FreeSurfer brain region Mean.ctx.lh.inferiortemporal: Mean intensity FreeSurfer brain region Mean.ctx.lh.insula: Mean intensity FreeSurfer brain region Mean.ctx.lh.isthmuscingulate: Mean intensity FreeSurfer brain region Mean.ctx.lh.lateraloccipital: Mean intensity FreeSurfer brain region Mean.ctx.lh.lateralorbitofrontal: Mean intensity FreeSurfer brain region Mean.ctx.lh.lingual: Mean intensity FreeSurfer brain region Mean.ctx.lh.medialorbitofrontal: Mean intensity FreeSurfer brain region Mean.ctx.lh.middletemporal: Mean intensity FreeSurfer brain region Mean.ctx.lh.paracentral: Mean intensity FreeSurfer brain region Mean.ctx.lh.parahippocampal: Mean intensity FreeSurfer brain region Mean.ctx.lh.parsopercularis: Mean intensity FreeSurfer brain region Mean.ctx.lh.parsorbitalis: Mean intensity FreeSurfer brain region Mean.ctx.lh.parstriangularis: Mean intensity FreeSurfer brain region Mean.ctx.lh.pericalcarine: Mean intensity FreeSurfer brain region Mean.ctx.lh.postcentral: Mean intensity FreeSurfer brain region Mean.ctx.lh.posteriorcingulate: Mean intensity FreeSurfer brain region Mean.ctx.lh.precentral: Mean intensity FreeSurfer brain region Mean.ctx.lh.precuneus: Mean intensity FreeSurfer brain region Mean.ctx.lh.rostralanteriorcingulate: Mean intensity FreeSurfer brain region Mean.ctx.lh.rostralmiddlefrontal: Mean intensity FreeSurfer brain region Mean.ctx.lh.superiorfrontal: Mean intensity FreeSurfer brain region Mean.ctx.lh.superiorparietal: Mean intensity FreeSurfer brain region Mean.ctx.lh.superiortemporal: Mean intensity FreeSurfer brain region Mean.ctx.lh.supramarginal: Mean intensity FreeSurfer brain region Mean.ctx.lh.temporalpole: Mean intensity FreeSurfer brain region Mean.ctx.lh.transversetemporal: Mean intensity FreeSurfer brain region Mean.ctx.rh.bankssts: Mean intensity FreeSurfer brain region Mean.ctx.rh.caudalanteriorcingulate: Mean intensity FreeSurfer brain region Mean.ctx.rh.caudalmiddlefrontal: Mean intensity FreeSurfer brain region Mean.ctx.rh.cuneus: Mean intensity FreeSurfer brain region Mean.ctx.rh.entorhinal: Mean intensity FreeSurfer brain region Mean.ctx.rh.frontalpole: Mean intensity FreeSurfer brain region Mean.ctx.rh.fusiform: Mean intensity FreeSurfer brain region Mean.ctx.rh.inferiorparietal: Mean intensity FreeSurfer brain region Mean.ctx.rh.inferiortemporal: Mean intensity FreeSurfer brain region Mean.ctx.rh.insula: Mean intensity FreeSurfer brain region Mean.ctx.rh.isthmuscingulate: Mean intensity FreeSurfer brain region Mean.ctx.rh.lateraloccipital: Mean intensity FreeSurfer brain region Mean.ctx.rh.lateralorbitofrontal: Mean intensity FreeSurfer brain region Mean.ctx.rh.lingual: Mean intensity FreeSurfer brain region Mean.ctx.rh.medialorbitofrontal: Mean intensity FreeSurfer brain region Mean.ctx.rh.middletemporal: Mean intensity FreeSurfer brain region Mean.ctx.rh.paracentral: Mean intensity FreeSurfer brain region Mean.ctx.rh.parahippocampal: Mean intensity FreeSurfer brain region Mean.ctx.rh.parsopercularis: Mean intensity FreeSurfer brain region Mean.ctx.rh.parsorbitalis: Mean intensity FreeSurfer brain region Mean.ctx.rh.parstriangularis: Mean intensity FreeSurfer brain region Mean.ctx.rh.pericalcarine: Mean intensity FreeSurfer brain region Mean.ctx.rh.postcentral: Mean intensity FreeSurfer brain region Mean.ctx.rh.posteriorcingulate: Mean intensity FreeSurfer brain region Mean.ctx.rh.precentral: Mean intensity FreeSurfer brain region Mean.ctx.rh.precuneus: Mean intensity FreeSurfer brain region Mean.ctx.rh.rostralanteriorcingulate: Mean intensity FreeSurfer brain region Mean.ctx.rh.rostralmiddlefrontal: Mean intensity FreeSurfer brain region Mean.ctx.rh.superiorfrontal: Mean intensity FreeSurfer brain region Mean.ctx.rh.superiorparietal: Mean intensity FreeSurfer brain region Mean.ctx.rh.superiortemporal: Mean intensity FreeSurfer brain region Mean.ctx.rh.supramarginal: Mean intensity FreeSurfer brain region Mean.ctx.rh.temporalpole: Mean intensity FreeSurfer brain region Mean.ctx.rh.transversetemporal: Mean intensity FreeSurfer brain region Mean.non.WM.hypointensities: Mean intensity FreeSurfer brain region Volume_mm3.3rd.Ventricle: Volume FreeSurfer brain region Volume_mm3.4th.Ventricle: Volume FreeSurfer brain region Volume_mm3.Brain.Stem: Volume FreeSurfer brain region Volume_mm3.CC_Anterior: Volume FreeSurfer brain region Volume_mm3.CC_Central: Volume FreeSurfer brain region Volume_mm3.CC_Mid_Anterior: Volume FreeSurfer brain region Volume_mm3.CC_Mid_Posterior: Volume FreeSurfer brain region Volume_mm3.CC_Posterior: Volume FreeSurfer brain region Volume_mm3.CSF: Volume FreeSurfer brain region Volume_mm3.Left.Accumbens.area: Volume FreeSurfer brain region Volume_mm3.Left.Amygdala: Volume FreeSurfer brain region Volume_mm3.Left.Caudate: Volume FreeSurfer brain region Volume_mm3.Left.Cerebellum.Cortex: Volume FreeSurfer brain region Volume_mm3.Left.Cerebellum.White.Matter: Volume FreeSurfer brain region Volume_mm3.Left.Cerebral.White.Matter: Volume FreeSurfer brain region Volume_mm3.Left.Hippocampus: Volume FreeSurfer brain region Volume_mm3.Left.Inf.Lat.Vent: Volume FreeSurfer brain region Volume_mm3.Left.Lateral.Ventricle: Volume FreeSurfer brain region Volume_mm3.Left.Pallidum: Volume FreeSurfer brain region Volume_mm3.Left.Putamen: Volume FreeSurfer brain region Volume_mm3.Left.Thalamus: Volume FreeSurfer brain region Volume_mm3.Left.VentralDC: Volume FreeSurfer brain region Volume_mm3.Left.choroid.plexus: Volume FreeSurfer brain region Volume_mm3.Left.vessel: Volume FreeSurfer brain region Volume_mm3.Optic.Chiasm: Volume FreeSurfer brain region Volume_mm3.Right.Accumbens.area: Volume FreeSurfer brain region Volume_mm3.Right.Amygdala: Volume FreeSurfer brain region Volume_mm3.Right.Caudate: Volume FreeSurfer brain region Volume_mm3.Right.Cerebellum.Cortex: Volume FreeSurfer brain region Volume_mm3.Right.Cerebellum.White.Matter: Volume FreeSurfer brain region Volume_mm3.Right.Cerebral.White.Matter: Volume FreeSurfer brain region Volume_mm3.Right.Hippocampus: Volume FreeSurfer brain region Volume_mm3.Right.Inf.Lat.Vent: Volume FreeSurfer brain region Volume_mm3.Right.Lateral.Ventricle: Volume FreeSurfer brain region Volume_mm3.Right.Pallidum: Volume FreeSurfer brain region Volume_mm3.Right.Putamen: Volume FreeSurfer brain region Volume_mm3.Right.Thalamus: Volume FreeSurfer brain region Volume_mm3.Right.VentralDC: Volume FreeSurfer brain region Volume_mm3.Right.choroid.plexus: Volume FreeSurfer brain region Volume_mm3.Right.vessel: Volume FreeSurfer brain region Volume_mm3.Unknown: Volume FreeSurfer brain region Volume_mm3.WM.hypointensities: Volume FreeSurfer brain region Volume_mm3.ctx.lh.bankssts: Volume FreeSurfer brain region Volume_mm3.ctx.lh.caudalanteriorcingulate: Volume FreeSurfer brain region Volume_mm3.ctx.lh.caudalmiddlefrontal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.cuneus: Volume FreeSurfer brain region Volume_mm3.ctx.lh.entorhinal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.frontalpole: Volume FreeSurfer brain region Volume_mm3.ctx.lh.fusiform: Volume FreeSurfer brain region Volume_mm3.ctx.lh.inferiorparietal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.inferiortemporal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.insula: Volume FreeSurfer brain region Volume_mm3.ctx.lh.isthmuscingulate: Volume FreeSurfer brain region Volume_mm3.ctx.lh.lateraloccipital: Volume FreeSurfer brain region Volume_mm3.ctx.lh.lateralorbitofrontal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.lingual: Volume FreeSurfer brain region Volume_mm3.ctx.lh.medialorbitofrontal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.middletemporal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.paracentral: Volume FreeSurfer brain region Volume_mm3.ctx.lh.parahippocampal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.parsopercularis: Volume FreeSurfer brain region Volume_mm3.ctx.lh.parsorbitalis: Volume FreeSurfer brain region Volume_mm3.ctx.lh.parstriangularis: Volume FreeSurfer brain region Volume_mm3.ctx.lh.pericalcarine: Volume FreeSurfer brain region Volume_mm3.ctx.lh.postcentral: Volume FreeSurfer brain region Volume_mm3.ctx.lh.posteriorcingulate: Volume FreeSurfer brain region Volume_mm3.ctx.lh.precentral: Volume FreeSurfer brain region Volume_mm3.ctx.lh.precuneus: Volume FreeSurfer brain region Volume_mm3.ctx.lh.rostralanteriorcingulate: Volume FreeSurfer brain region Volume_mm3.ctx.lh.rostralmiddlefrontal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.superiorfrontal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.superiorparietal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.superiortemporal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.supramarginal: Volume FreeSurfer brain region Volume_mm3.ctx.lh.temporalpole: Volume FreeSurfer brain region Volume_mm3.ctx.lh.transversetemporal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.bankssts: Volume FreeSurfer brain region Volume_mm3.ctx.rh.caudalanteriorcingulate: Volume FreeSurfer brain region Volume_mm3.ctx.rh.caudalmiddlefrontal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.cuneus: Volume FreeSurfer brain region Volume_mm3.ctx.rh.entorhinal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.frontalpole: Volume FreeSurfer brain region Volume_mm3.ctx.rh.fusiform: Volume FreeSurfer brain region Volume_mm3.ctx.rh.inferiorparietal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.inferiortemporal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.insula: Volume FreeSurfer brain region Volume_mm3.ctx.rh.isthmuscingulate: Volume FreeSurfer brain region Volume_mm3.ctx.rh.lateraloccipital: Volume FreeSurfer brain region Volume_mm3.ctx.rh.lateralorbitofrontal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.lingual: Volume FreeSurfer brain region Volume_mm3.ctx.rh.medialorbitofrontal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.middletemporal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.paracentral: Volume FreeSurfer brain region Volume_mm3.ctx.rh.parahippocampal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.parsopercularis: Volume FreeSurfer brain region Volume_mm3.ctx.rh.parsorbitalis: Volume FreeSurfer brain region Volume_mm3.ctx.rh.parstriangularis: Volume FreeSurfer brain region Volume_mm3.ctx.rh.pericalcarine: Volume FreeSurfer brain region Volume_mm3.ctx.rh.postcentral: Volume FreeSurfer brain region Volume_mm3.ctx.rh.posteriorcingulate: Volume FreeSurfer brain region Volume_mm3.ctx.rh.precentral: Volume FreeSurfer brain region Volume_mm3.ctx.rh.precuneus: Volume FreeSurfer brain region Volume_mm3.ctx.rh.rostralanteriorcingulate: Volume FreeSurfer brain region Volume_mm3.ctx.rh.rostralmiddlefrontal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.superiorfrontal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.superiorparietal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.superiortemporal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.supramarginal: Volume FreeSurfer brain region Volume_mm3.ctx.rh.temporalpole: Volume FreeSurfer brain region Volume_mm3.ctx.rh.transversetemporal: Volume FreeSurfer brain region Volume_mm3.non.WM.hypointensities: Volume FreeSurfer brain region bi_Accumbens.area: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Amygdala: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Caudate: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Cerebellum.Cortex: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Cerebellum.White.Matter: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Cerebral.White.Matter: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Hippocampus: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Inf.Lat.Vent: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Lateral.Ventricle: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Pallidum: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Putamen: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_Thalamus: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_VentralDC: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_choroid.plexus: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_vessel: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_bankssts: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_caudalanteriorcingulate: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_caudalmiddlefrontal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_cuneus: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_entorhinal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_frontalpole: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_fusiform: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_inferiorparietal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_inferiortemporal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_insula: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_isthmuscingulate: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_lateraloccipital: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_lateralorbitofrontal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_lingual: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_medialorbitofrontal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_middletemporal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_paracentral: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_parahippocampal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_parsopercularis: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_parsorbitalis: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_parstriangularis: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_pericalcarine: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_postcentral: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_posteriorcingulate: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_precentral: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_precuneus: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_rostralanteriorcingulate: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_rostralmiddlefrontal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_superiorfrontal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_superiorparietal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_superiortemporal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_supramarginal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_temporalpole: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_transversetemporal: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region bi_totalWM: Volume-weighted bilateral Standard Uptake Value Ratios FreeSurfer brain region","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_Tau_PET_Stanford.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"imaging_Tau_PET_Stanford: Imaging - Tau PET (Stanford Pipeline) — imaging_Tau_PET_Stanford","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_retinal.html","id":null,"dir":"Reference","previous_headings":"","what":"imaging_retinal: Imaging - Retinal — imaging_retinal","title":"imaging_retinal: Imaging - Retinal — imaging_retinal","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_retinal.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"imaging_retinal: Imaging - Retinal — imaging_retinal","text":"","code":"data(imaging_retinal)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_retinal.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"imaging_retinal: Imaging - Retinal — imaging_retinal","text":"data frame 498 rows 10 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_retinal.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"imaging_retinal: Imaging - Retinal — imaging_retinal","text":"SUBSTUDY: NA BID: NA ExamDate_DAYS_CONSENT: Date scan obtained (Derived days since study consent date) ExamDate_DAYS_T0: Date scan obtained (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) Eye: Eye imaged Field: Exact location NumberOfImages: Number images NumberPassingImages: Number images pass-IQ Exclude: Indicate excluded analysis RAIModelScore: Index discriminate score based PET Amyloid Status","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_retinal.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"imaging_retinal: Imaging - Retinal — imaging_retinal","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_volumetric_mri.html","id":null,"dir":"Reference","previous_headings":"","what":"imaging_volumetric_mri: Imaging - Volumetric MRI Results — imaging_volumetric_mri","title":"imaging_volumetric_mri: Imaging - Volumetric MRI Results — imaging_volumetric_mri","text":"ATRI external analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_volumetric_mri.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"imaging_volumetric_mri: Imaging - Volumetric MRI Results — imaging_volumetric_mri","text":"","code":"data(imaging_volumetric_mri)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_volumetric_mri.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"imaging_volumetric_mri: Imaging - Volumetric MRI Results — imaging_volumetric_mri","text":"data frame 2951 rows 58 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_volumetric_mri.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"imaging_volumetric_mri: Imaging - Volumetric MRI Results — imaging_volumetric_mri","text":"SUBSTUDY: NA BID: NA Date_DAYS_CONSENT: Date Exam (Derived days since study consent date) Date_DAYS_T0: Date Exam (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) LeftCorticalGrayMatter: Cortical Gray Matter Left Side Volume RightCorticalGrayMatter: Cortical Gray Matter Right Side Volume LeftLateralVentricle: Superior Lateral Ventricle Left Side Volume RightLateralVentricle: Superior Lateral Ventricle Right Side Volume LeftInferiorLateralVentricle: Inferior Lateral Ventricle Left Side Volume RightInferiorLateralVentricle: Inferior Lateral Ventricle Right Side Volume LeftThalamus: Thalamus Left Side Volume RightThalamus: Thalamus Right Side Volume LeftCaudate: Caudate Left Side Volume RightCaudate: Caudate Right Side Volume LeftPutamen: Putamen Left Side Volume RightPutamen: Putamen Right Side Volume LeftPallidum: Pallidum Left Side Volume RightPallidum: Pallidum Right Side Volume LeftHippocampus: Hippocampus Left Side Volume RightHippocampus: Hippocampus Right Side Volume LeftAmygdala: Amygdala Left Side Volume RightAmygdala: Amygdala Right Side Volume LeftVentralDiencephalon: Ventral Diencephalon Left Side Volume RightVentralDiencephalon: Ventral Diencephalon Right Side Volume LeftCerebellarWhiteMatter: Cerebellar White Matter Left Side Volume RightCerebellarWhiteMatter: Cerebellar White Matter Right Side Volume LeftCerebellarGrayMatter: Cerebellar Gray Matter Left Side Volume RightCerebellarGrayMatter: Cerebellar Gray Matter Right Side Volume LeftWMHypo: Cerebral WM Hypointensities* Left Side Volume RightWMHypo: Cerebral WM Hypointensities* Right Side Volume LeftEntorhinal: Entorhinal Cortex Left Side Volume RightEntorhinal: Entorhinal Cortex Right Side Volume LeftFusiform: Fusiform Cortex Left Side Volume RightFusiform: Fusiform Cortex Right Side Volume LeftInferiorparietal: Inferior Parietal Left Side Volume RightInferiorparietal: Inferior Parietal Right Side Volume LeftInferiortemporal: Inferior Temporal Cortex Left Side Volume RightInferiortemporal: Inferior Temporal Cortex Right Side Volume LeftMiddletemporal: Middle Temporal Cortex Left Side Volume RightMiddletemporal: Middle Temporal Cortex Right Side Volume LeftParahippocampal: Parahippocampal Cortex Left Side Volume RightParahippocampal: Parahippocampal Cortex Right Side Volume LeftSuperiorfrontal: Superior Frontal Cortex Left Side Volume RightSuperiorfrontal: Superior Frontal Cortex Right Side Volume LeftSuperiorparietal: Superior Parietal Lobule Left Side Volume RightSuperiorparietal: Superior Parietal Lobule Right Side Volume LeftSuperiortemporal: Superior Temporal Cortex Left Side Volume RightSuperiortemporal: Superior Temporal Cortex Right Side Volume LeftTemporalpole: Temporal Pole Left Side Volume RightTemporalpole: Temporal Pole Right Side Volume 3rdVentricle: 3rd Ventricle Total Volume 4thVentricle: 4th Ventricle Total Volume 5thVentricle: 5th Ventricle Total Volume Brainstem: Brainstem Total Volume ForebrainParenchyma: Forebrain Parenchyma Total Volume IntraCranialVolume: Intracranial Volume Total Volume HOC: Hippocampal Occupancy Score: Ratio hippocampal volume sum hippocampal volume inferior lateral ventricle VISCODE: NA","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/imaging_volumetric_mri.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"imaging_volumetric_mri: Imaging - Volumetric MRI Results — imaging_volumetric_mri","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/mmse.html","id":null,"dir":"Reference","previous_headings":"","what":"mmse: Mini Mental State Exam — mmse","title":"mmse: Mini Mental State Exam — mmse","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/mmse.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"mmse: Mini Mental State Exam — mmse","text":"","code":"data(mmse)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/mmse.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"mmse: Mini Mental State Exam — mmse","text":"data frame 26765 rows 41 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/mmse.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"mmse: Mini Mental State Exam — mmse","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: MMSELOC: assessment done? WORDLIST: word list used? MMDATE: 1. today's date? MMYEAR: 2. year? MMMONTH: 3. month? MMDAY: 4. day week today? MMSEASON: 5. season ? MMHOSPIT: 6. name hospital (clinic, place)? MMFLOOR: 7. floor ? MMCITY: 8. town city ? MMAREA: 9. county (district, borough, area) ? MMSTATE: 10. state ? MMBALL: 11. Word 1 MMFLAG: 12. Word 2 MMTREE: 13. Word 3 MMTRIALS: 13a. Enter number trials MMDLTR: 14. Indicate first letter MMLLTR: 15. Indicate second letter MMRLTR: 16. Indicate third letter MMOLTR: 17. Indicate fourth letter MMWLTR: 18. Indicate fifth letter MMWORLD: Attention sub-score (WORLD Backwards - CERAD scoring method) MMBALLDL: 19. Word 1 MMFLAGDL: 20. Word 2 MMTREEDL: 21. Word 3 MMWATCH: 22. Show participant wrist watch ask \"?\" MMPENCIL: 23. Repeat pencil. MMREPEAT: 24. Say, \"Repeat : ifs, ands, buts.\" MMHAND: 25. Takes paper right hand. MMFOLD: 26. Folds paper half. MMONFLR: 27. Puts paper floor. MMREAD: 28. Present piece paper reads, \"CLOSE EYES,\" say: \"Read says.\" MMWRITE: 29. Give participant blank piece paper say: \"Write sentence.\" MMDRAW: <big header>Construction<\/big header><p>30. Present participant Construction Stimulus page. Say, \"Copy design.\"<\/p> MMSCORE: MMSE TOTAL SCORE MMSE: MMSE (PACC Audio Verification)","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/mmse.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"mmse: Mini Mental State Exam — mmse","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/phyneuro.html","id":null,"dir":"Reference","previous_headings":"","what":"phyneuro: Physical and Neurological Exam — phyneuro","title":"phyneuro: Physical and Neurological Exam — phyneuro","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/phyneuro.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"phyneuro: Physical and Neurological Exam — phyneuro","text":"","code":"data(phyneuro)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/phyneuro.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"phyneuro: Physical and Neurological Exam — phyneuro","text":"data frame 11479 rows 22 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/phyneuro.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"phyneuro: Physical and Neurological Exam — phyneuro","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: PXHEADEY: Head, Eyes, Ears, Nose Throat PXCARD: Cardiac PXPULM: Pulmonary PXABDOM: Abdomen PXMUSCUL: Musculoskeletal PXEDEMA: Edema PXEDSEV: Severity <!–Edema–> PXSKIN: Skin PXOTHER: (Physical) NXGAIT: Gait NXMOTOR: Motor Strength NXSENSOR: Sensory NXTREMOR: Tremor NXFINGER: Cerebellar - Finger Nose NXHEEL: Cerebellar - Heel Shin NXNERVE: Cranial Nerves NXOTHER: (Neurological)","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/phyneuro.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"phyneuro: Physical and Neurological Exam — phyneuro","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/psychwell.html","id":null,"dir":"Reference","previous_headings":"","what":"psychwell: Assessment of Psychological Well-Being — psychwell","title":"psychwell: Assessment of Psychological Well-Being — psychwell","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/psychwell.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"psychwell: Assessment of Psychological Well-Being — psychwell","text":"","code":"data(psychwell)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/psychwell.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"psychwell: Assessment of Psychological Well-Being — psychwell","text":"data frame 21777 rows 29 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/psychwell.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"psychwell: Assessment of Psychological Well-Being — psychwell","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: PWBMETHOD: Method Collection: GDSATIS: 1. basically satisfied life? GDDROP: 2. dropped many activities interests? GDEMPTY: 3. feel life empty? GDBORED: 4. often get bored? GDSPIRIT: 5. good spirits time? GDAFRAID: 6. afraid something bad going happen ? GDHAPPY: 7. feel happy time? GDHELP: 8. often feel helpless? GDHOME: 9. prefer stay home, rather going new things? GDMEMORY: 10. feel problems memory ? GDALIVE: 11. think wonderful alive now? GDWORTH: 12. feel pretty worthless way now? GDENERGY: 13. feel full energy? GDHOPE: 14. feel situation hopeless? GDBETTER: 15. think people better ? GDTOTAL: Total Score STCALM: 1. felt calm STTENSE: 2. tense STUPSET: 3. felt upset STRELAX: 4. relaxed STCONTENT: 5. felt content STWORRY: 6. worried STAITOTAL: Total Score","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/psychwell.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"psychwell: Assessment of Psychological Well-Being — psychwell","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ptdemog.html","id":null,"dir":"Reference","previous_headings":"","what":"ptdemog: Participant Demographics — ptdemog","title":"ptdemog: Participant Demographics — ptdemog","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ptdemog.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"ptdemog: Participant Demographics — ptdemog","text":"","code":"data(ptdemog)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ptdemog.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"ptdemog: Participant Demographics — ptdemog","text":"data frame 6945 rows 21 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ptdemog.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"ptdemog: Participant Demographics — ptdemog","text":"SUBSTUDY: NA BID: NA VISCODE: NA EXAMDATE_DAYS_CONSENT: Examination Date (Derived days since study consent date) EXAMDATE_DAYS_T0: Examination Date (Derived days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date]) PTGENDER: Gender PTAGE: Age Screening Visit PTETHNIC: Ethnic Category PTRACE: Racial Categories PTLANG: Language used testing (one may checked must remain throughout study) PTPLANG: language used testing primary language? PTEDUCAT: Education (years) PTMARRY: Marital Status PTNOTRT: Participant Retired? PTHOME: Type Residence","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ptdemog.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"ptdemog: Participant Demographics — ptdemog","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/rss.html","id":null,"dir":"Reference","previous_headings":"","what":"rss: Research Satisfaction Survey — rss","title":"rss: Research Satisfaction Survey — rss","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/rss.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"rss: Research Satisfaction Survey — rss","text":"","code":"data(rss)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/rss.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"rss: Research Satisfaction Survey — rss","text":"data frame 7430 rows 17 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/rss.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"rss: Research Satisfaction Survey — rss","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: RSSCOMP: Survey completed : RSSQUAL: 1. rate quality tests attention received participation study? RSSEXPECT: 2. extent research program met expectations? RSSRECOM: 3. friend inquire research program, recommend ? RSSREDO: 4. chance redo decision participate research program, think choose participate? RSSBEST: 5. like best study? RSSLEAST: 6. like least? RSSMED: Study medication: RSSTST: Tests/Procedures: RSSVIS: Number visits: RSSOTH: : RSSIPAD: 8. rate quality iPad Testing?","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/rss.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"rss: Research Satisfaction Survey — rss","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ruib.html","id":null,"dir":"Reference","previous_headings":"","what":"ruib: Resource Use Inventory - Brief — ruib","title":"ruib: Resource Use Inventory - Brief — ruib","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ruib.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"ruib: Resource Use Inventory - Brief — ruib","text":"","code":"data(ruib)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ruib.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"ruib: Resource Use Inventory - Brief — ruib","text":"data frame 9148 rows 18 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ruib.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"ruib: Resource Use Inventory - Brief — ruib","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: RUIBCOMP: Form completed : BRADMIT: 1. past one year, many times admitted hospital overnight stay? BREXAM: 2. past 3 months, many times examined health care professional (including study related examinations)? BRHELP: Paid help: BRUPHELP: Un-paid help: VOLUNTEER: 4a. volunteer work? VOLHRS: yes, many hours per week EMPLOY: 4b. engaged paid employment? EMPHRS: yes, many hours per week LOST: 4c. past 3 months, lost time volunteer work paid employment due health reasons? LOSTHRS: yes, many hours per week RESIDENCE: 5. changed residence past year? RESTYPE: Yes, please select best description new residence:","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ruib.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"ruib: Resource Use Inventory - Brief — ruib","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ruib1.html","id":null,"dir":"Reference","previous_headings":"","what":"ruib1: Resource Use Inventory - Brief: Hospital Admissions Log — ruib1","title":"ruib1: Resource Use Inventory - Brief: Hospital Admissions Log — ruib1","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ruib1.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"ruib1: Resource Use Inventory - Brief: Hospital Admissions Log — ruib1","text":"","code":"data(ruib1)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ruib1.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"ruib1: Resource Use Inventory - Brief: Hospital Admissions Log — ruib1","text":"data frame 1106 rows 6 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ruib1.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"ruib1: Resource Use Inventory - Brief: Hospital Admissions Log — ruib1","text":"SUBSTUDY: NA BID: NA VISCODE: NA RECNO: NA BR1NIGHT: Number Nights BR1TYPE: Diagnosis Type","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/ruib1.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"ruib1: Resource Use Inventory - Brief: Hospital Admissions Log — ruib1","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/spinfo.html","id":null,"dir":"Reference","previous_headings":"","what":"spinfo: Study Partner Information — spinfo","title":"spinfo: Study Partner Information — spinfo","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/spinfo.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"spinfo: Study Partner Information — spinfo","text":"","code":"data(spinfo)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/spinfo.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"spinfo: Study Partner Information — spinfo","text":"data frame 7646 rows 12 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/spinfo.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"spinfo: Study Partner Information — spinfo","text":"SUBSTUDY: NA BID: NA VISCODE: NA RECNO: NA BPID: Study Partner ID Number: INFRELAT: Relationship study partner participant INFGENDER: Gender study partner INFAGE: study partner 90 older? INFAGESP: , age study partner: INFLIVE: study partner participant live together? INFHRS: many hours per week study partner spend participant -person? INFHRSOT: -person, many hours per week study partner spend participant?","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/spinfo.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"spinfo: Study Partner Information — spinfo","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/views.html","id":null,"dir":"Reference","previous_headings":"","what":"views: Views & Perceptions of Amyloid Imaging — views","title":"views: Views & Perceptions of Amyloid Imaging — views","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/views.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"views: Views & Perceptions of Amyloid Imaging — views","text":"","code":"data(views)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/views.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"views: Views & Perceptions of Amyloid Imaging — views","text":"data frame 10296 rows 16 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/views.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"views: Views & Perceptions of Amyloid Imaging — views","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: VMETHOD: Method Collection: VSEEK: 1. seek information preventative measures (e.g., change diet, exercise, lifestyle changes) VEASE: 2. put mind ease found elevated amyloid PET scan. VRISK: 3. know risk developing Alzheimer's disease dementia. VPART: 4. able participate anti-amyloid clinical trials (A4 trial) VCNTRB: 5. desire contribute research Alzheimer's disease VAFFAIR: 6. arrange personal affairs VCNFRM: 7. confirm feeling might already developing symptoms Alzheimer's disease dementia VPREP: 8. prepare family possible illness future VCURIOUS: 9. Curiosity VOTHER: 10. (please list)","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/views.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"views: Views & Perceptions of Amyloid Imaging — views","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/vitals.html","id":null,"dir":"Reference","previous_headings":"","what":"vitals: Vital Signs — vitals","title":"vitals: Vital Signs — vitals","text":"ATRI clinical analysis dataset.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/vitals.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"vitals: Vital Signs — vitals","text":"","code":"data(vitals)"},{"path":"https://atri-biostats.github.io/A4LEARN/reference/vitals.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"vitals: Vital Signs — vitals","text":"data frame 21827 rows 19 variables.","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/vitals.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"vitals: Vital Signs — vitals","text":"SUBSTUDY: NA BID: NA VISCODE: NA DONE: assessment/procedure done? NDREASON: , reason done: VSWEIGHT: 1a. Weight VSWTUNIT: 1b. Weight units STDWT: Standard Weight VSHEIGHT: 2a. Height VSHTUNIT: 2b. Height Units STDHT: Standard Height VSBPSYS: 3a. Systolic VSBPDIA: 3b. Diastolic VSPULSE: 4. Seated Pulse Rate VSRESP: 5. Respirations VSTEMP: 6a. Temperature VSTEMPUN: 6b. Temperature Units VSTMPSRC: 6c. Temperature Source STDTEMP: Standard Temperature","code":""},{"path":"https://atri-biostats.github.io/A4LEARN/reference/vitals.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"vitals: Vital Signs — vitals","text":"","code":"if (FALSE) { # \\dontrun{ browseVignettes('A4LEARN') } # }"}]
